apvo-ex101_158.htm



Exhibit 10.1

 

 



 

 

 

AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT

dated as of August 6, 2018 by and among

APTEVO THERAPEUTICS INC., APTEVO BIOTHERAPEUTICS LLC,

APTEVO RESEARCH AND DEVELOPMENT LLC,

 

and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers,

 

and

 

MIDCAP FINANCIAL TRUST,

 

as Agent, and

THE LENDERS

 

FROM TIME TO TIME PARTY HERETO





 

 

 
 
 



 



MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 
 


TABLE OF CONTENTS

 

Page                                                                                                                                ARTICLE 1 - DEFINITIONS1

Section 1.1Certain Defined Terms1

Section 1.2Accounting Terms and Determinations24

Section 1.3Other Definitional and Interpretive Provisions25

ARTICLE 2 - LOANS25

Section 2.1Loans25

Section 2.2Interest, Interest Calculations and Certain Fees28

Section 2.3Notes29

Section 2.4Reserved30

Section 2.5Reserved30

Section 2.6General Provisions Regarding Payment; Loan Account30

Section 2.7Maximum Interest30

Section 2.8Taxes; Capital Adequacy31

Section 2.9Appointment of Borrower Representative34

Section 2.10Joint and Several Liability; Rights of Contribution; Subordination

and Subrogation35

Section 2.11Reserved37

Section 2.12Termination; Restriction on Termination37

ARTICLE 3 - REPRESENTATIONS AND WARRANTIES37

Section 3.1Existence and Power38

Section 3.2Organization and Governmental Authorization; No Contravention38

Section 3.3Binding Effect38

Section 3.4Capitalization38

Section 3.5Financial Information38

Section 3.6Litigation39

 



1

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 3.7Ownership of Property39

Section 3.8No Default39

Section 3.9Labor Matters39

Section 3.10Regulated Entities39

Section 3.11Margin Regulations39

Section 3.12Compliance With Laws; Anti-Terrorism Laws39

Section 3.13Taxes40

Section 3.14Compliance with ERISA40

Section 3.15Consummation of Financing Documents; Brokers41

Section 3.16Reserved41

Section 3.17Material Contracts41

Section 3.18Compliance with Environmental Requirements; No Hazardous

Materials41

Section 3.19Intellectual Property and License Agreements41

Section 3.20Solvency42

Section 3.21Full Disclosure42

Section 3.22Interest Rate42

Section 3.23Subsidiaries42

Section 3.24Reserved42

Section 3.25Accuracy of Schedules42

ARTICLE 4 - AFFIRMATIVE COVENANTS42

Section 4.1Financial Statements and Other Reports42

Section 4.2Payment and Performance of Obligations43

Section 4.3Maintenance of Existence43

Section 4.4Maintenance of Property; Insurance43

Section 4.5Compliance with Laws and Material Contracts45

Section 4.6Inspection of Property, Books and Records45

 



2

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 4.7Use of Proceeds45

Section 4.8Estoppel Certificates45

Section 4.9Notices of Material Contracts, Litigation and Defaults45

Section 4.10Hazardous Materials; Remediation47

Section 4.11Further Assurances47

Section 4.12Reserved48

Section 4.13Power of Attorney48

Section 4.14Reserved49

Section 4.15Schedule Updates49

Section 4.16Intellectual Property and Licensing49

Section 4.17Regulatory Reporting and Covenants51

ARTICLE 5 - NEGATIVE COVENANTS52

Section 5.1Debt; Contingent Obligations52

Section 5.2Liens52

Section 5.3Distributions52

Section 5.4Restrictive Agreements52

Section 5.5Payments and Modifications of Subordinated Debt52

Section 5.6Consolidations, Mergers and Sales of Assets; Change in Control52

Section 5.7Purchase of Assets, Investments53

Section 5.8Transactions with Affiliates53

Section 5.9Modification of Organizational Documents53

Section 5.10Modification of Certain Agreements53

Section 5.11Conduct of Business53

Section 5.12Reserved53

Section 5.13Limitation on Sale and Leaseback Transactions53

Section 5.14Deposit Accounts and Securities Accounts; Payroll and Benefits

Accounts53

 



3

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 5.15Compliance with Anti-Terrorism Laws54

Section 5.16Change in Accounting55

ARTICLE 6 - FINANCIAL COVENANTS55

Section 6.1Additional Defined Terms55

Section 6.2Minimum Net Commercial Product Revenue55

Section 6.3Minimum Cash55

Section 6.4Evidence of Compliance55

ARTICLE 7 - CONDITIONS56

Section 7.1Conditions to Closing56

Section 7.2Conditions to Each Loan56

Section 7.3Searches56

Section 7.4Post Closing Requirements57

ARTICLE 8 – REGULATORY MATTERS57

Section 8.1Reserved57

Section 8.2Representations and Warranties57

Section 8.3Healthcare Operations59

ARTICLE 9 - SECURITY AGREEMENT60

Section 9.1Generally60

Section 9.2Representations and Warranties and Covenants Relating to

Collateral60

ARTICLE 10 - EVENTS OF DEFAULT64

Section 10.1Events of Default64

Section 10.2Acceleration and Suspension or Termination of Term Loan

Commitment66

Section 10.3UCC Remedies67

Section 10.4Reserved68

Section 10.5Default Rate of Interest68

 



4

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 10.6Setoff Rights69

Section 10.7Application of Proceeds69

Section 10.8Waivers70

Section 10.9Injunctive Relief71

Section 10.10Marshalling; Payments Set Aside71

ARTICLE 11 - AGENT72

Section 11.1Appointment and Authorization72

Section 11.2Agent and Affiliates72

Section 11.3Action by Agent72

Section 11.4Consultation with Experts72

Section 11.5Liability of Agent72

Section 11.6Indemnification73

Section 11.7Right to Request and Act on Instructions73

Section 11.8Credit Decision73

Section 11.9Collateral Matters73

Section 11.10Agency for Perfection74

Section 11.11Notice of Default74

Section 11.12Assignment by Agent; Resignation of Agent; Successor Agent74

Section 11.13Payment and Sharing of Payment75

Section 11.14Right to Perform, Preserve and Protect76

Section 11.15Additional Titled Agents76

Section 11.16Amendments and Waivers76

Section 11.17Assignments and Participations77

Section 11.18Funding and Settlement Provisions Applicable When Non-Funding

Lenders Exist80

Section 11.19Reserved80

Section 11.20Definitions80

 



5

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


ARTICLE 12 - MISCELLANEOUS81

Section 12.1Survival81

Section 12.2No Waivers81

Section 12.3Notices82

Section 12.4Severability82

Section 12.5Headings82

Section 12.6Confidentiality83

Section 12.7Waiver of Consequential and Other Damages83

Section 12.8GOVERNING LAW; SUBMISSION TO JURISDICTION83

Section 12.9WAIVER OF JURY TRIAL84

Section 12.10Publication; Advertisement84

Section 12.11Counterparts; Integration85

Section 12.12No Strict Construction85

Section 12.13Lender Approvals85

Section 12.14Expenses; Indemnity85

Section 12.15RESERVED86

Section 12.16Reinstatement86

Section 12.17Successors and Assigns87

Section 12.18USA PATRIOT Act Notification87

Section 12.19Existing Agreements Superseded; Exhibits and Schedules87

 

 

 

 

 

 

 

 

 

 

 

 

vi

 



MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 
 


AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT

 

THIS AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (as the

same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of August 6, 2018 (the “Closing Date”) by and among APTEVO THERAPEUTICS INC., a Delaware corporation, APTEVO BIOTHERAPEUTICS LLC, a Delaware limited liability company, APTEVO RESEARCH AND DEVELOPMENT LLC, a Delaware limited liability company and any additional borrower that may hereafter be added to this Agreement (each, individually as a “Borrower”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lender, and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender.

 

RECITALS

 

WHEREAS, Borrowers, Agent and certain Lenders are parties to that certain Credit and Security Agreement, dated as of August 4, 2016 (the “Original Closing Date”) (as amended, supplemented or  otherwise modified and in effect immediately prior to the date hereof, the “Original Credit Agreement”), pursuant to which Agent and certain Lenders agreed to make certain financing facilities available to Borrowers, including a term loan in the original principal amount of Twenty Million Dollars ($20,000,000), all of which remains outstanding as of the date hereof;

 

WHEREAS, in connection with the continued working capital and other needs of the Borrowers, Borrowers have requested, among other things, that Agent and Lenders, (a) extend the maturity date of loans under the Original Credit Agreement, and (b) amend certain other economic terms, covenants and other provisions of the Original Credit Agreement; and

 

WHEREAS, Agent and Lenders have agreed to the requests of Borrowers on the terms and conditions set forth herein and in the other Financing Documents.

 

Borrowers have requested that Lenders continue to make available to Borrowers the financing facilities as described herein. Lenders are willing to continuing extending such credit to Borrowers under the terms and conditions herein set forth.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, Borrowers, Lenders and Agent agree as follows:

 

ARTICLE 1 - DEFINITIONS

 

Section 1.1Certain Defined Terms. The following terms have the following meanings:

 

“Acceleration Event” means the occurrence of an Event of Default (a) in respect of which Agent has declared all or any portion of the Obligations to be immediately due  and  payable  pursuant  to Section 10.2, and/or (b) pursuant to either Section 10.1(e) and/or Section 10.1(f).

 

“Account Debtor” means “account debtor”, as defined in Article 9 of the UCC, and any other obligor in respect of an Account.

 



1

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Accounts” means, collectively, (a) any right to payment of a monetary obligation, whether or not earned by performance, (b) without duplication, any “account” (as defined in the UCC), any accounts receivable (whether in the form of payments for services rendered or goods sold, rents, license fees or otherwise), any “health-care-insurance receivables” (as defined in the UCC), any “payment intangibles” (as defined in the UCC) and all other rights to payment and/or reimbursement of every kind and description, whether or not earned by performance, (c) all accounts, “general intangibles” (as defined in the UCC), Intellectual Property, rights, remedies, Guarantees, “supporting obligations” (as defined in the UCC), “letter-of-credit rights” (as defined in the UCC) and security interests in respect of the foregoing, all rights of enforcement and collection, all books and records evidencing or related to the foregoing, and all rights under the Financing Documents in respect of the foregoing, (d) all information and data compiled or derived by any Borrower or to which any Borrower is entitled in respect of or related to the foregoing, and (e) all proceeds of any of the foregoing.

 

“Additional Titled Agents” has the meaning set forth in Section 11.15.

 

“Affiliate” means, with respect to any Person, (a) any Person that directly or indirectly controls such Person, (b) any Person which is controlled by or is under common control with such controlling Person, and (c) each of such Person’s (other than, with respect to any Lender, any Lender’s) officers or directors (or Persons functioning in substantially similar roles) and the spouses, parents, descendants and siblings of such officers, directors or other Persons. As used in this definition, the term “control” of a Person means the possession, directly or indirectly, of the power to vote ten percent (10%) or more of any class of voting securities of such Person or to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

“Agent” means MCF, in its capacity as administrative agent for itself and for Lenders hereunder, as such capacity is established in, and subject to the provisions of, Article 11, and the successors and permitted assigns of MCF in such capacity.

 

“Anti-Terrorism Laws” means any Laws relating to terrorism or money laundering, including, without limitation, Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws comprising or implementing the Bank Secrecy Act, and the Laws administered by OFAC.

 

“Applicable Margin” means seven and six tenths percent (7.60%).

 

“Aptevo Therapeutics” means Aptevo Therapeutics Inc., a Delaware corporation.

 

“Asset Disposition” means any sale, lease, license, transfer, assignment or other consensual disposition by any Credit Party of any asset.

 

“Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy”, as the same may be amended, modified or supplemented from time to time, and any successor statute thereto.

 

“Base LIBOR Rate” means, for each Interest Period, the rate per annum, determined by Agent in accordance with its customary procedures, and utilizing such electronic or other quotation sources as it considers appropriate (rounded upwards, if necessary, to the next 1/100%), to be the rate at which Dollar deposits (for delivery on the first day of such Interest Period or, if such day is not a Business Day on the preceding Business Day) in the amount of $1,000,000 are offered to major banks in the London interbank market on or about 11:00 a.m. (Eastern time) two (2) Business Days prior to the commencement of such Interest Period, for a term comparable to such Interest Period, which determination shall be conclusive in the absence of manifest error.

 



2

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Base Rate” means a per annum rate of interest equal to the greater of (a) three and one half percent (3.5%) and (b) the rate of interest announced, from time to time, within Wells Fargo Bank, National Association (“Wells Fargo”) at its principal office in San Francisco as its “prime rate,” with the understanding that the “prime rate” is one of Wells Fargo’s base rates (not necessarily the lowest of such rates) and serves as the basis upon which effective rates of interest are calculated for those loans making reference thereto and is evidenced by the recording thereof after its announcement in such internal publications as Wells Fargo may designate; provided, however, that Agent may, upon prior written notice to Borrower, choose a reasonably comparable index or source to use as the basis for the Base Rate.

 

“Blocked Person” means any Person: (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) owned or controlled by, or acting for or on behalf of, any Person that is listed  in the annex  to,  or  is  otherwise subject  to  the provisions  of,  Executive Order  No. 13224, (c) with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) that commits, threatens or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224, or (e) that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list or is named as a “listed person” or “listed entity” on other lists made under any Anti-Terrorism Law.

 

“Borrower” and “Borrowers” has the meaning set forth in the introductory paragraph hereto. “Borrower Unrestricted Cash” has the meaning set forth in Section 6.1.

“Borrower Representative” means Aptevo Therapeutics, in its capacity as Borrower Representative pursuant to the provisions of Section 2.9, or any successor Borrower Representative selected by Borrowers and approved by Agent.

 

“Business Day” means any day except a Saturday, Sunday or other day on which either the New York Stock Exchange is closed, or on which commercial banks in Washington, DC and New York City are authorized by law to close.

 

“CERCLA” means the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C.A. § 9601 et seq., as the same may be amended from time to time.

 

“Change in Control” means any of the following events: (a) any Person other than another Borrower or two or more Persons acting in concert shall have acquired beneficial ownership, directly or indirectly, of, or shall have acquired by contract or otherwise, or shall have entered into a contract or arrangement that, upon consummation, will result in its or their acquisition of or control over, voting  stock of any Borrower (or other securities convertible into such voting stock) representing more than 50% of the combined voting power of all voting stock of any Borrower; (b) any Borrower ceases to own, directly or indirectly, 100% of the capital stock of any of its Subsidiaries (with the exception of any Subsidiaries permitted to be dissolved, merged or otherwise disposed of to the extent otherwise permitted by this Agreement); or (c) the occurrence of a “Change of Control” or “Change in Control” or terms of similar import under any document or instrument governing or relating to Debt of or equity in such Person. As used herein, “beneficial ownership” shall have the meaning provided in Rule 13d-3 of the Securities and Exchange Commission under the Securities Exchange Act of 1934.

 

“Closing Date” has the meaning set forth in the introductory paragraph hereto.

 

“CMS” means the federal Centers for Medicare and Medicaid Services (formerly the federal Health Care Financing Administration), and any successor Governmental Authority.

 



3

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Code” means the Internal Revenue Code of 1986, as amended from time to time.

 

“Collateral” means all property, now existing or hereafter acquired, mortgaged or pledged to, or purported to be subjected to a Lien in favor of, Agent, for the benefit of Agent and Lenders, pursuant to this Agreement and the Security Documents, including, without limitation, all of the property described in Schedule 9.1 hereto, but excluding any Excluded Property.

 

“Commercial Products” means the IXINITY product and any other commercial products developed or in-licensed by the Borrowers in accordance with the terms of this Agreement.

 

“Commitment Annex” means Annex A to this Agreement.

 

“Compliance Certificate” means a certificate, duly executed by a Responsible Officer of Borrower Representative, appropriately completed and substantially in the form of Exhibit B hereto.

 

“Consolidated Subsidiary” means, at any date, any Subsidiary the accounts of which would be consolidated with those of “parent” Borrower (or any other Person, as the context may require hereunder) in its consolidated financial statements if such statements were prepared as of such date.

 

“Contingent Obligation” means, with respect to any Person, any direct or indirect liability of such Person: (a) with respect to any Debt of another Person (a “Third Party Obligation”) if the purpose or intent of such Person incurring such liability, or the effect thereof, is to provide assurance to the  obligee of such Third Party Obligation that such Third Party Obligation will be paid or discharged, or that any agreement relating thereto will be complied with, or that any holder of such Third Party Obligation will be protected, in whole or in part, against loss with respect thereto; (b) with respect to any undrawn portion of any letter of credit issued for the account of such Person or as to which such Person is otherwise liable for the reimbursement of any drawing; (c) under any Swap Contract, to the extent not yet due and payable; (d) to make take-or-pay or similar payments if required regardless of nonperformance  by any other party or parties to an agreement; or (e) for any obligations of another Person pursuant to any Guarantee or pursuant to any agreement to purchase, repurchase or otherwise acquire any obligation or any property constituting security therefor, to provide funds for the payment or discharge of such obligation or to preserve the solvency, financial condition or level of income of another Person. The amount of any Contingent Obligation shall be equal to the amount of the obligation so Guaranteed or otherwise supported or, if not a fixed and determinable amount, the maximum amount so Guaranteed or otherwise supported.

 

“Controlled Group” means all members of any group of corporations and all members of a group of trades or businesses (whether or not incorporated) under common control which, together with any Borrower, are treated as a single employer under Section 414(b), (c), (m) or (o) of the Code or  Section 4001(b) of ERISA.

 

“Correction” means repair, modification, adjustment, relabeling, destruction or inspection (including patient monitoring) that is outside of routine monitoring and monitoring required under applicable Laws of a product without its physical removal to some other location.

 

“Credit Exposure” means, at any time, any portion of the Term Loan Commitments and of any other Obligations that remains outstanding; provided, however, that no Credit Exposure shall be deemed to exist solely due to the existence of contingent indemnification liability, absent the assertion of a claim, or the known existence of a claim reasonably likely to be asserted, with respect thereto.

 



4

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Credit Party” means any Guarantor under a Guarantee of the Obligations or any part thereof, any Borrower and any other Person (other than Agent, a Lender or a participant of a Lender), whether  now existing or hereafter acquired or formed, that becomes obligated as a borrower, guarantor, surety, indemnitor, pledgor, assignor or other obligor under any Financing Document, and any Person whose equity interests or portion thereof have been pledged or hypothecated to Agent under any Financing Document; provided, however, that in no event shall any Excluded Foreign Subsidiary or Excluded Domestic Holdco be a “Credit Party” for purposes of this Agreement or the other Financing Documents.

 

“Debt” of a Person means at any date, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or other  similar instruments, (c) all obligations of such Person to pay the deferred purchase price of property or services, except trade accounts payable arising in the Ordinary Course of Business and which do not remain unpaid more than ninety (90) days past the invoice date, (d) all capital leases of such Person,

(e)all non-contingent obligations of such Person to reimburse any bank or other Person in respect of amounts paid under a letter of credit, banker’s acceptance or similar instrument, (f) all equity securities of such Person subject to repurchase or redemption other than at the sole option of such Person, (g) all obligations secured by a Lien on any asset of such Person, whether or not such obligation is otherwise an obligation of such Person, (h) “earnouts”, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature of such Person arising out of purchase and sale contracts but in each case solely to the extent carried on the balance sheet of such Person as a liability in accordance with GAAP, (i) all Debt of others Guaranteed by such Person, and (j) the principal balance outstanding under any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing product.

 

“Default” means any condition or event which with the giving of notice or lapse of time or both would, unless cured or waived, become an Event of Default.

 

“Defined Period” has the meaning set forth in Section 6.1.

 

“Deposit Account” means a “deposit account” (as defined in Article 9 of the UCC), an investment account, or other account in which funds are held or invested for credit to or for the benefit of any Borrower.

 

“Deposit Account Control Agreement” means an agreement, in form and substance reasonably satisfactory to Agent, among Agent, any Borrower and each financial institution in which such Borrower maintains a Deposit Account, which agreement provides that (a) such financial institution shall comply with instructions originated by Agent directing disposition of the funds in such Deposit Account without further consent by the applicable Borrower, and (b) such financial institution shall agree that it shall have no Lien on, or right of setoff or recoupment against, such Deposit Account or the contents thereof, other than in respect of usual and customary service fees and returned items, and containing such other terms and conditions as Agent may reasonably require.

 

“Distribution” means as to any Person (a) any dividend or other distribution (whether in cash, securities or other property) on any equity interest in such Person (except those payable solely in its equity interests of the same class), or (b) any payment by such Person on account of (i) the purchase, redemption, retirement, defeasance, surrender, cancellation, termination or acquisition of any equity interests in such Person or any claim respecting the purchase or sale of any equity interest in such Person, or (ii) any option, warrant or other right to acquire any equity interests in such Person.

 

“Dollars” or “$” means the lawful currency of the United States of America.

 



5

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Drug Application” means a biologic license application for any Product, as appropriate, as that term is defined in the FDCA.

 

“Emergent” means Emergent BioSolutions Inc., a Delaware corporation.

 

“Emergent Spinoff Transaction” means the legal reorganization of Emergent separating its life sciences businesses into two independent, publicly-traded companies (the “Separation”) to consist of (i) Aptevo Therapeutics, which will be the spun-off entity that will own and operate Emergent’s biosciences business and (ii) Emergent, which will own and operate the other business, it being understood and agreed that the spin-off transaction related to the foregoing shall be as described in the Form 10 filed by Emergent with the United States Securities and Exchange Commission on April 15, 2015, as amended by Amendment 1 thereto filed May 31, 2016, Amendment 2 thereto filed June 28, 2016, Amendment 3 thereto filed on July 7, 2016, and Amendment 4 thereto filed on July 13, 2016 (as amended by the foregoing and pursuant to any other filings made by Emergent with the United States Securities and Exchange Commission prior to the Closing Date, the “Form 10”) and in accordance with the Separation and Distribution Agreement.

 

“Emergent Spinoff Documents” means the Separation and Distribution Agreement by and between Emergent and Aptevo Therapeutics, dated as of July 29, 2016, as amended, restated, supplemented or otherwise modified from time to time prior to the Closing Date (the “Separation and Distribution Agreement”), the Transition Services Agreement, dated as of July 29, 2016, by and between Emergent and Aptevo Therapeutics, the Product License Agreement, dated as of July 29, 2016, by and between Emergent and Aptevo Therapeutics, the Trademark License Agreement, dated as of July 29, 2016, by and between Emergent and Aptevo Therapeutics, the Canadian Distributor Agreement, dated as of July 29, 2016, by and between Emergent and Aptevo Therapeutics, the Manufacturing Services Agreement, dated as of July 29, 2016, by and between Emergent and Aptevo Therapeutics and each other document, agreement and/or instrument executed by Borrower in connection therewith and with the Emergent Spinoff Transaction.

 

“Environmental Laws” means any present and future federal, state and local laws, statutes, ordinances, rules, regulations, standards, policies and other governmental directives or requirements pertaining to the environment, natural resources, pollution, health (including any environmental clean-up statutes and all regulations adopted by any local, state, federal or other Governmental Authority, and any statute, ordinance, code, order, decree, law rule or regulation all of which pertain to or impose liability or standards of conduct concerning medical waste or medical products, equipment or supplies), safety or clean-up that apply to any Borrower and relate to Hazardous Materials, including, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act of 1980 (42 U.S.C. § 9601 et seq.), the Resource Conservation and Recovery Act of 1976 (42 U.S.C. § 6901 et seq.), the Federal Water Pollution Control Act (33 U.S.C. § 1251 et seq.), the Hazardous Materials Transportation Act (49 U.S.C.

§ 5101 et seq.), the Clean Air Act (42 U.S.C. § 7401 et seq.), the Federal Insecticide, Fungicide and Rodenticide Act (7 U.S.C. § 136 et seq.), the Emergency Planning and Community Right-to-Know Act (42 U.S.C. § 11001 et seq.), the Occupational Safety and Health Act (29 U.S.C. § 651 et seq.), the Residential Lead-Based Paint Hazard Reduction Act (42 U.S.C. § 4851 et seq.), any analogous state or local laws, any amendments thereto, and the regulations promulgated pursuant to said laws, together with all amendments from time to time to any of the foregoing.

 

“ERISA” means the Employee Retirement Income Security Act of 1974, as the same may be amended, modified or supplemented from time to time, and any successor statute thereto, and any and all rules or regulations promulgated from time to time thereunder.

 



6

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“ERISA Plan” means any “employee benefit plan”, as such term is defined in Section 3(3) of ERISA (other than a Multiemployer Plan), which any Borrower maintains, sponsors or contributes to, or, in the case of an employee benefit plan which is subject to Section 412 of the Code or Title IV of ERISA, to which any Borrower (including as a result of its membership of the Controlled Group) may have any liability, including any liability by reason of having been a substantial employer within the meaning of Section 4063 of ERISA at any time during the preceding five (5) years, or by reason of being deemed to be a contributing sponsor under Section 4069 of ERISA.

 

“Event of Default” has the meaning set forth in Section 10.1.

 

“Excluded Domestic Holdco” means a wholly-owned Subsidiary of Borrower substantially all the assets of which consist of capital stock or other equity interests in the Excluded Foreign Subsidiary held directly or indirectly by such Subsidiary and that does not engage in any business, operations or activity other than that of a holding company. For the avoidance of  doubt, it is understood and agreed  that no Excluded Domestic Holdcos exist as of the Closing Date.

 

“Excluded Foreign Subsidiaries” means, collectively, (a) Aptevo Europe Limited and (b) each other Subsidiary of Borrower not organized under the laws of the United States, a state thereof, or the District of Columbia (a “Foreign Subsidiary”) to the extent a 956 Impact (as defined below) exists with respect to such Subsidiary. A “956 Impact” will be deemed to exist to the extent the issuance of a guaranty by, grant of a Lien by, or pledge of greater than two-thirds of the voting stock of, a Foreign Subsidiary would in the reasonable judgment of the Borrowers results in material incremental income tax liability as a result of the application of Section 956 of the Code, taking into account actual anticipated repatriation of funds, foreign tax credits and other relevant factors.

 

“Excluded Property” means, collectively:

 


	
(a)
	
voting shares of any (A) Excluded Foreign Subsidiary of Borrower or (B) Excluded Domestic Holdco, in each case, in excess of 65% of all of the issued and outstanding voting shares of capital stock of such subsidiary if, in each case, a pledge of a greater percentage would result in a 956 Impact existing;
	
 




 


	
(b)
	
any lease, license, contract, property right (including without limitation any jointly owned or jointly developed Intellectual Property rights) or agreement as to which, if and to the extent that, and only for so long as the grant of a security interest therein shall (1) constitute or result in a breach, termination or default under any such lease, license, contract, property right or agreement or render it unenforceable, (2) be prohibited by any applicable law or (3) require the consent of any third party that cannot be obtained after the use of commercially reasonable efforts to obtain such consent (in each case of clauses (1), (2) and (3), other than to the extent that any such breach, termination, default, prohibition or requirement for consent would be rendered ineffective pursuant to Sections 9-406 or 9-408 of the UCC of any relevant jurisdiction or any other applicable Law); provided that such security interest shall attach immediately to each portion of such lease, license, contract, property rights or agreement that does not result in any of the consequences specified above; and
	
 




 


	
(c)
	
prior to the occurrence of a Springing IP Event, Intellectual Property except to the extent that it is necessary under applicable law to have a Lien and security interest in any such Intellectual Property in order to have a perfected Lien and security interest in and to IP Proceeds (provided that, for avoidance of doubt, neither Agent nor any Lender shall have any right to transfer or dispose of any Intellectual Property as a result of this clause (c)), and for the avoidance of any doubt, the Collateral shall include, and Agent shall have a Lien and security interest in, (i) all IP Proceeds, (ii) all payments with respect to IP Proceeds that are received after the commencement of a bankruptcy or
	
 





	
(a)
	

	
 






7

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


insolvency proceeding and (iii) except to the extent excluded by clause (b) above, all license and sublicense agreements to which any Borrower is a party and all rights granted to such Borrower thereunder, including without limitation, the license and sublicense agreements entered into between any Borrower and Emergent in connection with the Emergent Spinoff Transaction; provided, however, that, upon the occurrence of a Springing IP Event and continuing at all times thereafter (whether or not the Springing IP Event continues), Intellectual Property shall no longer constitute “Excluded Property” pursuant to this clause (c) (but may, for the avoidance of doubt, be excluded by other clauses of this definition to the extent applicable) and the Collateral shall immediately include all Intellectual Property of each Borrower (including, for the avoidance of doubt, all IP Proceeds but excluding Intellectual Property excluded by other clauses of this definition) automatically and without notice or any further action by Agent, any Lender or any Credit Party,

 


	
 
	
(d)
	
intent to use trademark applications,




 


	
(e)
	
at all times during the Wells Fargo LC Period, the Wells Fargo LC Cash Collateral Account, all cash and cash equivalents deposited therein and all identifiable proceeds thereof,
	
 




 

provided, however, “Excluded Property” shall not include any proceeds, products, substitutions, receivables or replacements of Excluded Property (unless such proceeds, products, substitutions, receivables or replacements would otherwise constitute Excluded Property)

 

“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any intergovernmental agreement (and any associated rules or regulations promulgated thereunder) entered into in connection therewith, and any agreement entered into pursuant to Section 1471(b)(1) of the Code.

 

“FDA” means the Food and Drug Administration of the United States of America, any comparable state or local Governmental Authority, any comparable Governmental Authority in any non- United States jurisdiction, and any successor agency of any of the foregoing.

 

“FDCA” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated thereunder.

 

“Fee Letter” means each agreement between Agent and Borrower relating to fees payable to Agent, for its own account, in connection with the execution of this Agreement, including, without limitation, any amendments and restatements thereof.

 

“Financing Documents” means this Agreement, any Notes, the Security Documents, each Fee Letter, each subordination or intercreditor agreement pursuant to which any Debt and/or any Liens securing such Debt is subordinated to all or any portion of the Obligations and all other documents, instruments and agreements related to the Obligations and heretofore executed, executed concurrently herewith or executed at any time and from time to time hereafter, as any or all of the same may be amended, supplemented, restated or otherwise modified from time to time in accordance with the terms hereof.

 

“GAAP” means generally accepted accounting principles set forth from time to time in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board (or agencies with similar functions of comparable stature and authority within the United States accounting profession), which are applicable to the circumstances as of the date of determination.

 



8

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“General Intangible” means any “general intangible” as defined in Article 9 of the UCC, and any personal property, including things in action, other than accounts, chattel paper, commercial tort claims, deposit accounts, documents, goods, instruments, investment property, letter-of-credit rights, letters of credit, money, and oil, gas or other minerals before extraction, but including payment intangibles and software.

 

“Good Manufacturing Practices” means current good manufacturing practices, as set forth in  21 C.F.R. Parts 210 and 211.

 

“Governmental Authority” means any nation or government, any state, local or other political subdivision thereof, and any agency, department or Person exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government.

 

“Guarantee” by any Person means any obligation, contingent or otherwise, of such Person directly or indirectly guaranteeing any Debt or other obligation of any other Person and, without limiting the generality of the foregoing, any obligation, direct or indirect, contingent or otherwise, of such Person

(a)to purchase or pay (or advance or supply funds for the purchase or payment of) such Debt or other obligation (whether arising by virtue of partnership arrangements, by agreement to keep-well, to purchase assets, goods, securities or services, to take-or-pay, or to maintain financial statement conditions or otherwise), or (b) entered into for the purpose of assuring in any other manner the obligee of such Debt or other obligation of the payment thereof or to protect such obligee against loss in respect thereof (in whole or in part), provided, however, that the term Guarantee shall not include endorsements for collection or deposit in the Ordinary Course of Business. The term “Guarantee” used as a verb has a corresponding meaning.

 

“Guarantor” means any Credit Party that has executed or delivered, or shall in the future execute or deliver, any Guarantee of any portion of the Obligations.

 

“Hazardous Materials” means petroleum and petroleum products and compounds containing them, including gasoline, diesel fuel and oil; explosives, flammable materials; radioactive materials; polychlorinated biphenyls and compounds containing them; lead and lead-based paint; asbestos or asbestos-containing materials; underground or above-ground storage tanks, whether empty or containing any substance; any substance the presence of which is prohibited by any Environmental Laws; toxic mold, any substance that requires special handling; and any other material or substance now or in the future defined as a “hazardous substance,” “hazardous material,” “hazardous waste,” “toxic substance,” “toxic pollutant,” “contaminant,” “pollutant” or other words of similar import within the meaning of any Environmental Law, including: (a) any “hazardous substance” defined as such in (or for purposes of) CERCLA, or any so-called “superfund” or “superlien” Law, including the judicial interpretation thereof;

(b)any “pollutant or contaminant” as defined in 42 U.S.C.A. § 9601(33); (c) any material now defined as “hazardous waste” pursuant to 40 C.F.R. Part 260; (d) any petroleum or petroleum by-products, including crude oil or any fraction thereof; (e) natural gas, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel; (f) any “hazardous chemical” as defined pursuant to 29 C.F.R. Part 1910; (g) any toxic or harmful substances, wastes, materials, pollutants or contaminants (including, without limitation, asbestos, polychlorinated biphenyls, flammable explosives, radioactive materials, infectious substances, materials containing lead-based paint or raw materials which include hazardous constituents); and (h) any other toxic substance or contaminant that is subject to any Environmental Laws.

 

“Healthcare Laws” means all applicable Laws relating to the procurement, development, provision, clinical and non-clinical evaluation or investigation, product approval, manufacture, production, analysis, distribution, importation, exportation, use, handling, quality, reimbursement, sale, labeling, advertising, promotion, or postmarket requirements of any biologic, Product, or other product

 



9

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


(including, without limitation, any ingredient or component of the foregoing products) subject to regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. et seq.) and similar state or foreign laws, pharmacy laws, Medicare, Medicaid, and all Laws pursuant to which Permits are issued, in each case, as the same may be amended from time to time.

 

“Instrument” means “instrument”, as defined in Article 9 of the UCC.

 

“Intellectual Property” means all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.

 

“Intellectual Property Security Agreement” means an Intellectual Property Security Agreement in the form attached hereto as Exhibit G, which agreement shall become effective in accordance with the terms of Section 4.16(f).

 

“Interest Period” means any period commencing on the first day of a calendar month and ending on the last day of such calendar month.

 

“Inventory” means “inventory” as defined in Article 9 of the UCC.

 

“Investment” means, with respect to any Person, directly or indirectly, (a) to purchase or acquire any stock or stock equivalents, or any obligations or other securities of, or any interest in, any Person, including the establishment or creation of a Subsidiary, (b) to make or commit to make any acquisition (including through licensing) of (i) of all or substantially all of the assets of another Person, or (ii) any business, Product, business line or product line, division or other unit operation of any Person or (c) make or purchase any advance, loan, extension of credit or capital contribution to, or any other investment in, any Person.

 

“IP Proceeds” means, collectively, all cash, Accounts, license and royalty fees, claims, products, awards, judgments, insurance claims, and other revenues, proceeds or income, arising out of, derived  from or relating to any Intellectual Property of any Borrower, and any claims for damage by way of any past, present or future infringement of any Intellectual Property of any Borrower (including, without limitation, all cash, royalty fees, other proceeds, Accounts and General Intangibles that consist of rights of payment to or on behalf of a Borrower and the proceeds from the sale, licensing or other disposition of all or any part of, or rights in, any Intellectual Property by or on behalf of a Credit Party).

 

“Laws” means any and all federal, state, provincial, territorial, local and foreign statutes, laws, judicial decisions, regulations, ordinances, rules, judgments, orders, decrees, codes, injunctions, permits, governmental agreements and governmental restrictions, whether now or hereafter in effect, which are applicable to any Credit Party in any particular circumstance. “Laws” includes, without limitation, Healthcare Laws and Environmental Laws.

 

“Lender” means each of (a) MCF, in its capacity as a lender hereunder, (b) each other Person party hereto in its capacity as a lender hereunder, (c) each other Person that becomes a party hereto as Lender pursuant to and as permitted by Section 11.17, and (d) the respective successors of all of the foregoing, and “Lenders” means all of the foregoing.

 



10

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“LIBOR Rate” means, for each Loan, a per annum rate of interest equal to the greater of (a) one half of one percent (0.5)% and (b) the rate determined by Agent (rounded upwards, if necessary, to the next 1/100th%) by dividing (i) the Base LIBOR Rate for the Interest Period, by (ii) the sum of one minus the daily average during such Interest Period of the aggregate maximum reserve requirement (expressed as a decimal) then imposed under Regulation D of the Board of Governors of the Federal Reserve System (or any successor thereto) for “Eurocurrency Liabilities” (as defined therein).

 

“Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind, in respect of such asset. For the purposes of this Agreement and the other Financing Documents, any Borrower or any Subsidiary shall be deemed to own subject to a Lien any asset which it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such asset.

 

“Litigation” means any action, suit or proceeding before any court, mediator, arbitrator or Governmental Authority.

 

“Loan Account” has the meaning set forth in Section 2.6(b).

 

“Loan(s)” means the Term Loan and each and every advance under the Term Loan. All references herein to the “making” of a Loan or words of similar import shall mean, with respect to the Term Loan, the making of any advance in respect of a Term Loan.

 

“Market Withdrawal” means a Person’s Removal or Correction of a distributed product which involves a minor violation that would not be subject to legal action by the FDA or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc.

 

“Material Adverse Effect” means with respect to any event, act, condition or occurrence of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding), whether singly or in conjunction with any other event or events, act or acts, condition or conditions, occurrence or occurrences, whether or not related, a material adverse change in, or a material adverse effect upon, any of (a) the condition (financial or otherwise), operations, business, properties or prospects of any of the Credit Parties, (b) the rights and remedies of Agent or Lenders under any Financing Document, or the ability of any Credit Party to perform any of its obligations under any Financing Document to which it is a party, (c) the legality, validity or enforceability of any Financing Document, (d) the existence or perfection of any security interest granted in any Financing Document,

(e) the value of any material Collateral, or (f) a material impairment of the prospect of repayment of any portion of the Obligations.

 

“Material Contracts” means (a) the Operative Documents, (b) Subordinated Debt Documents,

(c)the agreements listed on Schedule 3.17, (d) [reserved] (e) the Venus Purchase Documents, and (f) any agreement or contract to which such Credit Party or its Subsidiaries is a party the loss or termination of which would reasonably be expected to result in a Material Adverse Effect.

 

“Material Intangible Assets” means all of (i) Borrower’s Intellectual Property and (ii) license or sublicense agreements or other agreements with respect to rights in Intellectual Property, in each case that are material to the condition (financial or other), business or operations of Borrower.

 

“Maturity Date” means the date that is February 1, 2023. “Maximum Lawful Rate” has the meaning set forth in Section 2.7.

 



11

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“MCF” means MidCap Financial Trust, a Delaware statutory trust, and its successors and permitted assigns.

 

“Medicaid” means the medical assistance programs administered by state agencies and approved by CMS pursuant to the terms of Title XIX of the Social Security Act, codified at 42 U.S.C. 1396 et seq.

 

“Medicare” means the program of health benefits for the aged and disabled administered by CMS pursuant to the terms of Title XVIII of the Social Security Act, codified at 42 U.S.C. 1395 et seq.

 

“Multiemployer Plan” means a multiemployer plan within the meaning of Section 4001(a)(3) of ERISA to which any Borrower or any other member of the Controlled Group (or any Person who in the last five years was a member of the Controlled Group) is making or accruing an obligation to make contributions or has within the preceding five plan years (as determined on the applicable date of determination) made contributions.

 

“Net Commercial Product Revenue” has the meaning set forth in Section 6.1. “Notes” has the meaning set forth in Section 2.3.

“Notice of Borrowing” means a notice of a Responsible Officer of Borrower Representative, appropriately completed and substantially in the form of Exhibit D hereto.

 

“Obligations” means all obligations, liabilities and indebtedness (monetary (including, without limitation, the payment of interest and other amounts arising after the commencement of any case with respect to any Credit Party under the Bankruptcy Code or any similar statute which would accrue and become due but for the commencement of such case, whether or not such amounts are allowed or allowable in whole or in part in such case) or otherwise) of each Credit Party under this Agreement or any other Financing Document, in each case howsoever created, arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing, or due or to become due.

 

“OFAC” means the U.S. Department of Treasury Office of Foreign Assets Control.

 

“OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

 

“Operative Documents” means the Financing Documents and the Emergent Spinoff Documents. “Original Credit Agreement” has the meaning set forth in the Recitals hereto.

“Original Closing Date” has the meaning set forth in the Recitals hereto.

 

“Ordinary Course of Business” means, in respect of any transaction involving any Credit Party, the ordinary course of business of such Credit Party, as conducted by such Credit Party in a manner consistent with past practices in all material respects.

 

“Organizational Documents” means, with respect to any Person other than a natural person, the documents by which such Person was organized (such as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without limitation, any certificates of designation for preferred stock or other forms of preferred equity) and which relate to the internal

 



12

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


governance of such Person (such as by-laws, a partnership agreement or an operating agreement, joint venture agreement, limited liability company agreement or members agreement), including any and all shareholder agreements or voting agreements relating to the capital stock or other equity interests of such Person.

 

“Participant Register” has the meaning set for in Section 11.17(a)(iii).

 

“Payment Account” means the account specified on the signature pages hereof into which all payments by or on behalf of each Borrower to Agent under the Financing Documents shall be made, or such other account as Agent shall from time to time specify by notice to Borrower Representative.

 

“Payment Notification” means a written notification substantially in the form of Exhibit E

hereto.

 

“PBGC” means the Pension Benefit Guaranty Corporation and any Person succeeding to any or all of its functions under ERISA.

 

“Pension Plan” means any ERISA Plan that is subject to Section 412 of the Code or Title IV of

ERISA.

 

“Perfection Certificate” means the Perfection Certificate delivered to Agent as of the Closing Date, together with any amendments thereto required under this Agreement.

 

“Permit” means all licenses, certificates, accreditations, product approvals, provider numbers or provider authorizations, supplier numbers, marketing authorizations, drug authorizations and approvals, other authorizations, registrations, permits, consents and approvals required under an applicable Law to be held by a Credit Party, and which are issued or required under Laws applicable to the business of Borrower or any of its Subsidiaries or necessary in the manufacturing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution or delivery of goods or services under Laws applicable to the business of Borrower or any of its Subsidiaries. Without limiting the generality of the foregoing, “Permit” includes any Regulatory Required Permit.

 

“Permitted Asset Dispositions” means the following Asset Dispositions, provided, however, that at the time of such Asset Disposition, no Default or Event of Default exists or would result from such Asset Disposition:

 


	
 
	
(a)
	
dispositions of Inventory in the Ordinary Course of Business and not pursuant to




any bulk sale;

 


	
(b)
	
dispositions of furniture, fixtures and equipment in the Ordinary Course of Business that the applicable Borrower or Subsidiary determines in good faith is no longer used or useful in, or is surplus to, the business of such Borrower and its Subsidiaries;
	
 




 


	
 
	
(c)
	
dispositions consisting of, or entry into, Permitted Licenses;




 


	
(d)
	
dispositions of obsolete or worn out furniture, fixtures and equipment, whether now owned or hereafter acquired, in the Ordinary Course of Business;
	
 




 


	
 
	
(e)
	
dispositions approved by Agent;





	
 
	
(a)
	







13

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(f)
	
the abandonment in the Ordinary Course of Business of Intellectual Property (other than Material Intangible Assets) that is no longer used or useful to Borrowers or their  Subsidiaries;
	
 




 


	
(g)
	
dispositions of Accounts to a third party in connection with the compromise, settlement or collection thereof in the Ordinary Course of Business exclusive of factoring or similar arrangements;
	
 




 


	
 
	
(h)
	
the termination of Swap Contracts in the Ordinary Course of Business;




 


	
(i)
	
the expiration or termination of the license for a monoclonal antibody therapeutic that is currently in pre-clinical development for Alzheimer’s disease and
	
 




 


	
(j)
	
dispositions of assets other than those described in clauses (a) through (i) above for cash at fair value if all of the following conditions are met: (i) the assets are not Intellectual Property,
	
 




(ii) the applicable Borrower or Subsidiary determines in good faith is no longer used or useful in the business of such Borrower and its Subsidiaries, (iii) the market value of assets sold or otherwise disposed of in any single transaction or series of related transactions does not exceed $250,000 and the aggregate market value of the assets sold or otherwise disposed of in any fiscal year does not exceed $500,000 and

(iv)the net cash proceeds of such disposition are applied to the extent required by Section 2.1(a)(ii)(B)(iii).

 

“Permitted Contest” means, with respect to any tax obligation or other obligation allegedly or potentially owing from any Borrower or its Subsidiary to any governmental tax authority or other third party, a contest maintained in good faith by appropriate proceedings promptly instituted and diligently conducted and with respect to which such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall have been made on the books and records and financial statements of the applicable Credit Party(ies); provided, however, that (a) compliance with the obligation that is the subject of such contest is effectively stayed during such challenge; (b) Borrowers’ and their Subsidiaries’ title to, and its right to use, the Collateral is not adversely affected thereby and Agent’s Lien and priority on the Collateral are not adversely affected, altered or impaired thereby; (c) Borrowers have given Agent notice of the commencement of such contest and upon request by Agent, from time to time, notice of the status of such contest by Borrowers and/or confirmation of the continuing satisfaction of this definition; (d) the Collateral or any part thereof or any interest therein shall not be in any danger of being sold, forfeited or lost by reason of such contest by Borrowers or their Subsidiaries; and (e) upon a final determination of such contest, Borrowers and their Subsidiaries shall promptly comply with the requirements thereof.

 

“Permitted Contingent Obligations” means

 


	
(a)
	
Contingent Obligations arising in respect of the Debt under the Financing Documents or with respect to other Permitted Debt (other than pursuant to clause (k) of the definition thereof), provided that (i) any such Contingent Obligation is subordinated to the Obligations to the same extent as the Debt to which it relates is subordinated to the Obligations and (ii) no Credit Party may incur Contingent Obligations under this clause (a) in respect of Debt incurred by any Person that is not a Borrower or Guarantor;
	
 




 


	
(b)
	
Contingent Obligations resulting from endorsements for collection or deposit in the Ordinary Course of Business;
	
 





	
(a)
	

	
 






14

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(c)
	
Contingent Obligations outstanding on the Closing Date and set forth on Schedule 5.1 (including any Permitted Refinancings thereof);
	
 




 


	
(d)
	
Contingent Obligations incurred in the Ordinary Course of Business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed
	
 




$250,000 in the aggregate at any time outstanding;

 


	
(e)
	
Contingent Obligations arising under indemnity agreements with title insurers to cause such title insurers to issue title insurance policies;
	
 




 


	
(f)
	
Contingent Obligations arising with respect to customary indemnification obligations in favor of purchasers in connection with dispositions of personal property assets permitted under Section 5.6;
	
 




 


	
(g)
	
so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Contingent Obligations existing or arising under any Swap Contract, provided, however, that such obligations are (or were) entered into by Borrower or an Affiliate in the Ordinary Course of Business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation;
	
 




 


	
(h)
	
Contingent Obligations of Borrower, incurred during the Wells Fargo LC Period under or pursuant to the Wells Fargo Standby Letter of Credit Agreement in respect of the Wells Fargo Letters of Credit, provided that the aggregate amount of such Contingent Obligations shall not, at any time, when combined with the Debt set forth in clause (i) of the definition of “Permitted Debt”, exceed
	
 




$3,500,000; and

 


	
(i)
	
other Contingent Obligations not permitted by clauses (a) through (g) above, not to exceed $250,000 in the aggregate at any time outstanding.
	
 




 

“Permitted Debt” means:

 


	
(a)
	
Borrowers’ and their Subsidiaries’ Debt to Agent and each Lender under this Agreement and the other Financing Documents;
	
 




 


	
(b)
	
Debt incurred as a result of endorsing negotiable instruments received in the Ordinary Course of Business;
	
 




 


	
(c)
	
purchase money Debt and capital leases not to exceed $1,000,000 at any time (whether in the form of a loan or a lease) used solely to acquire equipment used in the Ordinary Course of Business and secured only by such equipment;
	
 




 


	
(d)
	
Debt existing on the Closing Date and described on Schedule 5.1 (including any Permitted Refinancings thereof);
	
 




 


	
(e)
	
so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Debt existing or arising under any Swap Contract, provided, however, that such obligations are (or were) entered into by Borrower or an Affiliate in the Ordinary Course of Business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation;
	
 





	
(a)
	

	
 






15

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(f)
	
Debt in the form of insurance premiums financed through the applicable insurance company;
	
 




 


	
 
	
(g)
	
trade accounts payable arising and which do not remain unpaid more than ninety




(90) days past the invoice date and in the Ordinary Course of Business, or which are the subject of a Permitted Contest;

 


	
(h)
	
without limiting the provisions of Section 5.7 with respect to any Investment by a Credit Party, Debt consisting of unsecured intercompany loans and advances (i) incurred by any Borrower owing to one or more other Borrowers, or (ii) incurred by any Excluded Foreign Subsidiary owing to any Borrower in an amount for all Excluded Foreign Subsidiaries not to exceed $600,000 incurred in any fiscal year;
	
 




 


	
(i)
	
Debt of Borrower, incurred during the Wells Fargo LC Period under or pursuant to the Wells Fargo Standby Letter of Credit Agreement in respect of the Wells Fargo Letters of Credit, provided that the aggregate amount of such Debt shall not, at any time, when combined with the Contingent Obligations set forth in clause (h) of the definition of “Permitted Contingent Obligations”, exceed $3,500,000;
	
 




 


	
 
	
(j)
	
any Subordinated Debt;




 


	
 
	
(k)
	
Debt consisting of Permitted Contingent Obligations;




 


	
(l)
	
intercompany Debt arising from loans made (i) by a Borrower or Secured Guarantor to another Borrower or Secured Guarantor, (ii) by a non-Credit Party Subsidiary of a Borrower to another non-Credit Party Subsidiary of a Borrower, or (iii) any non-Credit Party Subsidiary to a Credit Party (so long as such Debt is subordinated to the Obligations owed by the Credit Parties under the Financing Documents);
	
 




 


	
 
	
(m)
	
the Separation Obligations;




 


	
 
	
(n)
	
Debt arising from the honoring of an Instrument drawn against insufficient




funds;

 


	
(o)
	
Debt related to commercial credit cards that, in the aggregate outstanding at any one time, does not exceed $400,000, which Debt may be secured by Liens permitted pursuant to clause
	
 





	
 
	
(l)
	
of the definition of Permitted Liens;




 


	
(p)
	
Debt in respect of taxes, assessments, or government charges to the extent not resulting in an Event of Default and which is the subject of a Permitted Contest; and
	
 




 


	
(q)
	
unsecured debt not included in clauses (a) through (p) above that in the aggregate outstanding at any time does not exceed $500,000.
	
 




 

“Permitted Distributions” means the following Distributions: (a) dividends by any Subsidiary of any Borrower or Secured Guarantor to such parent Borrower or Secured Guarantor; (b) dividends payable solely in common stock; and (c) repurchases of stock of former employees, directors or consultants pursuant to stock purchase agreements so long as an Event of Default does not exist at the time of such repurchase and would not exist after giving effect to such repurchase, provided, however, that such repurchase does not exceed $250,000 in the aggregate per fiscal year.

 



16

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Permitted Investments” means:

 


	
 
	
(a)
	
Investments shown on Schedule 5.7 and existing on the Closing Date;




 


	
 
	
(b)
	
cash and cash equivalents;




 


	
(c)
	
Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the Ordinary Course of Business;
	
 




 


	
(d)
	
Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the Ordinary Course of Business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrowers or their Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrowers’ Board of Directors  (or other governing body), but the aggregate of all such loans outstanding may not exceed $250,000 at any time;
	
 




 


	
(e)
	
Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the Ordinary Course of Business;
	
 




 


	
(f)
	
Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the Ordinary Course of Business, provided, however, that this subpart (f) shall not apply to Investments of Borrowers in any Subsidiary;
	
 




 


	
(g)
	
Investments consisting of Deposit Accounts in which Agent has received a Deposit Account Control Agreement (other than Excluded Accounts to the extent Borrower is compliance with the provisions set forth in Section 5.14);
	
 




 


	
(h)
	
Investments by any Borrower in any Subsidiary now owned or hereafter created by such Borrower, which Subsidiary is a Borrower or has provided a Guarantee of the Obligations of the Borrowers which Guarantee is secured by a Lien granted by such Subsidiary to Agent in all or substantially all of its property of the type described in Schedule 9.1 hereto and otherwise made in compliance with Section 4.11(d);
	
 




 


	
(i)
	
Investments by any Borrower or Secured Guarantor in another Borrower or Secured Guarantor;
	
 




 


	
(j)
	
Investments of cash and cash equivalents in an Excluded Foreign Subsidiary (either directly or through an Excluded Domestic Holdco) but solely to the extent that the aggregate amount of such Investments with respect to all Excluded Foreign Subsidiaries does not, at any time, exceed $600,000 in the aggregate in any fiscal year; provided that in no event shall the aggregate amount of Investments made in any Excluded Foreign Subsidiary exceed the amount necessary (as reasonably determined by the Borrowers) to fund the current and projected annual operating expenses of such Excluded Foreign Subsidiary (taking into account its revenue from other sources);
	
 




 


	
(k)
	
Investments by any Excluded Foreign Subsidiary or Excluded Domestic Holdco in any other Excluded Foreign Subsidiary or Excluded Domestic Holdco;
	
 




 


	
 
	
(l)
	
to the extent constituting an Investment, the entering into of any Permitted




License;

 



17

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(m)
	
in-licenses by Borrowers or their Subsidiaries of Intellectual Property (and rights thereto) and other technology solely in furtherance of preclinical research and development in the areas of hematology, infectious diseases and immuno-oncology (it being understood that Borrower shall not be prohibited from maintaining such an in-license if, after such in-license is entered into, the research and development undertaken in connection with such in-license becomes clinical in nature);
	
 




 


	
(n)
	
Investments consisting of extensions of credit in the nature of Accounts or notes receivable arising from the grant of trade credit in the Ordinary Course of Business; and
	
 




 

(o)other Investments in an amount not exceeding $500,000 in the aggregate. “Permitted License” means:


	
(a)
	
any license or sublicense of Intellectual Property rights (including licenses or sublicenses thereto) of a Credit Party to a Borrower or Secured Guarantor;
	
 




 


	
(b)
	
any non-exclusive license or sublicense of Intellectual Property rights (including licenses or sublicenses thereto) of Borrower or its Subsidiaries so long as all such licenses are granted to third parties or Subsidiaries in the Ordinary Course of Business, do not result in a legal transfer of title to the licensed property, and (except in the case of non-exclusive licenses by a Credit Party to a Subsidiary thereof) have been granted in exchange for fair consideration;
	
 




 


	
(c)
	
any exclusive license or sublicense of Intellectual Property rights (including licenses or sublicenses thereto) of Borrower or its Subsidiaries to a  third party so long as such licenses do not result in a legal transfer of title to the licensed property, are exclusive solely as to discrete geographical areas outside of North America, and have been granted in exchange for fair consideration;
	
 




 


	
(d)
	
any exclusive license or sublicense of Intellectual Property rights (including licenses or sublicenses thereto) of Borrower or its Subsidiaries to a third party to the extent such Intellectual Property rights relate solely to preclinical Products (not, for the avoidance of doubt, clinical Products, Commercial Products or any other commercial Product) and so long as such licenses do not result in a legal transfer of title to the licensed property and have been granted in exchange for fair consideration; and
	
 




 


	
(e)
	
to the extent not otherwise permitted pursuant to clauses (a)-(d) above, any exclusive license or sublicense of Intellectual Property rights (including licenses or sublicenses thereto) of Borrower or its Subsidiaries to a third party to the extent such Intellectual Property rights relate solely to clinical Products (not, for the avoidance of doubt, Commercial Products or any other commercial Product) and so long as such licenses do not result in a legal transfer of title to the licensed property and have been granted in exchange for fair consideration; provided that, in each case, either (i)(x)Borrower has provided Agent copies of the proposed license documentation and such other information as Agent may reasonably request related to such license at least five (5) Business Days prior to Borrower’s entry into such license and (y) Agent has consented to Borrower’s (or its Subsidiary’s) entry into such license; or (ii) Borrower has prepaid the Term Loans in accordance with Section 2.1(a)(ii)(B)(iv) on the date Borrower or its Subsidiary enters into such license.
	
 




 

“Permitted Liens” means:

 


	
(a)
	
deposits or pledges of cash to secure obligations under workmen’s compensation, social security or similar laws, or under unemployment insurance (but excluding Liens
	
 





	
(a)
	

	
 






18

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


arising under ERISA or, with respect to any Pension Plan or Multiemployer Plan, the Code) pertaining to a Borrower’s or its Subsidiary’s employees, if any;

 


	
(b)
	
deposits or pledges of cash to secure bids, tenders, contracts (other than contracts for the payment of money or the deferred purchase price of property or services), leases, statutory obligations, surety and appeal bonds and other obligations of like nature arising in the Ordinary Course of Business;
	
 




 


	
(c)
	
carrier’s, warehousemen’s, mechanic’s, workmen’s, materialmen’s or other like Liens on Collateral arising in the Ordinary Course of Business with respect to obligations which are not due, or which are being contested pursuant to a Permitted Contest;
	
 




 


	
(d)
	
Liens for taxes or other governmental charges not at the time delinquent or thereafter payable without penalty or the subject of a Permitted Contest;
	
 




 


	
(e)
	
attachments, appeal bonds, judgments and other similar Liens on Collateral for sums not exceeding $250,000 in the aggregate arising in connection with court proceedings; provided, however, that the execution or other enforcement of such Liens is effectively stayed and the claims secured thereby are the subject of a Permitted Contest;
	
 




 


	
(f)
	
with respect to real estate, easements, rights of way, restrictions, minor defects or irregularities of title, none of which, individually or in the aggregate, materially interfere with the benefits of the security intended to be provided by the Security Documents, materially affect the value or marketability of the Collateral, impair the use or operation of the Collateral for the use currently being made thereof or impair Borrowers’ ability to pay the Obligations in a timely manner or impair the use of the Collateral or the ordinary conduct of the business of any Borrower or any Subsidiary and which, in the case of any real estate that is part of the Collateral, are set forth as exceptions to or subordinate matters in the title insurance policy accepted by Agent insuring the lien of the Security Documents;
	
 




 


	
 
	
(g)
	
Liens and encumbrances in favor of the Agent under the Financing Documents;




 


	
(h)
	
Liens existing on the Closing Date and set forth on Schedule 5.2 (including any Permitted Refinancings thereof);
	
 




 


	
(i)
	
any Lien on any equipment securing Debt permitted under subpart (c) of the definition of Permitted Debt, provided, however, that such Lien attaches concurrently with or within twenty (20) days after the acquisition thereof;
	
 




 


	
(j)
	
Liens for Taxes or that are the subject of a Permitted Contest or statutory Liens for Taxes that are not yet due;
	
 




 


	
(k)
	
precautionary financing statements in connection with operating leases or consigned goods in the Ordinary Course of Business;
	
 




 


	
(l)
	
Liens in favor of Wells Fargo in respect of the Wells Fargo Cash Collateral Account and amounts therein solely to secure obligations of Borrower in respect of credit cards provided by Wells Fargo to Borrower;
	
 




 


	
(m)
	
during the Wells Fargo LC Period, Liens on the Wells Fargo LC Cash Collateral Account and the cash and cash equivalents deposited therein, in an aggregate amount not to exceed
	
 





	
(a)
	

	
 






19

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


$3,500,000, securing Borrower’s obligations under the Wells Fargo Standby Letter of Credit Agreement and the Wells Fargo Letters of Credit;

 


	
 
	
(n)
	
to the extent constituting the granting of a Lien, the making of a Permitted Asset




Disposition.

 

“Permitted Modifications” means (a) such amendments or other modifications to a Borrower’s or Subsidiary’s Organizational Documents as are required under this Agreement or by applicable Law and fully disclosed to Agent within thirty (30) days after such amendments or modifications have become effective, and (b) such amendments or modifications to a Borrower’s or Subsidiary’s Organizational Documents (other than those involving a reorganization of a Borrower or Subsidiary under the laws of a different jurisdiction) that would not adversely affect the rights and interests of Agent or Lenders and fully disclosed to Agent within thirty (30) days after such amendments or modifications have become effective.

 

“Permitted Refinancing” means Debt constituting a refinancing or extension of Debt permitted under clauses (c) or (d) of the definition of Permitted Debt and that (a) has an aggregate outstanding principal amount not greater than the aggregate principal amount of the Debt being refinanced or extended, (b) has a weighted average maturity (measured as of the date of such refinancing or extension) and maturity no shorter than that of the Debt being refinanced or extended, (c) is not entered into as part of a sale leaseback transaction, (d) is not secured by a Lien on any assets other than the collateral securing the Debt being refinanced or extended, (e) the obligors of which are the same as the obligors of the Debt being refinanced or extended and (f) is otherwise on terms no less favorable to Credit Parties and their Subsidiaries, taken as a whole, than those of the Debt being refinanced or extended.

 

“Person” means any natural person, corporation, limited liability company, professional association, limited partnership, general partnership, joint stock company, joint venture, association, company, trust, bank, trust company, land trust, business trust or other organization, whether or not a  legal entity, and any Governmental Authority.

 

“Products” means, from time to time, any products currently manufactured, sold, developed, tested or marketed by any Borrower or any of its Subsidiaries.

 

“Pro Rata Share” means (a) with respect to a Lender’s obligation to make advances in respect of a Term Loan and such Lender’s right to receive payments of principal and interest with respect to the Term Loans, the Term Loan Commitment Percentage of such Lender, and (b) for all other purposes (including, without limitation, the indemnification obligations arising under Section 11.6) with respect to any Lender, the percentage obtained by dividing (i) the Term Loan Commitment Amount of such Lender (or, in the event the Term Loan Commitment shall have been terminated, such Lender’s then outstanding principal advances of such Lender under the Term Loan), by (ii) the sum of the Term Loan Commitment (or, in the event the Term Loan Commitment shall have been terminated, the then outstanding principal advances of such Lenders under the Term Loan) of all Lenders.

 

“Recall” means a Person’s removal or Correction of a marketed product that the FDA considers to be in violation of the laws it administers and against which the FDA would initiate legal action, e.g., seizure.

 

“Register” has the meaning set forth in Section 11.17(a)(iii).

 

“Registered Intellectual Property” means any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing.

 



20

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Regulatory Reporting Event” has the meaning set forth in Section 4.17.

 

“Regulatory Required Permit” means any and all licenses, approvals and permits issued by the FDA, or any other applicable Governmental Authority, including without limitation Drug Applications, necessary for the testing, manufacture, marketing or sale of any Product by any applicable Borrower(s) and its Subsidiaries as such activities are being conducted by such Borrower and its Subsidiaries with respect to such Product at such time and any drug listings and drug establishment registrations under 21

U.S.C. Section 510 as may be required under applicable Laws, and those issued by State governments for the conduct of Borrower’s or any Subsidiary’s business.

 

“Required Lenders” means at any time Lenders holding (a) fifty percent (50%) or more of the sum of the Term Loan Commitment (taken as a whole), or (b) if the Term Loan Commitment has been terminated, fifty percent (50%) or more of the then aggregate outstanding principal balance of the Loans.

 

“Responsible Officer” means any of the Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Treasurer, Comptroller, Vice President of Finance, or any other officer of the  applicable Borrower reasonably acceptable to Agent.

 

“SEC” means the United States Securities and Exchange Commission.

 

“Secured Guarantor” means any Credit Party that has executed or delivered, or shall in the future execute or deliver to Agent, any Guarantee of all or any portion of the Obligations, the obligations under which are secured by all or substantially all of its property of the type described in Schedule 9.1 hereto (other than Excluded Property).

 

“Securities Account” means a “securities account” (as defined in Article 9 of the UCC), an investment account, or other account in which investment property or securities are held or invested for credit to or for the benefit of any Borrower.

 

“Securities Account Control Agreement” means an agreement, in form and substance reasonably satisfactory to Agent, among Agent, any applicable Borrower and each securities intermediary in which such Borrower maintains a Securities Account pursuant to which Agent shall obtain “control” (as defined in Article 9 of the UCC) over such Securities Account.

 

“Security Document” means this Agreement, the Intellectual Property Security Agreement and any other agreement, document or instrument executed concurrently herewith or at any time hereafter pursuant to which one or more Credit Parties or any other Person either (a) Guarantees payment or performance of all or any portion of the Obligations, and/or (b) provides, as security for all or any portion of the Obligations, a Lien on any of its assets in favor of Agent for its own benefit and the benefit of the Lenders, as any or all of the same may be amended, supplemented, restated or otherwise modified from time to time in accordance with the terms hereof.

 

“Separation Obligations” means indemnification obligations of the Borrower and/or its Subsidiaries in favor of Emergent and/or its subsidiaries in connection with the Emergent Spinoff Transaction under the Emergent Spinoff Documents.

 

“Solvent” means, with respect to any Person, that such Person (a) owns and will own assets the fair saleable value of which are (i) greater than the total amount of its debts and liabilities (including subordinated and Contingent Obligations), and (ii) greater than the amount that will be required to pay the probable liabilities of its then existing debts as they become absolute and matured considering all financing alternatives and potential asset sales reasonably available to it; (b) has capital that is not

 



21

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


unreasonably small in relation to its business as presently conducted or after giving effect to any contemplated transaction; and (c) does not intend to incur and does not believe that it will incur debts beyond its ability to pay such debts as they become due.

 

“Springing IP Event” means that, on any date, the Borrowers have allowed, as of the close of business on any day, the aggregate Borrower Unrestricted Cash to be less than $25,000,000.

 

“Stated Rate” has the meaning set forth in Section 2.7.

 

“Subordinated Debt” means any Debt of Borrowers incurred pursuant to the terms of the Subordinated Debt Documents and with the prior written consent of Agent, all of which documents must be in form and substance acceptable to Agent in its sole discretion. As of the Closing Date, there is no Subordinated Debt.

 

“Subordinated Debt Documents” means any documents evidencing and/or securing Debt governed by a Subordination Agreement, all of which documents must be in form and substance acceptable to Agent in its sole discretion. As of the Closing Date, there are no Subordinated Debt Documents.

 

“Subordination Agreement” means any agreement between Agent and another creditor of Borrowers, as the same may be amended, supplemented, restated or otherwise modified from time to time in accordance with the terms thereof, pursuant to which the Debt owing from any Borrower(s) and/or the Liens securing such Debt granted by any Borrower(s) to such creditor are subordinated in any way to the Obligations and the Liens created under the Security Documents, the terms and provisions of such Subordination Agreements to have been agreed to by and be acceptable to Agent in the exercise of its sole discretion.

 

“Subsidiary” means, with respect to any Person, (a) any corporation of which an aggregate of more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, capital stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned legally or beneficially by such Person or one or more Subsidiaries of such Person, or with respect to which any such Person has the right to vote or designate the vote of more than fifty percent (50%) of such capital stock whether by proxy, agreement, operation of law or otherwise, and (b) any partnership or limited liability company in which such Person and/or one or more Subsidiaries of such Person shall have an interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%) or of which any such Person is a general partner or may exercise the powers of a general partner. Unless the context otherwise requires, each reference to a Subsidiary shall be a reference to a Subsidiary of a Borrower.

 

“Swap Contract” means any “swap agreement”, as defined in Section 101 of the Bankruptcy Code, that is obtained by Borrower to provide protection against fluctuations in interest or currency exchange rates, but only if Agent provides its prior written consent to the entry into such “swap agreement”.

 

“Taxes” has the meaning set forth in Section 2.8.

 

“Termination Date” means the earlier to occur of (a) the Maturity Date, (b) any date on which Agent accelerates the maturity of the Loans pursuant to Section 10.2, or (c) the termination date stated in any notice of termination of this Agreement provided by Borrowers in accordance with Section 2.12.

 



22

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Term Loan” has the meaning set forth in Section 2.1(a)(i).

 

“Term Loan Commitment” means the sum of each Lender’s Term Loan Commitment Amount, which is equal to $20,000,000.00 in the aggregate for all such Lender’s as of the Closing Date.

 

“Term Loan Commitment Amount” means, (a) as to any Lender that is a Lender on the Closing Date, the dollar amount set forth opposite such Lender’s name on the Commitment Annex under the column “Term Loan Commitment Amount”, as such amount may be adjusted from time to time by any amounts assigned (with respect to such Lender’s portion of Term Loans outstanding and its commitment to make advances in respect of the Term Loan) pursuant to the terms of any and all effective assignment agreements to which such Lender is a party, and (b) as to any Lender that becomes a Lender after the Closing Date, the amount of the “Term Loan Commitment Amount(s)” of other Lender(s) assigned to such new Lender pursuant to the terms of the effective assignment agreement(s) pursuant to which such new Lender shall become a Lender, as such amount may be adjusted from time to time by any amounts assigned (with respect to such Lender’s portion of Term Loans outstanding and its commitment to make advances in respect of the Term Loan) pursuant to the terms of any and all effective assignment agreements to which such Lender is a party.

 

“Term Loan Commitment Percentage” means, as to any Lender, (a) on the Closing Date, the percentage set forth opposite such Lender’s name on the Commitment Annex under the column “Term Loan Commitment Percentage” (if such Lender’s name is not so set forth thereon, then, on the Closing Date, such percentage for such Lender shall be deemed to be zero), and (b) on any date following the Closing Date, the percentage equal to the Term Loan Commitment Amount of such Lender on such date divided by the Term Loan Commitment on such date.

 

“Third Party Payor” means Medicare, Medicaid, TRICARE, and other state or federal health care program, Blue Cross and/or Blue Shield, private insurers, managed care plans and any other Person or entity which presently or in the future maintains Third Party Payor Programs.

 

“Third Party Payor Programs” means all payment and reimbursement programs, sponsored by a Third Party Payor, in which a Borrower participates.

 

“TRICARE” means the program administered pursuant to 10 U.S.C. Section 1071 et. seq), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes.

 

“UCC” means the Uniform Commercial Code of the State of New York or of any other state the laws of which are required to be applied in connection with the perfection of security interests in any Collateral.

 

“United States” means the United States of America.

 

“Venus Escrow Agreement” means the “Escrow Agreement”, as defined in the Venus Purchase Agreement.

 

“Venus Purchase Agreement” means that certain LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo Therapeutics, Aptevo BioTherapeutics, Saol International Limited, a Bermuda company, and Venus BioTherapeutics Sub LLC, a Delaware limited liability company.

 



23

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


“Venus Purchase Documents” means the Venus Purchase Agreement, the Venus Escrow Agreement and each other material agreement and/or instrument executed by Borrower in connection therewith.

 

“Wells Fargo Cash Collateral Account” means that certain Deposit Account #4059551978 of Borrower at Wells Fargo established and maintained for the sole purpose of providing cash collateral in favor of Wells Fargo for obligations of Borrower in respect of certain commercial credit credits provided to Borrower by Wells Fargo; provided that the aggregate amount on deposit in such Deposit Account shall not at any time exceed $400,000.

 

“Wells Fargo LC Cash Collateral Account” means one or more certificates of deposit of Borrower maintained at Wells Fargo (including without limitation certificate of deposit number 1139862385) that are segregated from and not commingled with any other funds of Borrower or its Subsidiaries, the aggregate balance of which shall not at any time exceed 105% of the face value of the Wells Fargo Letters of Credit then outstanding, and which shall constitute the sole security for the obligations of Borrower under the Wells Fargo Standby Letter of Credit Agreement and the Wells Fargo Letters of Credit.

 

“Wells Fargo LC Period” means the period commencing on the February 23, 2018and terminating on the date Borrower receives all or substantially all of its anticipated value added tax refunds from the Italian government, the Wells Fargo Letters of Credit have expired or been terminated and the Borrower’s obligations under the Wells Fargo Standby Letter of Credit Agreement have terminated.

 

“Wells Fargo Letters of Credit” means those certain letters of credit issued during the Wells Fargo LC Period by Wells Fargo for the account of Borrowers pursuant to the Wells Fargo Standby Letter of Credit Agreement, but solely to the extent required by the beneficiary thereof in order for Borrowers to receive value added tax refunds from the Italian government; provided, however, that the aggregate face value of all such letters of credit may not exceed $3,500,000 at any time outstanding.

 

“Wells Fargo Standby Letter of Credit Agreement” means that certain Standby Letter of Credit Agreement, dated as of February 23, 2018, pursuant to which Wells Fargo has agreed to issue letters of credit for the account of Borrower and Borrower has agreed to reimburse Wells Fargo for amounts drawn under such letters of credit, as amended, supplemented or otherwise modified from time  to time in accordance with the terms hereof and thereof.

 

Section 1.2 Accounting Terms and Determinations. Unless otherwise specified herein, all accounting terms used herein shall be interpreted, all accounting determinations hereunder (including, without limitation, determinations made pursuant to the exhibits hereto) shall be made, and all financial statements required to be delivered hereunder shall be prepared on a consolidated basis in accordance with GAAP applied on a basis consistent  with the most recent audited consolidated financial statements of each Borrower and its Consolidated Subsidiaries delivered to Agent on or prior to the Closing Date. If at any time any change in GAAP would affect the computation of any financial ratio or financial requirement set forth in any Financing Document, and either Borrowers or the Required Lenders shall so request, Agent, the Lenders and Borrowers shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP; provided, however, that until so amended, (a) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (b) Borrowers shall provide to Agent and the Lenders financial statements and other documents required under this Agreement which include a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. Any obligations of a Person under a lease (whether existing now or entered into in the future) that is not (or would not be) a capital lease obligation under GAAP as in effect prior to giving effect to FASB

 



24

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Accounting Standards Update No. 2016-02, Leases, shall not be treated as a capital lease obligation solely as a result of the adoption of changes in GAAP. Notwithstanding any other provision contained herein,  all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made, without giving effect to any election under Statement of Financial Accounting Standards 159 (or any other Financial Accounting Standard having a similar result or effect) to value any Debt or other liabilities of any Credit Party or any Subsidiary of any Credit Party at “fair value”, as defined therein.

 

Section 1.3 Other Definitional and Interpretive Provisions. References in this Agreement to “Articles”, “Sections”, “Annexes”, “Exhibits”, or “Schedules” shall be to Articles, Sections, Annexes, Exhibits or Schedules of or to this Agreement unless otherwise specifically provided. Any term defined herein may be used in the singular or plural. “Include”, “includes” and “including” shall be deemed to be followed by “without limitation”. Except as otherwise specified or limited herein, references to any Person include the successors and assigns of such Person. References “from” or “through” any date  mean, unless otherwise specified, “from and including” or “through and including”, respectively. Unless otherwise specified herein, the settlement of all payments and fundings hereunder between or among the parties hereto shall be made in lawful money of the United States and in immediately available funds. References to any statute or act shall include all related current regulations and all amendments to such statutes, acts and regulations, and any successor statutes, acts and regulations. All amounts used for purposes of financial calculations required to be made herein shall be without duplication. References to any statute or act, without additional reference, shall be deemed to refer to federal statutes and acts of the United States. References to any agreement, instrument or document shall include all schedules, exhibits, annexes and other attachments thereto. References to any agreement, instrument or document shall include all amendments thereto, to the extent permitted herby. As used in this Agreement, the meaning of the term “material” or the phrase “in all material respects” is intended to refer to an act, omission, violation or condition which reflects or would reasonably be expected to result in a Material Adverse Effect. References to capitalized terms that are not defined herein, but are defined in the UCC, shall have the meanings given them in the UCC. All references herein to times of day shall be references to daylight or standard time, as applicable.

 

ARTICLE 2 - LOANS

 

Section 2.1Loans.

 


	
 
	
(a)
	
Term Loans.




 


	
(i)
	
Term Loan Amounts. On the terms and subject to the conditions set  forth herein and in the other Financing Documents, each Lender with a Term Loan Commitment severally hereby agrees to make to Borrowers a term loan on the Closing Date in an original aggregate principal amount equal to the Term Loan Commitment (the “Term Loan”). Each such Lender’s obligation to fund the Term Loan shall be limited to such Lender’s Term Loan Commitment Percentage, and no Lender shall have any obligation to fund any portion of any Term Loan required to be funded by any other Lender, but not so funded. No Borrower  shall have any right to reborrow any portion of the Term Loan that is repaid or prepaid from time to time. The Term Loan shall be deemed to be funded in one advance on the Closing Date by  rolling over the outstanding principal amount of the Term Loans under (and as defined in) the Original Credit Agreement.
	
 





	
(i)
	

	
 






25

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
 
	
(ii)
	
Scheduled Repayments; Mandatory Prepayments; Optional Prepayments.




 


	
 
	
(A)
	
There shall become due and payable, and Borrowers shall repay each Term Loan through, scheduled payments as set forth on Schedule 2.1 attached hereto. Notwithstanding the payment schedule set forth above, the outstanding principal amount of each Term Loan shall become immediately due and payable in full on the Termination Date.
	
 




 


	
 
	
(B)
	
There shall become due and payable and Borrowers shall prepay the Term Loans in the following amounts and at the following times:
	
 




 


	
 
	
(i)
	
Unless Agent shall otherwise consent in writing, on the date on which any Credit Party (or Agent as loss payee or assignee) receives any casualty proceeds in excess of $250,000 with respect to assets upon which Agent maintained a Lien, an amount equal to one hundred percent (100%) of such proceeds (net of out-of-pocket expenses and repayment of secured debt permitted under clause (c) of the definition of Permitted Debt and encumbering the  property that suffered such casualty), or such lesser portion of such proceeds as Agent shall elect to apply to the Obligations;
	
 




 


	
 
	
(ii)
	
an amount equal to any interest that is deemed to be in excess of the Maximum Lawful Rate (as defined below) and is required to be applied to the reduction of the principal balance of the Loans by any Lender as provided for in Section 2.7;
	
 




 


	
 
	
(iii)
	
unless Agent shall otherwise consent in writing, upon receipt by any Credit Party of the proceeds of any Asset Disposition in excess of
	
 




$250,000 in any fiscal year that is not made in the Ordinary Course of Business, an amount equal to one hundred percent (100%) of the net cash proceeds of such asset disposition (net of out-of-pocket expenses and repayment of secured debt permitted under clause (c) of the definition of Permitted Debt and encumbering such asset), or such lesser portion as Agent shall elect to apply to the Obligations;

 


	
 
	
(iv)
	
if Borrower or any of its Subsidiaries enters into any Permitted License pursuant to clause (e)(ii) of the definition thereof, Borrower shall prepay the Term Loans in an amount equal to the greater of (x) fifty (50%) of the aggregate upfront consideration received by Borrower in connection with its entering into such license and (y) thirty-five percent (35%) of the aggregate outstanding principal balance of the Term Loans on the date Borrower enters into such license; provided that in no event shall the prepayment required to be made by Borrower pursuant to this Section 2.1(a)(ii)(B)(iv) with respect to any single Permitted License exceed (x) an amount equal to fifty percent (50%) of the aggregate outstanding principal balance of the Term Loans on the date Borrower enters into such Permitted License or (y) the aggregate upfront consideration recorded by Borrower in connection with entering into such Permitted License;
	
 




 

Notwithstanding clause (B)(i) and (B)(iii) above, respectively, the foregoing and so long as no Event of Default then exists: (1) any such casualty proceeds may be used by Borrowers within two hundred seventy (270) days from the receipt of such proceeds to replace or repair any assets in respect of which such proceeds were paid so long as prior to the receipt of such proceeds, Borrowers have delivered to Agent a reinvestment plan

 



26

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


detailing such replacement or repair; and (2) proceeds of asset dispositions that are not made in the Ordinary Course of Business may be used by Borrowers within two hundred seventy (270) days from the receipt of such proceeds to purchase new or replacement assets of comparable value; and

 


	
 
	
(C)
	
Borrowers may from time to time, with at least five (5) Business Days prior delivery to Agent of an appropriately completed Payment Notification, prepay the Term Loan in whole or in part; provided, however, that each such prepayment (other than a prepayment in whole) shall be in an amount equal to $1,000,000 or a higher  integral multiple of $1,000,000 and shall be accompanied by any applicable fees, as set forth in Section 2.2 or any Fee Letter.
	
 




 


	
(iii)
	
All Prepayments. Except as this Agreement may specifically provide otherwise, all prepayments of the Term Loan shall be applied by Agent to the Obligations in inverse order of maturity. The monthly payments required under Schedule 2.1 shall continue in the same amount (for so long as the Term Loan and/or (if applicable) any advance thereunder shall remain outstanding) notwithstanding any partial prepayment, whether mandatory or optional, of the Term Loan. Notwithstanding anything to the contrary contained in the foregoing, in the event that there have been multiple advances under the Term Loan each of which such advances has a separate amortization schedule of principal payments under Schedule 2.1 attached hereto, each prepayment of the Term Loan shall be applied by Agent to reduce and prepay the principal balance of the earliest-made advance then outstanding in the inverse order of maturity of the scheduled payments with respect to such advance until such earliest-made advance is paid in full (and to the extent the total amount of any such partial prepayment shall exceed the outstanding principal balance of such earliest-made advance, the remainder of such prepayment shall be applied successively to the remaining advances under the Term Loan in the direct order of the respective advance dates in the manner provided for in this sentence).
	
 




 


	
 
	
(iv)
	
LIBOR Rate.




 


	
 
	
(A)
	
Except as provided in subsection (C) below, the Term Loan shall accrue interest at the LIBOR Rate plus the Applicable Margin.
	
 




 


	
 
	
(B)
	
The LIBOR Rate may be adjusted by Agent with respect to any Lender on a prospective basis to take into account any additional or increased costs to such Lender of maintaining or obtaining any eurodollar deposits or increased costs, in each case, due to changes in applicable Law occurring subsequent to the commencement of the then applicable Interest Period, including changes in tax laws (except changes in Taxes or taxes excluded from the definition of Taxes in Section 2.8 hereof) and changes in the reserve requirements imposed by the Board of Governors of the Federal Reserve System (or any successor), which additional or increased costs would increase the cost of funding loans bearing interest based upon the LIBOR Rate; provided, however, that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “change in applicable Law”, regardless of the date enacted, adopted or issued. In any such event, the affected Lender shall  give Borrowers  and Agent notice of such a determination and adjustment and Agent promptly shall transmit
	
 





	
 
	
(A)
	

	
 






27

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


the notice to each other Lender and, upon its receipt of the notice from the affected Lender, Borrowers may, by notice to such affected Lender (I) require such Lender to furnish to Borrowers a statement setting forth the basis for adjusting such LIBOR Rate and the method for determining the amount of such adjustment, or (II) repay the Loans bearing interest based upon the LIBOR Rate with respect to which such adjustment is made.

 


	
 
	
(C)
	
In the event that any change in market conditions or any law, regulation, treaty, or directive, or any change therein or in the interpretation  of application thereof, shall at any time after the date hereof, in the reasonable opinion of any Lender, make it unlawful or impractical for such Lender to maintain Loans bearing interest based upon the LIBOR Rate or to continue such maintaining, or to determine or charge interest rates at the LIBOR Rate, such Lender shall give notice of such changed circumstances to Agent and Borrowers and Agent promptly shall transmit the notice to each other Lender, (I) in the case of the pro rata share of the Term Loan held by such Lender and then outstanding, the date specified in such Lender’s notice shall be deemed to be the last day of the Interest Period of such portion of the Term Loan, and interest upon such portion thereafter shall accrue interest at the Base Rate plus the Applicable Margin, and (II) such portion of the Term Loan shall continue to accrue interest at the Base Rate plus the Applicable Margin until such Lender determines that it would no longer be unlawful or impractical to maintain such Term Loan at the LIBOR Rate.
	
 




 


	
 
	
(D)
	
Anything to the contrary contained herein notwithstanding, neither Agent nor any Lender is required actually to acquire eurodollar deposits to fund or otherwise match fund any Obligation as to which interest accrues based on the LIBOR Rate.
	
 




 

Section 2.2Interest, Interest Calculations and Certain Fees.

 


	
(a)
	
Interest. From and following the Closing Date, except as expressly set forth in this Agreement, Loans and the other Obligations shall bear interest at the sum of the LIBOR Rate plus the Applicable Margin. Interest on the Loans shall be paid monthly in arrears on the first (1st) day of each month and on the maturity of such Loans, whether by acceleration or otherwise. Interest on all  other Obligations shall be payable upon demand. The Borrowers hereby agree that all accrued and unpaid interest due and owing to the Lenders under (and as defined in) the Original Credit Agreement as of the Closing Date shall be paid in cash by the Borrowers to the Agent, for the benefit of such Lenders, on the first (1st) day of the first calendar month following the Closing Date.
	
 




 


	
 
	
(b)
	
Reserved.




 


	
(c)
	
Fee Letter. In addition to the other fees set forth herein, the Borrowers agree to pay Agent the fees set forth in the Fee Letter.
	
 




 


	
 
	
(d)
	
Reserved.




 


	
 
	
(e)
	
Reserved.




 


	
(f)
	
Origination Fee. Contemporaneous with Borrowers execution of the Original Credit Agreement, Borrowers paid to Agent, for its own account and not for the benefit of any other Lenders, a fee in an amount equal to the aggregate amount of the Term Loan Commitment as in effect on the Original Closing Date multiplied by one half of one percent (0.5%). All fees paid pursuant to this
	
 





	
(a)
	

	
 






28

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


paragraph were fully earned when due and payable and were non-refundable as of the Original Closing Date.

 


	
 
	
(g)
	
Reserved.




 


	
 
	
(h)
	
Reserved.




 


	
 
	
(i)
	
Reserved.




 


	
 
	
(j)
	
Reserved.




 


	
(k)
	
Audit Fees. Borrowers shall pay to Agent, for its own account and not for the benefit of any other Lenders, all reasonable fees and expenses in connection with audits and inspections of Borrowers’ books and records, audits, valuations or appraisals of the Collateral, audits of Borrowers’ compliance with applicable Laws and such other matters as Agent shall deem appropriate, which shall be due and payable on the first Business Day of the month following the date of issuance by Agent of a written request for payment thereof to Borrowers. Notwithstanding the foregoing, so long as no Event of Default has occurred and is continuing, Borrowers shall not be required to reimburse Agent for more than two (2) audits per fiscal year.
	
 




 


	
(l)
	
Wire Fees. Borrowers shall pay to Agent, for its own account and not for the account of any other Lenders, on written demand, fees for incoming and outgoing wires made for the account of Borrowers, such fees to be based on Agent’s then current wire fee schedule (available upon written request of the Borrowers).
	
 




 


	
(m)
	
Late Charges. If payments of principal (other than a final installment  of principal upon the Termination Date), interest due on the Obligations, or any other amounts due hereunder or under the other Financing Documents are not timely made and remain overdue for a period of five (5) days, Borrowers, without notice or demand by Agent, promptly shall pay to Agent, for its own account and not for the benefit of any other Lenders, as additional compensation to Agent in administering the Obligations, an amount equal to three percent (3.0%) of each delinquent payment.
	
 




 


	
(n)
	
Computation of Interest and Related Fees. All interest and fees under each Financing Document shall be calculated on the basis of a 360-day year for the actual number of days elapsed. The date of funding of a Loan shall be included in the calculation of interest. The date of payment of a Loan shall be excluded from the calculation of interest. If a Loan is repaid on the same day that it is made, one (1) day’s interest shall be charged.
	
 




 


	
(o)
	
Automated Clearing House Payments. If Agent so elects, monthly payments of principal, interest, fees, expenses or any other amounts due and owing from Borrower to Agent hereunder shall be paid to Agent by Automated Clearing House debit of immediately available funds from the financial institution account designated by Borrower Representative in the Automated Clearing House debit authorization executed by Borrowers or Borrower Representative in connection with this Agreement, and shall be effective upon receipt. Borrowers shall execute any and all forms and documentation necessary from time to time to effectuate such automatic debiting. In no event shall any such payments be refunded to Borrowers.
	
 




 

Section 2.3 Notes. The portion of the Loans made by each Lender shall be evidenced, if so requested by such Lender, by one or more promissory notes executed by Borrowers on a joint and several basis (each, a “Note”) in an original principal amount equal to such Lender’s Term Loan Commitments.

 



29

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 2.4Reserved.

 

Section 2.5Reserved.

 

Section 2.6General Provisions Regarding Payment; Loan Account.

 


	
(a)
	
All payments to be made by each Borrower under any Financing Document, including payments of principal and interest made hereunder and pursuant to any other Financing Document, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim. If any payment hereunder becomes due and payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension (it being understood and agreed that, solely for purposes of calculating financial covenants and computations contained herein and determining compliance therewith, if payment is made, in full, on  any such extended due date, such payment shall be deemed to have been paid on the original due date without giving effect to any extension thereto). Any payments received in the Payment Account before 12:00 Noon (Eastern time) on any date shall be deemed received by Agent on such date, and any payments received in the Payment Account at or after 12:00 Noon (Eastern time) on any date shall be deemed received by Agent on the next succeeding Business Day.
	
 




 


	
(b)
	
Agent shall maintain a loan account in the Register (the “Loan Account”) on its books to record Loans and other extensions of credit made by the Lenders hereunder or under any other Financing Document, and all payments thereon made by each Borrower. All entries in  the Loan  Account shall be made in accordance with Agent’s customary accounting practices as in effect from time to time. The balance in the Loan Account, as recorded in Agent’s books and records at any time shall be conclusive and binding evidence of the amounts due and owing to Agent by each Borrower absent manifest error; provided, however, that any failure to so record or any error in so recording shall not limit or otherwise affect any Borrower’s ultimate obligation to pay all amounts owing hereunder or  under any other Financing Document. Agent shall provide Borrowers with a monthly statement regarding the Loan Account. Unless any Borrower notifies Agent of any objection to any such statement (specifically describing the basis for such objection) within ninety (90) days after the date of receipt thereof, it shall be deemed final, binding and conclusive upon Borrowers in all respects as to all matters reflected therein.
	
 




 

Section 2.7 Maximum Interest. In  no  event  shall the interest  charged  with respect  to the Loans or any other Obligations of any Borrower under any Financing Document exceed the maximum amount permitted under the laws of the State of New York or of any other applicable jurisdiction. Notwithstanding anything to the contrary herein or elsewhere, if at any time the rate of interest payable hereunder or under any Note or other Financing Document (the “Stated Rate”) would exceed the highest rate of interest permitted under any applicable law to be charged (the “Maximum Lawful Rate”), then for so long as the Maximum Lawful Rate would be so exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided, however, that if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate, each Borrower shall, to the extent permitted by law, continue to pay interest at the Maximum Lawful Rate until such time as the total interest received is equal to the total interest which would have been received had the Stated Rate been (but for the operation of this provision) the interest rate payable. Thereafter, the interest rate payable shall be the Stated Rate unless and until the Stated Rate again would exceed the Maximum Lawful Rate, in which event this provision shall again apply. In no event shall the total interest received by any Lender exceed the amount which it could lawfully have received had the interest been calculated for the full term hereof at the Maximum Lawful Rate. If, notwithstanding the prior sentence, any Lender has received interest hereunder in excess of the Maximum Lawful Rate, such excess amount shall be applied to the reduction of the principal balance of

 



30

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


the Loans or to other amounts (other than interest) payable hereunder, and if no such principal or other amounts are then outstanding, such excess or part thereof remaining shall be paid to Borrowers. In computing interest payable with reference to the Maximum Lawful Rate applicable to any Lender, such interest shall be calculated at a daily rate equal to the Maximum Lawful Rate divided by the number of days in the year in which such calculation is made.

 

Section 2.8Taxes; Capital Adequacy.

 


	
(a)
	
All payments of principal and interest on the Loans and all other amounts payable hereunder shall be made free and clear of and without deduction for any present or future income, excise, stamp, documentary, payroll, employment, property or franchise taxes and other taxes, fees, duties, levies, assessments, withholdings or other charges of any nature whatsoever (including interest and penalties thereon) imposed by any taxing authority, excluding: (1) taxes imposed on or measured by Agent’s or any Lender’s net income (however denominated), franchise taxes, and branch profits taxes that are imposed by the jurisdiction (or any subdivision thereof) under which Agent or such Lender is organized or conducts business or that are imposed due to a present or former connection between such Agent or Lender and the jurisdiction imposing such tax (other than solely as the result of entering into any of the Financing Documents or taking any action thereunder) or, in the case of a Lender, has its applicable lending office; (2) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender  with respect to an applicable interest in a Loan pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan (other than pursuant to an assignment request by the Borrower under Section 2.8(d)) or (ii) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2.8(a) amounts with respect to such taxes were payable either to such Lender's assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, and (3) any U.S. federal withholding Taxes imposed under FATCA (all non-excluded items being called “Taxes”). If any withholding or deduction from any payment to be made by any Credit Party hereunder is required in respect of any Taxes pursuant to any applicable Law, then such Credit Party will: (i) pay directly to the relevant authority the full amount required to be so withheld or deducted; (ii) promptly forward to Agent an official receipt or other documentation reasonably satisfactory to Agent evidencing such payment to such authority; and (iii) pay to Agent for the account of Agent and Lenders such additional amount or amounts as is necessary to ensure that the net amount actually received by Agent and each Lender will equal the full amount Agent and such Lender would have received had no such withholding or deduction been required. If any Taxes are directly asserted against Agent or any Lender with respect to any payment received by Agent or such Lender hereunder, Agent or such Lender  may pay such Taxes and Borrowers will promptly pay such additional amounts (including any penalty, interest or reasonable out of pocket expense) as is necessary in order that the net amount received by such Person after the payment of such Taxes (including any Taxes on such additional amount) shall equal the amount such Person would have received had such Taxes not been asserted so long as such amounts have accrued on or after the day which is two hundred seventy (270) days prior to the date on which Agent or such Lender first made written demand therefor.
	
 




 


	
(b)
	
If any Borrower fails to pay any Taxes when due to the appropriate Governmental Authority, Borrowers shall indemnify Agent and Lenders promptly upon written demand therefor, for any incremental Taxes, interest or penalties that may become payable by Agent or any Lender as a result of any such failure. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.
	
 




 


	
(c)
	
Each Lender (whether a party hereto on the Closing Date or an assignee of an interest as a Lender under this Agreement after the Closing Date (unless such Lender was already a
	
 





	
(a)
	

	
 






31

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Lender hereunder immediately prior to such assignment))shall at the time or times reasonably requested by the Borrower or the Agent, deliver such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding, including, without limitation, the following:

 


	
(i)
	
Each Lender that is not a U.S. person as defined in Section 7701(a)(30) of the Code and (A) is a party hereto on the Closing Date or (B) purports to become an assignee of an interest as a Lender under this Agreement after the Closing Date (unless such Lender was already a Lender hereunder immediately prior to such assignment) (each such Lender a “Foreign Lender”) shall, to the extent it is legally entitled to do so, execute and deliver to each of Borrowers and Agent one or more (as Borrowers or Agent may reasonably request) United States Internal Revenue Service Forms W-8ECI, W-8BEN, W-8BEN-E, W-8IMY or W-8EXP (as applicable), or applicable successor form, and other applicable forms, certificates or documents prescribed by the United States Internal Revenue Service or reasonably requested by Agent certifying as to such Lender’s entitlement to a complete exemption from withholding or  deduction of Taxes, including, in the case of a Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate to the effect that such Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”);
	
 




 


	
(ii)
	
A Lender that is organized under the laws of the United States or any state thereof or the District of Columbia (each such Lender a “US Lender”) shall execute and deliver to each of Borrowers and Agent one or more (as Borrowers or Agent may reasonably request) United States Internal Revenue Service Forms W-9, or any applicable successor form. In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements; and
	
 




 


	
(iii)
	
If a payment made to a Lender under any Financing Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (iii), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.
	
 




 


	
(iv)
	
Borrowers shall not be required to pay additional amounts to any Lender pursuant to this Section 2.8 with respect to United States withholding and income Taxes to the extent that the obligation to pay such additional amounts would not have arisen but for the failure of such Lender to comply with this paragraph other than as a result of a change in law occurring after the date such Lender became a party to this Agreement or acquired its interest in a Loan, as applicable.
	
 





	
(i)
	

	
 






32

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(v)
	
Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.
	
 




 


	
(d)
	
If any Lender shall determine in its commercially reasonable judgment that the adoption or taking effect of, or any change in, any applicable Law regarding capital adequacy, in each instance, after the Original Closing Date, or any change after the Original Closing Date in the interpretation, administration or application thereof by any Governmental Authority, central bank or comparable agency charged with the interpretation, administration or application thereof, or the compliance by any Lender or any Person controlling such Lender with any request, guideline or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, central bank or comparable agency adopted or otherwise taking effect after the Original Closing Date, has or would have the effect of reducing the rate of return on such Lender’s or such controlling Person’s capital as a consequence of such Lender’s obligations hereunder to a level below that which such Lender or such controlling Person could have achieved but for such adoption, taking effect, change, interpretation, administration, application or compliance (taking into consideration such Lender’s or such controlling Person’s policies with respect to capital adequacy) then from time to time, upon written demand by such Lender (which demand shall be accompanied by a statement setting forth the basis for such demand and a calculation of the amount thereof in reasonable detail, a copy of which shall be furnished to Agent), Borrowers shall promptly pay to such Lender such additional amount as will compensate such Lender or such controlling Person for such reduction, so long as such amounts have accrued on or after the day which is two hundred seventy (270) days prior  to the date on which such Lender first made demand therefor; provided, however, that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States  or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “change in applicable Law”, regardless of the date enacted, adopted or issued.
	
 




 


	
(e)
	
If any Lender requires compensation under Section 2.8(d), or requires any Borrower to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.8(a), then, upon the written request of Borrower Representative, such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder (subject to the terms of this Agreement) to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or materially reduce amounts payable pursuant to any such subsection, as the case may be, in the future, and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender (as determined in its sole discretion). Borrowers hereby agree to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.
	
 




 


	
(f)
	
If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.8 (including by the payment of additional amounts pursuant to this Section 2.8), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant
	
 





	
(a)
	

	
 






33

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


to this paragraph (f) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (f), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph

(f)the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.

 


	
(g)
	
Each party’s obligations under this Section 2.8 shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender,  the termination of the obligations hereunder and the repayment, satisfaction or discharge of all obligations under any Financing Document.
	
 




 

Section 2.9Appointment of Borrower Representative.

 


	
(a)
	
Each Borrower hereby irrevocably appoints and constitutes Borrower Representative as its agent and attorney-in-fact to request and receive Loans in the name or on behalf of such Borrower and any other Borrowers, deliver Notices of Borrowing, give instructions with respect to the disbursement of the proceeds of the Loans , giving and receiving all other notices and consents hereunder or under any of the other Financing Documents and taking all other actions (including in respect of compliance with covenants) in the name or on behalf of any Borrower or Borrowers pursuant to this Agreement and the other Financing Documents. Agent and Lenders may disburse the Loans to such bank account of Borrower Representative or a Borrower or otherwise make such Loans to a Borrower, in each case as Borrower Representative may designate or direct, without notice to any other Borrower. Notwithstanding anything to the contrary contained herein, Agent may at any time and from time to time require that Loans to or for the account of any Borrower be disbursed directly to an operating account of such Borrower.
	
 




 


	
(b)
	
Borrower Representative hereby accepts the appointment by Borrowers to act as the agent and attorney-in-fact of Borrowers pursuant to this Section 2.9. Borrower Representative shall ensure that the disbursement of any Loans that are at any time requested by or to be remitted to or for the account of a Borrower, shall be remitted or issued to or for the account of such Borrower.
	
 




 


	
(c)
	
Each Borrower hereby irrevocably appoints and constitutes Borrower Representative as its agent to receive statements on account and all other notices from Agent, Lenders with respect to the Obligations or otherwise under or in connection with this Agreement and the other Financing Documents.
	
 




 


	
(d)
	
Any notice, election, representation, warranty, covenant, agreement or undertaking made or delivered by or on behalf of any Borrower by Borrower Representative shall be deemed for all purposes to have been made or delivered by such Borrower, as the case may be, and shall be binding upon and enforceable against such Borrower to the same extent as if the same had been made or delivered directly by such Borrower.
	
 




 


	
(e)
	
No resignation by or termination of the appointment of Borrower Representative as agent and attorney-in-fact as aforesaid shall be effective, except after ten (10) Business Days’ prior written notice to Agent. If Borrower Representative resigns under this Agreement, Borrowers shall be entitled to appoint a successor Borrower Representative (which shall be a Borrower and shall be
	
 





	
(a)
	

	
 






34

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


reasonably acceptable to Agent as such successor). Upon the acceptance of its appointment as successor Borrower Representative hereunder, such successor Borrower Representative shall succeed to all the rights, powers and duties of the retiring Borrower Representative and the term “Borrower Representative” shall mean such successor Borrower Representative for all purposes of this Agreement and the other Financing Documents, and the retiring or terminated Borrower Representative’s appointment, powers and duties as Borrower Representative shall be thereupon terminated.

 

Section 2.10Joint and Several Liability; Rights of Contribution; Subordination and Subrogation.

 


	
(a)
	
Borrowers are defined collectively to include all Persons named as one of the Borrowers herein; provided, however, that any references herein to “any Borrower”, “each Borrower” or similar references, shall be construed as a reference to each individual Person named as one of the Borrowers herein. Each Person so named shall be jointly and severally liable for all of the obligations of Borrowers under this Agreement. Each Borrower, individually, expressly understands, agrees and acknowledges, that the credit facilities would not be made available on the terms herein in the absence of the collective credit of all of the Persons named as the Borrowers herein, the joint and several liability of all such Persons, and the cross-collateralization of the collateral of all such Persons. Accordingly, each Borrower individually acknowledges that the benefit to each of the Persons named as one of the Borrowers as a whole constitutes reasonably equivalent value, regardless of the amount of the credit facilities actually borrowed by, advanced to, or the amount of collateral provided by, any individual Borrower. In addition, each entity named as one of the Borrowers herein hereby acknowledges and agrees that all of the representations, warranties, covenants, obligations, conditions, agreements and other terms contained in this Agreement shall be applicable to and shall be binding upon and measured and enforceable individually against each Person named as one of the Borrowers herein as well as all such Persons when taken together. By way of illustration, but without limiting the generality of the foregoing, the terms of Section 10.1 of this Agreement are to be applied to each individual Person named as one of the Borrowers herein (as well as to all such Persons taken as a whole), such that the occurrence of any of the events described in Section 10.1 of this Agreement as to any Person named as one of the Borrowers herein shall constitute an Event of Default even if such event has not occurred as to any other Persons named as the Borrowers or as to all such Persons taken as a whole.
	
 




 


	
(b)
	
Notwithstanding any provisions of this Agreement to the contrary, it is intended that the joint and several nature of the liability of each Borrower for the Obligations and the Liens granted by Borrowers to secure the Obligations, not constitute a Fraudulent Conveyance (as defined below).  Consequently, Agent, Lenders and each Borrower agree that if the liability of a Borrower for  the Obligations, or any Liens granted by such Borrower securing the Obligations would, but for the application of this sentence, constitute a Fraudulent Conveyance, the liability of such Borrower and the Liens securing such liability shall be valid and enforceable only to the maximum extent that would not cause such liability or such Lien to constitute a Fraudulent Conveyance, and the liability of such Borrower and this Agreement shall automatically be deemed to have been amended accordingly. For purposes hereof, the term “Fraudulent Conveyance” means a fraudulent conveyance under Section 548 of Chapter 11 of Title II of the Bankruptcy Code or a fraudulent conveyance or fraudulent transfer under the applicable provisions of any fraudulent conveyance or fraudulent transfer law or similar law of any state, nation or other governmental unit, as in effect from time to time.
	
 




 


	
(c)
	
Agent is hereby authorized, without notice or demand (except as otherwise specifically required under this Agreement) and without affecting the liability of any Borrower hereunder, at any time and from time to time, to (i) renew, extend or otherwise increase the time for payment of the Obligations; (ii) with the written agreement of any Borrower, change the terms relating to the Obligations of such Borrower or otherwise modify, amend or change the terms of any Note of such
	
 





	
(a)
	

	
 






35

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Borrower or other agreement, document or instrument now or hereafter executed by such Borrower and delivered to Agent for any Lender; (iii) accept partial payments of the Obligations; (iv) take and hold any Collateral for the payment of the Obligations or for the payment of any guaranties of the Obligations and exchange, enforce, waive and release any such Collateral; (v) apply any such Collateral and direct the order or manner of sale thereof as Agent, in its sole discretion, may determine; and (vi) settle, release, compromise, collect or otherwise liquidate the Obligations and any Collateral therefor in any manner, all guarantor and surety defenses being hereby waived by each Borrower. Without limitations of the foregoing, with respect to the Obligations, each Borrower hereby makes and adopts each of the agreements and waivers set forth in each Guarantee, the same being incorporated hereby by reference. Except as specifically provided in this Agreement or any of the other Financing Documents, Agent shall have the exclusive right to determine the time and manner of application of any payments or credits, whether received from any Borrower or any other source, and such determination shall be binding on all Borrowers. All such payments and credits may be applied, reversed and reapplied, in whole or in part, to any of the Obligations that Agent shall determine, in its sole discretion, without affecting the validity or enforceability of the Obligations of the other Borrowers.

 


	
(d)
	
Each Borrower hereby agrees that, except as hereinafter provided,  its obligations hereunder shall be unconditional, irrespective of (i) the absence of any attempt to collect the Obligations from any obligor or other action to enforce the same; (ii) the waiver or consent by Agent with respect to any provision of any instrument evidencing the Obligations, or any part thereof, or any other agreement heretofore, now or hereafter executed by a Borrower and delivered to Agent; (iii) failure by Agent to take any steps to perfect and maintain its security interest in, or to preserve its rights to, any security or collateral for the Obligations; (iv) the institution of any proceeding under the Bankruptcy Code, or any similar proceeding, by or against a Borrower or Agent’s election in any such proceeding of the application of Section 1111(b)(2) of the Bankruptcy Code; (v) any borrowing or grant of a security interest by a Borrower as debtor-in-possession, under Section 364 of the Bankruptcy Code; (vi) the disallowance, under Section 502 of the Bankruptcy Code, of all or any portion of Agent’s claim(s) for repayment of any of the Obligations; or (vii) any other circumstance other than payment in full of the Obligations which might otherwise constitute a legal or equitable discharge or defense of a guarantor or surety.
	
 




 


	
(e)
	
Borrowers hereby agree, as between themselves, that to the extent that Agent, on behalf of Lenders, shall have received from any Borrower any Recovery Amount (as defined below), then the paying Borrower shall have a right of contribution against each other Borrower in an amount equal to such other Borrower’s contributive share of such Recovery Amount; provided, however, that in the event any Borrower suffers a Deficiency Amount (as defined below), then the Borrower suffering the Deficiency Amount shall be entitled to seek and receive contribution from and against the other Borrowers in an amount equal to the Deficiency Amount; and provided, further, that in no event shall the aggregate amounts so reimbursed by reason of the contribution of any Borrower equal or exceed an amount that would, if paid, constitute or result in Fraudulent Conveyance. Until all Obligations have been paid and satisfied in full, no payment made by or for the account of a Borrower including, without limitation, (i) a payment made by such Borrower on behalf of the liabilities of any other Borrower, or
	
 




(ii)a payment made by any other Guarantor under any Guarantee, shall entitle such Borrower, by subrogation or otherwise, to any payment from such other Borrower or from or out of such other Borrower’s property. The right of each Borrower to receive any contribution under this Section 2.10(e) or by subrogation or otherwise from any other Borrower shall be subordinate in right of payment to the Obligations and such Borrower shall not exercise any right or remedy against such other Borrower  or any property of such other Borrower by reason of any performance of such Borrower of its joint and several obligations hereunder, until the Obligations have been paid and satisfied in full in cash (and as to which no right of claw-back under applicable preference or fraudulent transfer Laws has been asserted), and no Borrower shall exercise any right or remedy with respect to this Section 2.10(e) until the

(ii)



36

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Obligations have been paid and satisfied in full in cash (and as to which no right of claw-back under applicable preference or fraudulent transfer Laws has been asserted). As used in this Section 2.10(e), the term “Recovery Amount” means the amount of proceeds received by or credited to Agent from the exercise of any remedy of the Lenders under this Agreement or the other Financing Documents, including, without limitation, the sale of any Collateral. As used in this Section 2.10(e), the term “Deficiency Amount” means any amount that is less than the entire amount a Borrower is entitled to receive by way of contribution or subrogation from, but that has not been paid by, the other Borrowers in respect of any Recovery Amount attributable to the Borrower entitled to contribution, until the Deficiency Amount has been reduced to Zero Dollars ($0) through contributions and reimbursements made under the terms of this Section 2.10(e) or otherwise.

 

Section 2.11Reserved.

 

Section 2.12Termination; Restriction on Termination.

 


	
(a)
	
Termination by Lenders. In addition to the rights set forth in Section 10.2,  Agent may, and at the direction of Required Lenders shall, terminate this Agreement without notice upon or after the occurrence and during the continuance of an Event of Default.
	
 




 


	
(b)
	
Termination by Borrowers. Upon at least ten (10) Business Days’ prior written notice and pursuant to payoff documentation in form and substance reasonably satisfactory to Agent and Lenders, Borrowers may, at their option, terminate this Agreement. Any notice of termination given by Borrowers shall be an irrevocable notice (provided that such notice may be conditioned on closing the applicable refinancing or transfer for which such notice was given) unless all Lenders otherwise agree in writing and no Lender shall have any obligation to make any Loans on or after the termination date stated in such notice. Borrowers may elect to terminate this Agreement in its entirety only.  No section  of this Agreement or type of Loan available hereunder may be terminated singly.
	
 




 


	
(c)
	
Effectiveness of Termination. All of the Obligations shall be immediately due and payable upon the Termination Date. All undertakings, agreements, covenants, warranties and representations of Borrowers contained in the Financing Documents shall survive any such termination and Agent shall retain its Liens in the Collateral and Agent and each Lender shall retain all of its rights and remedies under the Financing Documents notwithstanding such termination until all Obligations have been discharged or paid, in full, in immediately available funds, including, without limitation, all Obligations under Section 2.2(g) and Section 2.2(h) and the terms of any fee letter resulting from such termination. Notwithstanding the foregoing or the payment in full of the Obligations, Agent shall not be required to terminate its Liens in the Collateral unless, with respect to any loss or damage Agent may incur as a result of dishonored checks or other items of payment received by Agent from Borrower  or any Account Debtor and applied to the Obligations, Agent shall, at its option, (i) have received a written agreement satisfactory to Agent, executed by Borrowers and by any Person whose loans or other advances to Borrowers are used in whole or in part to satisfy the Obligations, indemnifying Agent and each Lender from any such loss or damage or (ii) have retained cash Collateral or other Collateral for such period of time as Agent, in its discretion, may deem necessary to protect Agent and each Lender from any such loss or damage.
	
 




 

ARTICLE 3 - REPRESENTATIONS AND WARRANTIES

 

To induce Agent and Lenders to enter into this Agreement and to make the Loans and other credit accommodations contemplated hereby, each Borrower hereby represents and warrants to Agent and each Lender that:

 



37

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 3.1 Existence and Power. Each  Credit  Party  (a)  is  an  entity  as  specified  on  Schedule 3.1, (b) is duly organized, validly existing and in good standing under the laws of the jurisdiction specified on Schedule 3.1 and no other jurisdiction, (c) has the same legal name as it appears in such Credit Party’s Organizational Documents and an organizational identification number (if any), in each case as specified on Schedule 3.1, (d) has all powers and all Permits necessary or desirable in the operation of its business as presently conducted or as proposed to be conducted, except where the failure to have such Permits would not reasonably be expected to have a Material Adverse Effect, and (e) is qualified to do business as a foreign entity in each jurisdiction in which it is required to be so qualified, which jurisdictions as of the Closing Date are specified on Schedule 3.1, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect. Except as set forth on Schedule 3.1, no Credit Party (x) has had, over the five (5) year period preceding the Closing Date, any name other than its current name, or (y) was incorporated or organized under the laws of any jurisdiction other than its current jurisdiction of incorporation or organization.

 

Section 3.2  Organization  and  Governmental  Authorization;  No  Contravention.  The execution, delivery and performance by each Credit Party of the Operative Documents to which it is a party (a) are within its powers, (b) have been duly authorized by all necessary action pursuant to its Organizational Documents, (c) require no further action by or in respect of, or filing with, any Governmental Authority, except for the filings necessary to perfect the Liens created by the Operative Documents and (d) do not violate, conflict with or cause a breach or a default under (i) any Law applicable to any Credit Party in any material respect, (ii) any of the Organizational Documents of any Credit Party, or (iii) any material agreement or instrument binding upon it, except for such violations, conflicts, breaches or defaults as could not, with respect to this clause (iii), reasonably be expected to have a Material Adverse Effect.

 

Section 3.3 Binding Effect.  Each of the Operative Documents to which any Credit Party is a party constitutes a valid and binding agreement or instrument of such Credit Party, enforceable against such Credit Party in accordance with its respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.

 

Section 3.4    Capitalization.   The authorized  equity securities  of each  of the Credit Parties as of the Closing Date are as set forth on Schedule 3.4. All issued and outstanding equity securities of each  of the Credit Parties are duly authorized and validly issued, fully paid, nonassessable, free and clear of all Liens (other than Permitted Liens) other than those in favor of Agent for the benefit of Agent and Lenders, and such equity securities were issued in all material respects in compliance with all applicable Laws. The identity of the holders of the equity securities of each of the Credit Parties and the percentage of their fully-diluted ownership of the equity securities of each of the Credit Parties as of the Closing Date is set forth on Schedule 3.4. No shares of the capital stock or other equity securities of any Credit Party, other than those described above, are issued and outstanding as of the Closing Date. Except as set forth  on Schedule 3.4, as of the Closing Date there are no preemptive or other outstanding rights, options, warrants, conversion rights or similar agreements or understandings for the purchase or acquisition from any Credit Party of any equity securities of any such entity.

 

Section 3.5 Financial Information. All information delivered to Agent and pertaining to the financial condition of any Credit Party fairly presents the financial position of the Credit Parties (taken as a whole) as of such date in conformity with GAAP (and as to unaudited financial statements, subject to normal year-end adjustments and the absence of footnote disclosures). Since December 31, 2017, no event has occurred which would be reasonably likely to have a Material Adverse Effect.

 



38

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 3.6    Litigation.  Except as set forth on Schedule 3.6 as of the Closing Date, and except as hereafter disclosed to Agent in writing, there is no Litigation pending against, or to such Borrower’s knowledge threatened in writing against or affecting, any Credit Party. There is no Litigation pending which would be reasonably likely to have a Material Adverse Effect or which in any manner draws into question the validity of any of the Operative Documents.

 

Section 3.7 Ownership of Property. Each Borrower and each of its Subsidiaries is the lawful owner of, has good and marketable title to and is in lawful possession of, or has valid leasehold interests in, all properties, accounts and other assets (real or personal, tangible, intangible or mixed) purported or reported to be owned or leased (as the case may be) by such Person.

 

Section 3.8 No Default. No Event of Default, or to such Borrower’s knowledge, Default, has occurred and is continuing. No Credit Party is in breach or default under or with respect to any contract, agreement, lease or other instrument to which it is a party or by which its property is bound or affected, which breach or default would reasonably be expected to have a Material Adverse Effect

 

Section 3.9 Labor Matters. As of the Closing  Date,  there  are  no  strikes  or  other  labor disputes pending or, to any Borrower’s knowledge, threatened in writing against any Credit Party. Hours worked and payments made to the employees of the Credit Parties have not been in violation of the Fair Labor Standards Act or any other applicable Law dealing with such matters. All payments due from the Credit Parties, or for which any claim may be made against any of them, on account of wages and employee and retiree health and welfare insurance and other benefits have been paid or accrued as a liability on their books, as the case may be. The consummation of the transactions contemplated by the Financing Documents will not give rise to a right of termination or right of  renegotiation on the part of any union under any collective bargaining agreement to which it is a party or by which it is bound.

 

Section 3.10 Regulated Entities. No Credit Party is an “investment company” or a company “controlled” by an “investment company” or a “subsidiary” of an “investment company,” all within the meaning of the Investment Company Act of 1940.

 

Section 3.11 Margin Regulations. None of the proceeds from the Loans have been or will be used, directly or indirectly, for the purpose of purchasing or carrying any “margin stock” (as defined in Regulation U of the Federal Reserve Board), for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any “margin stock” or for any other purpose which might cause any of the Loans to be considered a “purpose credit” within the meaning of Regulation T, U or X of the Federal Reserve Board.

 

Section 3.12Compliance With Laws; Anti-Terrorism Laws.

 


	
(a)
	
Each Credit Party is in compliance with the requirements of all applicable Laws, except for such Laws the noncompliance with which would not reasonably be expected to have a Material Adverse Effect.
	
 




 


	
(b)
	
None of the Credit Parties and, to the knowledge of the Credit Parties, none of their Affiliates (i) is in violation of any Anti-Terrorism Law, (ii) engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any  of the prohibitions set forth in any Anti-Terrorism Law, (iii) is a Blocked Person, or is controlled by a Blocked Person, (iv) is acting or will act for or on behalf of a Blocked Person, (v) is associated with, or will become associated with, a Blocked Person or (vi) is providing, or will provide, material, financial or technical support or other services to or in support of acts of terrorism of a Blocked Person. No Credit Party nor, to the knowledge of any Credit Party, any of its Affiliates or agents acting or benefiting in any
	
 





	
(a)
	

	
 






39

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


capacity in connection with the transactions contemplated by this Agreement, (A) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of  any Blocked Person, or (B) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.

 

Section 3.13 Taxes. All U.S. federal and all other material foreign, state and local tax returns, reports and statements required to be filed by or on behalf of each Credit Party have been filed with the appropriate Governmental Authorities in all jurisdictions in which such returns, reports and statements are required to be filed and, except to the extent subject to a Permitted Contest, all Taxes (including real property Taxes) and other charges shown to be due and payable in respect thereof have been timely paid prior to the date on which any fine, penalty, interest, late charge or loss may be added thereto for nonpayment thereof. Except to the extent subject to a Permitted Contest, all material state and local sales and use Taxes required to be paid by each Credit Party have been paid. All federal and material state returns have been filed by each Credit Party for all periods for which returns were due with respect to employee income tax withholding, social security and unemployment taxes, and, except to the extent subject to a Permitted Contest, the amounts shown thereon to be due and payable have been paid in full or adequate provisions therefor have been made therefor on the financial statements of the Credit Parties.

 

Section 3.14Compliance with ERISA.

 


	
(a)
	
Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (i) each ERISA Plan (and the related trusts and funding agreements) complies in form and in operation with, has been administered in compliance with, and the terms of each ERISA Plan satisfy, the applicable requirements of ERISA and the Code; (ii) each ERISA Plan which is intended to be qualified under Section 401(a) of the Code is so qualified, and the United States Internal Revenue Service has issued a favorable determination letter with respect to each such ERISA Plan; and
	
 




(iii)no Credit Party has incurred liability for any excise tax under any of Sections 4971 through 5000 of the Code.

 


	
(b)
	
Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, each Borrower and each Subsidiary is in compliance with the applicable provisions of ERISA and the provisions of the Code relating to ERISA Plans and the regulations and published interpretations therein.  During the thirty-six (36) month period prior to the Closing Date or  the making of any Loan (i) no steps have been taken to terminate any Pension Plan, other than pursuant to a “standard termination,” within the meaning of Section 4041(b) of ERISA, and (ii) no contribution failure has occurred with respect to any Pension Plan sufficient to give rise to a Lien under Section 303(k) of ERISA or Section 430(k) of the Code and no event has occurred that would give rise to a Lien under Section 4068 of ERISA. No condition exists or event or transaction has occurred with respect to any Pension Plan which could result in the incurrence by any Credit Party of any liability, fine or penalty in an amount in excess of $500,000. No Credit Party has incurred liability to the PBGC (other than for current premiums) with respect to any employee Pension Plan. Except as would not reasonably be expected to result in material liability to any Credit Party, all contributions (if any) have been made on a timely basis to any Multiemployer Plan that are required to be made by any Credit Party or any other member of the Controlled Group under the terms of the plan or  of any collective bargaining agreement or by applicable Law; no Credit Party nor any member of the Controlled Group has withdrawn or  partially withdrawn from any Multiemployer Plan, incurred any withdrawal liability with respect to any such plan or received notice of any claim or demand for withdrawal liability or partial withdrawal liability from any such plan, and no Credit Party nor any member of the Controlled Group has received any notice that any Multiemployer Plan is in reorganization, that any such plan is or may be terminated, or that any such plan is or may become insolvent.
	
 





	
(a)
	

	
 






40

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 3.15 Consummation of Financing Documents; Brokers. Except for  fees payable to  Agent and/or Lenders and except as set forth on Schedule 3.15, no broker, finder or other intermediary  has brought about the obtaining, making or closing of the transactions contemplated by the Financing Documents, and except as set forth on Schedule 3.15 no Credit Party has or will have any obligation to any Person in respect of any finder’s or brokerage fees, commissions or other expenses in connection herewith or therewith.

 

Section 3.16Reserved.

 

Section 3.17 Material Contracts. Except for the Operative Documents and the agreements set forth on Schedule 3.17, as of the Closing Date there are no Material Contracts. The consummation of the transactions contemplated by the Financing Documents will not give rise to a right of termination in favor of any party to any Material Contract (other than any Credit Party), except for such Material Contracts the noncompliance with which would not reasonably be expected to have a Material Adverse Effect.

 

Section 3.18  Compliance with Environmental Requirements; No Hazardous Materials.  Except in each case as set forth on Schedule 3.18:

 


	
(a)
	
no notice, notification, demand, request for information, citation, summons, complaint or order has been issued, no complaint has been filed, no penalty has been assessed and no investigation or review is pending, or to such Borrower’s knowledge, threatened in writing by any Governmental Authority or other Person with respect to any (i) alleged violation by any Credit Party of any Environmental Law, (ii) alleged failure by any Credit Party to have any Permits required under any Environmental Law in connection with the conduct of its business or to comply with the terms and conditions thereof, (iii) any generation, treatment, storage, recycling, transportation or disposal of any Hazardous Materials by any Credit Party or any of its Subsidiaries, or (iv) release of Hazardous Materials caused by any Credit Party, any of its Subsidiaries, or any of its agents; and
	
 




 


	
(b)
	
no property now owned or, to the knowledge of each Borrower, leased by any Credit Party and, to the knowledge of each Borrower, no such property previously owned or leased by any Credit Party, to which any Credit Party has, directly or indirectly, transported or arranged for the transportation of any Hazardous Materials, is listed or, to such Borrower’s knowledge, proposed for listing, on the National Priorities List promulgated pursuant to CERCLA, or CERCLIS (as defined in CERCLA) or any similar state list or is the subject of federal, state or local enforcement actions or, to the knowledge of such Borrower, other investigations which may lead to claims against any Credit Party for clean-up costs, remedial work, damage to natural resources or personal injury claims, including, without limitation, claims under CERCLA except in the case of the forgoing as would not reasonably be expected to result in a Material Adverse Effect.
	
 




 

Section 3.19 Intellectual Property and License Agreements.  A  list  of  all  Registered  Intellectual Property of each Credit Party and all material in-bound license or sublicense agreements, material exclusive out-bound license or sublicense agreements, or other rights of any Credit Party to use material Intellectual Property (but excluding in-bound licenses of over-the-counter software that is commercially available to the public), as of the Closing Date and, as updated pursuant to Section 4.15, is set forth on Schedule 3.19. Schedule 3.19 shall be prepared by Borrower in the form provided by Agent and contain all information required in such form. Except for Permitted Licenses, each Credit Party is the sole owner of its material Intellectual Property free and clear of any Liens other than Permitted Liens. No part of the Material Intangible Assets has been judged invalid or unenforceable, in whole or in part, and to the Borrower’s knowledge, no claim has been made in writing that any part of the Intellectual Property violates the rights of any third party where the effect of such violation would reasonably be expected to have a Material Adverse Effect.

 



41

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 3.20 Solvency. After giving effect to the Loan advances and the liabilities  and obligations of each Borrower under the Operative Documents, each Borrower (after giving effect to all rights of such Borrower arising by virtue of Section 2.10(b) and any other rights of contribution or similar rights of such Borrower) is Solvent and the Credit Parties (taken as a whole) are Solvent.

 

Section 3.21 Full Disclosure. The  material  written  information  (financial  or  otherwise) relating to the Credit Parties, other than projections furnished by or on behalf of any Credit Party to Agent or any Lender in connection with the consummation of the transactions contemplated by the Operative Documents, when taken as a whole, is accurate and complete in all material respects and does not and will not, when taken as a whole, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not materially misleading in light of the circumstances under which such statements were made. All financial projections delivered to Agent and Lenders by Borrowers (or their agents) have been prepared on the basis of the assumptions stated therein. Such projections represent each Borrower’s good faith estimate of such Borrower’s future financial performance and such assumptions are believed by such Borrower to be fair and reasonable in light of current business conditions; provided, however, that it being understood that projections are as to future events and are not to be viewed as facts, projections are subject to significant uncertainties and contingencies, many of which are beyond Borrowers’ control, that Borrowers can give no assurance that such projections will be attained and that actual results during the period or periods covered by any such projections may differ significantly from the projected results and such differences may be material.

 

Section 3.22 Interest Rate. The rate of interest  paid under  the Notes  and the method and  manner of the calculation thereof do not violate any usury or other law or applicable Laws on the Closing Date, any of the Organizational Documents, or any of the Operative Documents.

 

Section 3.23 Subsidiaries. Borrowers do not own any stock, partnership interests,  limited liability company interests or other equity securities or Subsidiaries except for Permitted Investments.

 

Section 3.24Reserved.

 

Section 3.25 Accuracy of Schedules. All information set forth in the Schedules  to  this Agreement (including Schedule 3.19 and Schedule 8.2(a)) is true, accurate and complete as of the Closing Date, the date of delivery of the last Compliance Certificate and any other subsequent date in which Borrower is requested to update such Schedules in accordance with this Agreement. All information set forth in the Perfection Certificate is true, accurate and complete as of the Closing Date and any other subsequent date in which Borrower is requested to update such certificate in accordance with this Agreement.

 

ARTICLE 4 - AFFIRMATIVE COVENANTS

 

Each Borrower agrees that, so long as any Credit Exposure exists:

 

Section 4.1Financial Statements and Other  Reports.   Each Borrower  will deliver  to Agent:

(a)as soon as available, but no later than thirty (30) days after the last day of each month, a bank statement of each Borrower certified by a Responsible Officer and in a form reasonably acceptable to the Agent; (b) as soon as available, but no later than forty-five (45) days after the last day of each fiscal quarter, a company prepared consolidated balance sheet, cash flow and income statement covering Borrowers’ and their Consolidated Subsidiaries’ consolidated operations during the period, prepared under GAAP, consistently applied, certified by a Responsible Officer and in a form reasonably acceptable to Agent; (c) as soon as available, but no later than one hundred twenty (120) days after the last day of Borrower’s  fiscal  year,  audited consolidated  financial  statements  prepared under  GAAP, consistently

(a)



42

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


applied, together with an unqualified opinion on the financial statements from Ernst & Young or another independent certified public accounting firm acceptable to Agent in its reasonable discretion; (d) within five (5) Business Days of delivery or filing thereof, copies of all material statements, reports and notices made available to Borrowers’ security holders or to any holders of any Subordinated Debt and copies of all reports and other filings made by any Borrower with any stock exchange on which any securities of any Borrower are traded and/or the SEC; (e) a prompt written report of any legal actions pending or threatened in writing against any Borrower or any of its Subsidiaries that would reasonably be expected to result in damages or costs to any Borrower or any of its Subsidiaries of Five Hundred Thousand Dollars ($500,000) or more; (f) prompt written notice of an event that materially and adversely affects the value  of any Intellectual Property; (g) within sixty (60) days after the start of each fiscal year, projections for  the forthcoming two fiscal years, on a quarterly basis for the current year and on an annual basis for the subsequent year; and (h) promptly (and in any event within ten (10) days of any request therefor) such readily available other budgets, sales projections, operating plans and other financial information and information, reports or statements regarding the Borrowers, their business and the Collateral as Agent may from time to time reasonably request; provided, however, that reporting related to Regulatory Required Permits and/or Regulatory Reporting Events shall be governed by Section 4.16. Each Borrower will, within thirty (30) days after the last day of each month, deliver to Agent with the monthly financial statements described in clause (a) above, a duly completed Compliance Certificate signed by a Responsible Officer setting forth calculations showing compliance with the financial covenants set forth in this Agreement.

 

Section 4.2 Payment and Performance of Obligations. Each Borrower (a) will  pay  and discharge, and cause each Subsidiary to pay and discharge, on a timely basis as and when due, all of their respective obligations and liabilities, except for such obligations and/or liabilities (i) that may be the subject of a Permitted Contest, and (ii) the nonpayment or nondischarge of which would not reasonably  be expected to have a Material Adverse Effect or result in a Lien against any Collateral, except for Permitted Liens, (b) without limiting anything contained in the foregoing clause (a), and except to the extent subject to a Permitted Contest, pay all amounts due and owing in respect of taxes (including without limitation, payroll and withholding tax liabilities) on a timely basis as and when due, and in any case prior to the date on which any fine, penalty, interest, late charge or loss may be added thereto for nonpayment thereof, (c) will maintain, and cause each Subsidiary to maintain, in accordance with GAAP, reserves in respect of their respective obligations and liabilities as such obligations and liabilities are reasonably expected to become due and payable, and (d) will not breach or permit any Subsidiary to breach, or permit to exist any default under, the terms of any lease, commitment, contract, instrument or obligation to which it is a party, or by which its properties or assets are bound, except for such breaches or defaults which would not reasonably be expected to have a Material Adverse Effect.

 

Section 4.3 Maintenance of Existence. Each Borrower  will preserve, renew and keep in full force and effect and in good standing, and will cause each Subsidiary to preserve, renew and keep in full force and effect and in good standing, (a) their respective existence (except as resulting from transactions permitted by Section 5.6) and (b) their respective rights, privileges and franchises necessary or desirable in the normal conduct of business except, in case of this clause (b) where a failure to do so would not reasonably be expected to result in a Material Adverse Effect.

 

Section 4.4Maintenance of Property; Insurance.

 


	
(a)
	
Each Borrower will keep, and will cause each Subsidiary to keep, all property useful and necessary in its business in good working order and condition, ordinary wear and tear excepted. If all or any part of the Collateral necessary in its business becomes damaged or destroyed, each Borrower will, and will cause each Subsidiary to, promptly and completely repair and/or restore the affected Collateral in a good and workmanlike manner.
	
 





	
(a)
	

	
 






43

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(b)
	
Upon completion of any Permitted Contest, Borrowers shall, and will  cause each Subsidiary to, promptly pay the amount due, if any, and deliver to Agent proof of the completion of the contest and payment of the amount due, if any.
	
 




 


	
(c)
	
Each Borrower will maintain (i) property and casualty insurance on all real and personal property on an all risks basis (including the perils of flood, windstorm and quake, if applicable), covering the repair and replacement cost of all such property and coverage, business interruption and rent loss coverages with extended period of indemnity (for the period required by Agent from time to time) and indemnity for extra expense, in each case without application of coinsurance and with agreed amount endorsements, (ii) general and professional liability insurance (including products/completed operations liability coverage), and (iii) such other insurance coverage, in each case against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are customarily carried under similar circumstances by such other Persons; provided, however, that, in no event shall such insurance be in amounts or with coverage less than, or with carriers with credit ratings materially inferior to, any of the insurance or carriers in existence as of the Closing Date (or required to be in existence after the Closing Date under a Financing Document).
	
 




 


	
(d)
	
On or prior to the Closing Date, and at all times thereafter, each Borrower will cause Agent to be named as an additional insured, assignee and lender loss payee (which shall include, as applicable, identification as mortgagee), as applicable, on each policy of property, casualty or liability insurance required to be maintained pursuant to this Section 4.4 pursuant to endorsements in form and substance reasonably acceptable to Agent. Borrowers shall deliver to Agent and Lenders (i) on the Closing Date, a certificate from Borrowers’ insurance broker dated such date showing the amount of coverage as of such date, and that such policies will include effective waivers (whether under the terms of any such policy or otherwise) by the insurer of all claims for insurance premiums against all loss payees and additional insureds (other than Credit Parties) and all rights of subrogation against all loss payees and additional insureds (other than Credit Parties), and that if all or any part of such policy is canceled, terminated or expires, the insurer will forthwith give notice thereof to each additional insured or loss payee and that no cancellation, reduction in amount or material change in coverage thereof shall be effective until at least thirty (30) days after receipt by each additional insured, assignee and loss payee of written notice thereof (ten (10) days in the case of non-payment of premium), (ii) on an annual basis, and upon the request of any Lender through Agent from time to time all information as to the insurance carried reasonably requested by Agent, (iii) within five (5) Business Days of receipt of notice from any insurer, a copy of any notice of cancellation, nonrenewal or material change in coverage from that existing on the date of this Agreement, (iv) forthwith, notice of any cancellation or nonrenewal of coverage by any Borrower, and (v) at least twenty (20) Business Days prior to expiration of any policy of insurance, evidence of renewal of such insurance upon the terms and conditions herein required.
	
 




 


	
(e)
	
In the event any Borrower fails to provide Agent with evidence of the insurance coverage required by this Agreement promptly following request, Agent may purchase insurance at Borrowers’ expense to protect Agent’s interests in the Collateral. This insurance may, but need not, protect such Borrower’s interests. The coverage purchased by Agent may not pay any claim made by such Borrower or any claim that is made against such Borrower in connection with the Collateral. Such Borrower may later cancel any insurance purchased by Agent, but only after providing Agent with evidence that such Borrower has obtained insurance as required by this Agreement. If Agent purchases insurance for the Collateral, Borrowers will be responsible for the costs of that insurance to the fullest extent provided by law, including interest and other charges imposed by Agent in connection with the placement of the insurance, until the effective date of the cancellation or expiration of  the insurance.  The costs of the insurance may be added to the Obligations. The costs of the insurance may  be more than the cost of insurance such Borrower is able to obtain on its own.
	
 





	
(a)
	

	
 






44

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 4.5 Compliance with Laws and Material Contracts. Each Borrower will comply, and cause each Subsidiary to comply, with the requirements of all applicable Laws and Material Contracts, except to the extent that failure to so comply would not reasonably be expected to (a) have a Material Adverse Effect, or (b) result in any Lien upon a material portion of the assets of any such Person in favor of any Governmental Authority.

 

Section 4.6 Inspection of Property, Books and Records.  Each Borrower will keep, and will  cause each Subsidiary to keep, proper books of record substantially in accordance with GAAP in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities; and will permit, and will cause each Subsidiary to permit, at the sole cost of the applicable Borrower or any applicable Subsidiary, representatives of Agent and of any Lender (if accompanied by Agent) to visit and inspect any of their respective properties, to examine and make abstracts or copies from any of their respective books and records, to conduct a collateral audit and analysis of their respective operations and the Collateral, to verify the amount and age of the Accounts, the identity and credit of the respective Account Debtors, to review the billing practices of Borrowers and to discuss their respective affairs, finances and accounts with their respective officers, employees and independent public accountants as often as may reasonably be desired; provided that, in the absence of a Default or an Event of Default, such rights pursuant to this Section 4.6 may be exercised (a) during reasonable business hours,

(b)on at least two (2) Business Days advance written notice and (c) not more than twice per calendar year at the Borrowers’ expense; provided further that the restrictions set forth in clause (a) through (c) shall not apply during the existence and continuance of any Event of Default.

 

Section 4.7Use of  Proceeds.Borrowers shall use the proceeds of the Loans solely for

(a)transaction fees incurred in connection with the Financing Documents, and (b) for working capital needs of Borrowers and their Subsidiaries. No portion of the proceeds of the Loans will be used for family, personal, agricultural or household use.

 

Section 4.8      Estoppel Certificates.  After written request by Agent which, so long as no Event of Default has occurred and is continuing, shall be limited to one (1) such request per fiscal year of Borrowers, Borrowers, within fifteen (15) days and at their expense, will furnish Agent with a statement, duly acknowledged and certified, setting forth (a) the amount of the original principal amount of the Notes, and the unpaid principal amount of the Notes, (b) the rate of interest of the Notes, (c) the date payments of interest and/or principal were last paid, (d) any offsets or defenses to the payment of the Obligations, and if any are alleged, the nature thereof, (e) that the Notes and this Agreement have not been modified or if modified, giving particulars of such modification, and (f) that there has occurred and is then continuing no Default or if such Default exists, the nature thereof, the period of time it has existed, and the action being taken to remedy such Default. After written request by Agent, which, so long as no Event of Default has occurred and is continuing, shall be limited to one (1) such request per fiscal year of Borrowers, Borrowers, within fifteen (15) days and at their expense, will furnish Agent with a certificate, signed by a Responsible Officer of Borrowers, updating all of the representations and warranties contained in this Agreement and the other Financing Documents and making any required disclosures required to make such representations and warranties to be true, accurate and complete (after taking into such disclosures as if such representations and warranties provided for disclosure schedules) and certifying that all of the representations and warranties contained in this Agreement and the other Financing Documents, as updated pursuant to such certificate and such required disclosures, are true, accurate and complete in all material respects as of the date of such certificate.

 

Section 4.9Notices of Material Contracts, Litigation and Defaults.

 


	
(a)
	
Borrower shall provide three (3) Business Days (i) written notice to Agent of Borrower (1) executing and delivering any amendment, consent, waiver or other modification to any
	
 





	
(a)
	

	
 






45

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Material Contract which is material and adverse to such Material Contract or which would reasonably be expected to have a Material Adverse Effect or (2) receiving or delivering any notice of termination or default or similar notice in connection with any Material Contract and (ii) together with delivery of the Compliance Certificate due after such date (included as an update to any such schedule delivered therewith) the execution of any new Material Contract and/or any new material amendment, consent, waiver or other modification to any Material Contract not previously disclosed.

 


	
(b)
	
Borrowers will give prompt written notice to Agent (i) of any litigation or governmental proceedings pending or threatened (in writing) against Borrowers or other Credit Party which would reasonably be expected to have a Material Adverse Effect with respect to Borrowers or any other Credit Party or which in any manner calls into question the validity or enforceability of any Financing Document, (ii) upon any Borrower becoming aware of the existence of any Default or Event of Default, (iii) of any strikes or other labor disputes pending or, to any Borrower’s knowledge, threatened in writing against any Credit Party, which would reasonably be expected to have a Material Adverse Effect (iv) if there is any infringement or written claim of infringement by any other Person with respect to any Intellectual Property rights of any Credit Party that would reasonably be expected to have a Material Adverse Effect, or if there is any written claim by any other Person that any Credit Party in the conduct of its business is infringing on the Intellectual Property rights of others and an adverse resolution of such claim would reasonably be expected to have a Material Adverse Effect, and (v) of all returns, recoveries, disputes and claims that involve more than $250,000. Borrowers represent and warrant that Schedule 4.9 sets forth a complete list of all matters existing as of the Closing Date for which notice could be required under this Section and all litigation or governmental proceedings pending or threatened (in writing) against Borrowers or other Credit Party as of the Closing Date.
	
 




 


	
(c)
	
Borrower shall, and shall cause each Credit Party, to provide such further information (including copies of such documentation) as Agent or any Lender shall reasonably request with respect to any of the events or notices described in clauses (a) and (b) above. From the date hereof and continuing through the termination of this Agreement, Borrower shall, and shall cause each Credit Party to, make reasonably available to Agent and each Lender, without expense to Agent or any Lender, each Credit Party’s officers, employees and agents and books, to the extent that Agent or any Lender may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Agent or any Lender with respect to any Collateral or relating to a Credit Party.
	
 




 


	
(d)
	
Borrower shall, and shall cause each Credit Party to, promptly (but in any event within five (5) Business Days of any request therefor) deliver to Agent information and documentation reasonably requested by Agent or any Lender for purposes of compliance with applicable “know your customer” requirements under the PATRIOT Act or other applicable anti-money laundering laws.
	
 





	
(a)
	

	
 






46

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 4.10 Hazardous Materials; Remediation. If any release or disposal of Hazardous Materials shall occur or shall have occurred on any real property owned or leased by a Credit Party or any other assets of any Borrower or any other Credit Party, such Borrower will cause, or direct the applicable Credit Party to cause, the prompt containment and removal of such Hazardous Materials and the remediation of such real property or other assets to the extent required to comply with all applicable Environmental Laws and to preserve the value of such real property or other assets except as would not reasonably be expected to result in a Material Adverse Effect. Without limiting the generality of the foregoing, each Borrower shall, and shall cause each other Credit Party to, comply with each Environmental Law requiring the performance at any real property by any Credit Party of activities in response to the release or threatened release of a Hazardous Material except as would not reasonably be expected to have a Material Adverse Effect

 

Section 4.11Further Assurances.

 


	
(a)
	
Each Borrower will, and will cause each Subsidiary to, at its own cost and expense, promptly and duly take, execute, acknowledge and deliver all such further acts, documents and assurances as may from time to time be necessary or as Agent or the Required Lenders may from time to time reasonably request in order to carry out the intent and purposes of the Financing Documents and the transactions contemplated thereby, including all such actions to (i) establish, create, preserve, protect and perfect a first priority Lien (subject only to Permitted Liens) in favor of Agent for itself and for the benefit of Lenders on the Collateral (including Collateral acquired after the Original Closing Date),
	
 




(ii)unless Agent shall agree otherwise in writing, cause all Subsidiaries of Borrowers (other than Excluded Foreign Subsidiaries) to be jointly and severally obligated with the other Borrowers under all covenants and obligations under this Agreement, including the obligation to repay the Obligations.

 


	
(b)
	
Upon receipt of an affidavit of an authorized representative of Agent or  a Lender as to the loss, theft, destruction or mutilation of any Note or any other Financing Document which is not of public record, and, in the case of any such mutilation, upon surrender and cancellation of such Note or other applicable Financing Document, Borrowers will issue, in lieu thereof, a replacement Note or other applicable Financing Document, dated the date of such lost, stolen, destroyed or mutilated Note or other Financing Document in the same principal amount thereof and otherwise of like tenor.
	
 




 


	
(c)
	
Upon the request of Agent, Borrowers shall obtain a landlord’s agreement or mortgagee agreement, as applicable, from the lessor of each leased property or mortgagee of owned property with respect to any business location where any material portion of the Collateral included or the records relating to such Collateral and/or software and equipment relating to such records or Collateral, is stored or located (unless such books and records are also located at another business location that is subject to landlord’s or mortgagee agreement in favor of Agent), which agreement or letter shall be reasonably satisfactory in form and substance to Agent. Borrowers shall timely and fully pay and perform its obligations under all leases and other agreements with respect to each leased  location where any Collateral, or any records related thereto, is or may be located.
	
 




 


	
(d)
	
Borrower shall provide Agent with at least thirty (30) days (or such shorter period as Agent may accept in its sole discretion) prior written notice of its intention to create (or to the extent permitted under this Agreement, acquire) a new Subsidiary. Upon the formation (or to the extent permitted under this Agreement, acquisition) of a new Subsidiary, Borrowers shall (i) pledge, have pledged or cause or have caused to be pledged to Agent pursuant to a pledge agreement in form and substance satisfactory to Agent, all of the outstanding shares of equity interests or other equity interests of such new Subsidiary owned directly or indirectly by any Borrower (unless such shares constitute Excluded Property or are held by an Excluded Foreign Subsidiary or an Excluded Domestic Holdco), along with undated stock or equivalent powers for such certificates, executed in blank; (ii) unless Agent
	
 





	
(a)
	

	
 






47

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


shall agree otherwise in writing, cause such new Subsidiary (other than an Excluded Foreign Subsidiary or an Excluded Domestic Holdco) to take such other actions (including entering into or joining any Security Documents) as are necessary or advisable in the reasonable opinion of Agent in order to grant Agent, acting on behalf of the Lenders, a first priority Lien (subject to Permitted Liens) on all real and personal property of such Subsidiary in existence as of such date and in all after acquired property, which first priority Liens are required to be granted pursuant to this Agreement; (iii) unless Agent shall agree otherwise in writing, cause such new Subsidiary (other than an Excluded Foreign Subsidiary or an Excluded Domestic Holdco) to either (at the election of Agent) become a Borrower hereunder with joint and several liability for all obligations of Borrowers hereunder and under the other Financing Documents pursuant to a joinder agreement or other similar agreement in form and substance reasonably satisfactory to Agent or to become a Guarantor of the obligations of Borrowers hereunder and under the other Financing Documents pursuant to a guaranty and suretyship agreement in form and substance satisfactory to Agent; and (iv) cause such new Subsidiary (other than an Excluded Foreign Subsidiary or an Excluded Domestic Holdco) to deliver certified copies of such Subsidiary’s certificate or articles of incorporation, together with good standing certificates, by-laws (or other operating agreement or governing documents), resolutions of the Board of Directors or other governing body, approving and authorize the execution and delivery of the Security Documents, incumbency certificates and to execute and/or deliver such other documents and legal opinions or to take such other actions as may be reasonably requested by Agent, in each case, in form and substance reasonably satisfactory to Agent.

 


	
(e)
	
Borrower further agrees to comply, and cause its respective Subsidiaries to comply with the following requirements with respect to the Excluded Foreign Subsidiaries the total amount of cash and cash equivalents held by the Excluded Foreign Subsidiaries (collectively) shall not at any time exceed the lesser of (i) $3,000,000 in the aggregate; and (ii) the aggregate amount necessary to fund the current and projected operating expenses of each Excluded Foreign Subsidiary (after taking into account its revenue from other sources, in each case) as determined based on projections prepared by Borrower and approved by Agent (such approval not to be unreasonably withheld or delayed).
	
 




 


	
(f)
	
Following (a) the occurrence and continuation of an Event of Default and (b) the exercise by Agent of any right, option or remedy provided for hereunder, under any Financing Document or at law or in equity, Credit Parties shall cause each Excluded Foreign Subsidiary to declare and pay to the applicable Credit Party the maximum amount of dividends and other distributions in respect of its capital stock or other equity interest legally permitted to be paid by each such Excluded Foreign Subsidiary; provided that such Excluded Foreign Subsidiary shall be able to retain for working capital purposes such other amounts used by such Excluded Foreign Subsidiaries in the Ordinary Course of Business and as are reasonable necessary for its operations based on its current projections, as provided to the Agent pursuant to Section 4.1.
	
 




 

Section 4.12Reserved.

 

Section 4.13 Power of Attorney. Each of the authorized representatives of Agent is hereby irrevocably made, constituted and appointed the true and lawful attorney for Borrowers (without requiring any of them to act as such) with full power of substitution to do the following: (a) endorse the name of Borrowers upon any and all checks, drafts, money orders, and other instruments for the payment of  money that are payable to Borrowers and constitute collections on Borrowers’ Accounts; (b) so long as Agent has provided not less than five (5) Business Days’ prior written notice to Borrower to perform the same and Borrower has failed to take such action, execute in the name of Borrowers any schedules, assignments, instruments, documents, and statements that Borrowers are obligated to give Agent under this Agreement; (c) after the occurrence and during the continuance of an Event of Default, take any action Borrowers are required to take under this Agreement; (d) so long as Agent has provided not less than five (5) Business Days’ prior written notice to Borrower to perform the same and Borrower has

 



48

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


failed to take such action, do such other and further acts and deeds in the name of Borrowers that Agent may deem necessary or desirable to enforce any Account or other Collateral or perfect Agent’s security interest or Lien in any Collateral; and (e) after the occurrence and during the continuance of an Event of Default, do such other and further acts and deeds in the name of Borrowers that Agent may deem necessary or desirable to enforce its rights with regard to any Account or other Collateral. This power of attorney shall be irrevocable and coupled with an interest.

 

Section 4.14Reserved.

 

Section 4.15 Schedule Updates. Borrower shall, in the event of any  information  in  the Schedules becoming outdated, inaccurate, incomplete or misleading, deliver to Agent, together with the next Compliance Certificate required to be delivered under this Agreement after such event a proposed update to such Schedule correcting all outdated, inaccurate, incomplete or misleading information; provided, however, with respect to any proposed updates to the Schedules involving Permitted Liens, Permitted Debt or Permitted Investments, Agent will replace the respective Schedule attached hereto with such proposed update only if such updated information is consistent with the definitions of and limitations herein pertaining to Permitted Liens, Permitted Debt or Permitted Investments.

 

Section 4.16Intellectual Property and Licensing.

 


	
(a)
	
Together with each quarterly Compliance Certificate required to be delivered pursuant to Section 4.1 to the extent (A) Borrower acquires and/or develops any new Registered Intellectual Property registered in the United States or any new material foreign Registered Intellectual Property, in each case, for which it is the registered owner, or (B) Borrower enters into or becomes bound by any additional in-bound license or sublicense agreement, any additional exclusive out-bound license or sublicense agreement with respect to rights in Intellectual Property (other than (i) over-the-counter software that is commercially available to the public and (ii) in-bound license or sublicense agreements that are not material to Borrower’s business), or (C) there occurs any other material change in Borrower’s Registered Intellectual Property, in-bound licenses or sublicenses or exclusive out-bound licenses or sublicenses from that listed on Schedule 3.19 together with such Compliance Certificate, deliver to Agent an updated Schedule 3.19 reflecting such updated information. With respect to any updates to Schedule
	
 




3.19 involving exclusive out-bound licenses or sublicenses, such licenses shall be consistent with the definitions of and limitations herein pertaining to Permitted Licenses.

 


	
(b)
	
If Borrower obtains any Registered Intellectual Property registered in the United States or any material foreign Registered Intellectual Property, in each case, for which it is the registered owner, other than copyrights, mask works and related applications, which are addressed below, Borrower shall notify Agent on a quarterly basis and execute such documents and provide such other information (including, without limitation, copies of applications) and take such other actions as Agent shall request in its good faith business judgment to perfect and maintain a first priority perfected security interest (subject to Permitted Liens) in favor of Agent, for the ratable benefit of Lenders, in (x) prior to the occurrence of a Springing IP Event, the IP Proceeds or (y) upon the occurrence of a Springing IP Event, the Registered Intellectual Property (other than Excluded Property and any security interest that is not required to be perfected under the terms of this Agreement). Upon the occurrence of a Springing IP Event, Borrower shall take such actions as Agent shall request in its good faith business judgment to perfect and maintain a first priority perfected security interest (subject to Permitted Liens) in favor of Agent, for the ratable benefit of Lenders, in the Registered Intellectual Property (other than Excluded Property and any security interest that is not required to be perfected under the terms of this Agreement).
	
 




 


	
(c)
	
Borrower shall, if requested by Agent, take commercially reasonable steps (not involving the payment of money) to obtain the consent of, or waiver by, any person whose consent or
	
 





	
(a)
	

	
 






49

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


waiver is necessary for (x) all licenses or agreements to be deemed “Collateral” and for Agent to have a security interest in it that might otherwise be restricted or prohibited by Law or by the terms of any such license or agreement, whether now existing or entered into in the future, and (y) Agent to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Agent’s rights and remedies under this Agreement and the other Financing Documents.

 


	
(d)
	
Borrower shall own, or be licensed to use or otherwise have the right to use, all Material Intangible Assets. Borrower shall cause all Registered Intellectual Property to be duly and properly registered, filed or issued in the appropriate office and jurisdictions for such registrations, filings or issuances, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect. Borrower shall at all times conduct its business without material infringement of any Intellectual Property rights of others. Borrower shall (i) protect, defend and maintain the validity and enforceability of its Material Intangible Assets (ii) promptly advise Agent in writing of material infringements of its Material Intangible Assets, or of a material claim of infringement by Borrower on the Intellectual Property rights of others; and (iii) not allow any of Borrower’s Material Intangible Assets to be abandoned, invalidated, forfeited or dedicated to the public or to become unenforceable.
	
 




 


	
(e)
	
Borrower shall not become a party to, nor become bound by, any new material license or other agreement after the Closing Date with respect to which Borrower is the licensee that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or other property; provided that this clause (e) shall not prohibit the inclusion of customary anti-assignment provisions in such licenses or other agreements so long as the effect of such provisions would not cause such license or other agreement to be Excluded Property.
	
 




 


	
(f)
	
Each Borrower has executed and delivered to Agent the Intellectual Property Security Agreement. The Intellectual Property Security Agreement shall be held in escrow by Agent, and shall not be in force and effect, unless and until the occurrence of the Springing IP Event, at which time
	
 




(i) the Intellectual Property Security Agreement shall immediately and automatically become effective without any further action or consent by any Borrower and (ii) Agent shall be automatically authorized to file the Intellectual Property Security Agreement (including any updated schedules thereto delivered pursuant to Section 4.16(h)) with the United States Patent and Trademark Office and/or United States Copyright Office, as applicable.

 

(g)Upon the occurrence of a Springing IP Event and continuing at all times thereafter (whether or not the Springing IP Event continues), then automatically and without notice or any further action by Agent, any Lender or any Borrower (i) Agent shall be authorized to file UCC financing statements, financing statement amendments and security agreements (including any Intellectual Property Security Agreement) necessary or desirable to perfect such security interest in the Intellectual Property (other than Excluded Property and any security interest that is not required to be perfected under the terms of this Agreement), and (ii) each Borrower shall execute such other agreements and take such other actions as Agent may reasonably request to establish, perfect or protect Agent’s security interest in the Intellectual Property (other than Excluded Property and any security interest that is not required to be perfected under the terms of this Agreement).

 


	
(h)
	
Borrowers shall promptly (and in any event within three (3) Business Days of the occurrence thereof) provide Agent and each Lender with written notice of the occurrence of a Springing IP Event, which notice shall be accompanied by a certificate from an authorized executive officer from each Borrower (A) acknowledging that the Springing IP Event has occurred, (B) specifying the date on which the Springing IP Event occurred, and (C) acknowledging that Agent may exercise any rights it may have under this Agreement or any other Financing Document with respect to the Springing IP Event. Without limiting the foregoing, Borrowers shall promptly (and in any event within ten (10) days of the
	
 





	
(a)
	

	
 






50

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


occurrence of a Springing IP Event) provide Agent a supplement to the Intellectual Property Security Agreement certifying to and attaching true, correct and complete copies of updated schedules to the Intellectual Property Security Agreement and certifying that all Intellectual Property owned by each Borrower and registered in the United States as of the date of such certification is reflected on such schedules (other than Excluded Property).

 

Section 4.17Regulatory Reporting and Covenants.

 

(a)Borrower shall notify Agent and each Lender promptly, and in any event within 3 Business Days of receiving, becoming aware of or determining that, (each, a “Regulatory Reporting Event” and collectively, the “Regulatory Reporting Events”): (i) any Governmental Authority, specifically including the FDA is conducting or has conducted (A) if applicable, an inspection of any of Borrower’s or its Subsidiaries’ manufacturing facilities and processes for any Product which inspection has disclosed, and notification of which has been provided to Borrower in writing, of any material deficiencies or violations of Laws and/or the Regulatory Required Permits related to such thereto or (B) a material investigation or review of any Regulatory Required Permit (other than routine reviews in the Ordinary Course of Business associated with the renewal or maintenance of a Regulatory Required Permit which would not reasonably be expected to result in a Material Adverse Effect), (ii) development, testing, and/or manufacturing of any Product or provision of any service that is material to the business of Borrower or its Subsidiaries should cease, (iii) a Product that is material to the business of the Borrower or its Subsidiaries has been approved for marketing and sale, any marketing or sales of such Product should cease or such Product should be withdrawn from the marketplace, (v) adverse clinical trial test results with respect to any Product which have or would reasonably be expected to result in a Material Adverse Effect, (vi) any Product Recalls or voluntary Product withdrawals from any market which have or would reasonably be expected to result in a Material Adverse Effect or (vii) any significant failures in the manufacturing of any Product such that the amount of such Product successfully manufactured in accordance with all specifications thereof and any required payments to be made to Borrower therefor in any month shall decrease significantly with respect to the quantities of such Product and payments produced in the prior month, in each case, which would reasonably be expected to result in a Material Adverse Effect. Borrower shall provide to Agent or any Lender such further information (including  copies of such documentation) as Agent or any Lender shall reasonably request with respect to any such Regulatory Reporting Event.

 


	
(b)
	
Borrower shall, and shall cause each Credit Party to, obtain all Regulatory Required Permits necessary for compliance in all material respects with Laws with respect to testing, manufacturing, developing, selling or marketing of Products and shall, and shall cause each Credit Party to, maintain and comply in all material respects with all such Regulatory Required Permits, the noncompliance with which would have a Material Adverse Effect. In the event Borrower or any Credit Party obtains any new material Regulatory Required Permit or any information on the Schedule 8.2(a) becomes outdated, inaccurate, incomplete or misleading, Borrower shall, together with the next Compliance Certificate required to be delivered under this Agreement after such event, provide Agent with an updated Schedule 8.2(a) including such updated information.
	
 




 


	
(c)
	
If, after the Closing Date, (i) Borrower determines to manufacture, sell, develop, test or market any new Product, Borrower shall deliver prior written notice to Agent of such determination (which shall include a brief description of such Product) and, together with delivery of the next Compliance Certificate shall provide an updated Schedule 3.19 and Schedule 8.2(a) (Licensing and Products) (and copies of such Permits as Agent may request) reflecting updates related to such determination
	
 





	
(a)
	

	
 






51

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


ARTICLE 5 - NEGATIVE COVENANTS

 

Each Borrower agrees that, so long as any Credit Exposure exists:

 

Section 5.1    Debt; Contingent Obligations.   No Borrower  will, or  will permit any Subsidiary to, directly or indirectly, create, incur, assume, guarantee or otherwise become or remain directly or indirectly liable with respect to, any Debt, except for Permitted Debt. No Borrower will, or will permit any Subsidiary to, directly or indirectly, create, assume, incur or suffer to exist any Contingent Obligations, except for Permitted Contingent Obligations.

 

Section 5.2 Liens. No Borrower will, or will permit any Subsidiary to, directly or indirectly, create, assume or suffer to exist any Lien on any asset now owned or hereafter acquired by it, except for Permitted Liens.

 

Section 5.3 Distributions. No Borrower will, or will permit any Subsidiary to, directly or indirectly, declare, order, pay, make or set apart any sum for any Distribution, except for Permitted Distributions.

 

Section 5.4 Restrictive Agreements. No Borrower will, or will  permit  any Subsidiary to,  directly or indirectly (a) enter into or assume any agreement (other than the Financing Documents, any Subordinated Debt Documents, and any agreements for purchase money debt permitted under clause (c) of the definition of Permitted Debt) prohibiting the creation or assumption of any Lien upon its properties or assets, whether now owned or hereafter acquired, or (b) create or otherwise cause or suffer to exist or become effective any consensual encumbrance or restriction of any kind (except as provided by the Financing Documents) on the ability of any Subsidiary to: (i) pay or make Distributions to any Borrower or any Subsidiary; (ii) pay any Debt owed to any Borrower or any Subsidiary; (iii) make loans or advances to any Borrower or any Subsidiary; or (iv) transfer any of its property or assets to any Borrower or any Subsidiary.

 

Section 5.5 Payments and Modifications of Subordinated Debt. No Borrower  will, or  will  permit any Subsidiary to, directly or indirectly (a) declare, pay, make or set aside any amount for payment in respect of Subordinated Debt, except for payments made in full compliance with and expressly permitted under the Subordination Agreement, (b) amend or otherwise modify the terms of any Subordinated Debt, except for amendments or modifications made in full compliance with the Subordination Agreement relating thereto, or (c) declare, pay, make or set aside any amount for payment in respect of any Debt hereinafter incurred that, by its terms, or by separate agreement, is subordinated to the Obligations, except for payments permitted under the subordination provisions applicable thereto. Borrowers shall, prior to entering into any such amendment or modification, deliver to Agent reasonably in advance of the execution thereof, any final or execution form copy thereof.

 

Section 5.6Consolidations, Mergers and Sales of Assets; Change in Control.

 


	
(a)
	
No Borrower will, or will permit any Subsidiary to, directly or indirectly consolidate or merge or amalgamate with or into any other Person other than (a) consolidations or mergers among Borrowers where a Borrower is the surviving entity (provided that in the case of any consolidation or merger involving Aptevo Therapeutics, Aptevo Therapeutics shall be the surviving entity), (b) consolidations or mergers among a Guarantor and a Borrower so long as the Borrower is the surviving entity, (c) consolidations or mergers among Guarantors where the Guarantor is the surviving entity, (d) consolidations or mergers among Excluded Foreign Subsidiaries and (e) dissolutions or liquidations of Credit Parties (other than Aptevo Therapeutics) or their Subsidiaries so long as any assets of such dissolved or liquidated Person are transferred to a Borrower.
	
 





	
(a)
	

	
 






52

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(b)
	
No Borrower will, or will permit any Subsidiary to, directly or indirectly consummate any Asset Dispositions other than Permitted Asset Dispositions.
	
 




 


	
 
	
(c)
	
No Borrower will suffer or permit to occur any Change in Control.




 

Section 5.7 Purchase of Assets, Investments.  No  Borrower  will,  or  will  permit  any  Subsidiary to, directly or indirectly (a) without limiting clause (c) below, acquire or enter into any agreement to acquire any assets other than in the Ordinary Course of Business or as permitted under the definition of Permitted Investments; (b) engage or enter into any agreement to engage in any joint venture or statutory or common law partnership with any other Person; or (c) acquire or own or enter into any agreement to acquire or own any Investment in any Person other than Permitted Investments.

 

Section 5.8 Transactions with Affiliates. Except as otherwise disclosed on Schedule 5.8, and except for transactions that are disclosed to Agent in advance of being entered into and transactions which contain terms that are no less favorable to the applicable Borrower or any Subsidiary, as the case may be, than those which might be obtained from a third party not an Affiliate of any Credit Party, no Borrower will, or will permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property or the rendering of any service) with any Affiliate of any Borrower.

 

Section 5.9  Modification  of  Organizational Documents.   No Borrower  will,  or  will permit any Subsidiary to, directly or indirectly, amend or otherwise modify any Organizational Documents of such Person, except for Permitted Modifications.

 

Section 5.10 Modification of Certain Agreements. No Borrower will, or will permit any Subsidiary to, directly or indirectly, amend or otherwise modify any Material Contract, which amendment or modification in any case: (a) is contrary to the terms of this Agreement or any other Financing Document; (b) would reasonably be expected to be materially adverse to the rights, interests or privileges of Agent or the Lenders or their ability to enforce the same; or (c) would reasonably be expected to result in a Material Adverse Effect. Each Borrower shall, prior to entering into any amendment or other modification of any of the foregoing documents, deliver to Agent reasonably in advance of the execution thereof, any final or execution form copy of amendments or other modifications to such documents.

 

Section 5.11 Conduct of Business. No Borrower will,  or  will  permit  any  Subsidiary  to, directly or indirectly, engage in any line of business other than those businesses engaged in on the  Closing Date and other businesses reasonably related thereto. No Borrower will, or will permit any Subsidiary to, other than in the Ordinary Course of Business, change its normal billing payment and reimbursement policies and procedures with respect to its Accounts (including, without limitation, the amount and timing of finance charges, fees and write-offs).

 

Section 5.12Reserved.

 

Section 5.13 Limitation on Sale and Leaseback  Transactions.  No  Borrower  will,  or  will permit any Subsidiary to, directly or indirectly, enter into any arrangement with any Person whereby, in a substantially contemporaneous transaction, any Borrower or any Subsidiaries sells or transfers all or substantially all of its right, title and interest in an asset and, in connection therewith, acquires or leases back the right to use such asset.

 

Section 5.14 Deposit Accounts and Securities Accounts; Payroll and Benefits Accounts. No Borrower will, or will permit any Subsidiary (other than an Excluded Foreign Subsidiary or an Excluded Domestic Holdco) to, directly or indirectly, establish any new Deposit Account or Securities Account

 



53

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


without prior written notice to Agent, and unless Agent, such Borrower or such Subsidiary and the bank, financial institution or securities intermediary at which the account is to be opened enter into a Deposit Account Control Agreement or Securities Account Control Agreement prior to or concurrently with the establishment of such Deposit Account or Securities Account. Borrowers represent and warrant that Schedule 5.14 lists all of the Deposit Accounts and Securities Accounts of each  Borrower.  The provisions of this Section requiring Deposit Account Control Agreements shall not apply to (a) the Wells Fargo Cash Collateral Account, (b) the Wells Fargo LC Cash Collateral Account during the Wells Fargo LC Period, and (c) Deposit Accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrowers’ employees and identified to Agent by Borrowers as such (the Deposit Accounts in clauses (a) through (c), collectively, “Excluded Accounts”); provided, however, that at all times that any Obligations remain outstanding following the date that is thirty (30) days following the Closing Date (the “Post-Closing Payroll Account Period”), Borrower shall maintain one or more separate Deposit Accounts to hold any and all amounts to be used for payroll, payroll taxes and other employee wage and benefit payments, and shall not commingle any monies allocated for such purposes with funds in any other Deposit Account. Without limiting the foregoing, to the extent that any Deposit Account that is a subject to a Deposit Account Control Agreement holds any amounts to be used for payroll, payroll taxes and other employee wage and benefit payments (collectively, “Payroll Amounts”) during the Post-Closing Payroll Account Period, Agent agrees that, upon its exercise of remedies following an Event of Default during such period, it will not direct any Payroll Amounts (that have been reasonably identified by Borrower to Agent as such) to be disposed of other than to pay the applicable payroll, payroll taxes and other employee wage and benefit payments obligations.  With respect to accounts subject to a Deposit Account Control Agreement or Securities Account Control Agreement, Agent shall not deliver to the relevant depository, securities intermediary or commodities intermediary a notice or other instruction (i) directing disposition of funds in such account or (ii) which provides for exclusive control over such account by Agent, unless in either case an Event of Default has occurred and is continuing. Notwithstanding any other provision to the contrary contained herein, upon the expiration of the Wells Fargo LC Period, Borrowers shall promptly transfer all funds on deposit in the Wells Fargo LC Cash Collateral Account to a Deposit Account or Securities Account subject to a Deposit Account Control Agreement or a Securities Account Control Agreement in favor of Agent.

 

Section 5.15 Compliance with Anti-Terrorism Laws. Agent hereby notifies Borrowers that pursuant to the requirements of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is required to obtain, verify and record certain information and documentation that identifies Borrowers and their principals, which information includes the name and address of each Borrower and its principals and such other information that will allow Agent to identify such party in accordance with Anti-Terrorism Laws. No Borrower will, or will permit any Subsidiary to, directly or indirectly, knowingly enter into any Material Contracts with any Blocked Person or any Person listed on the OFAC Lists.  Each Borrower shall immediately notify Agent if such Borrower has knowledge that any Borrower, any additional Credit Party or any of their respective Affiliates or agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is or becomes a Blocked Person or (a) is convicted on,

(b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. No Borrower will, or will permit any Subsidiary to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property  or  interests  in  property  blocked  pursuant  to  Executive  Order  No. 13224, any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.

 



54

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 5.16 Change in Accounting. No Borrower shall,  and no  Borrower  shall  suffer  or permit any of its Subsidiaries to, (i) make any significant change in accounting treatment or reporting practices, except as required by GAAP or (ii) change the fiscal year or method for determining fiscal quarters of any Credit Party or of any consolidated Subsidiary of any Credit Party.

 

ARTICLE 6 - FINANCIAL COVENANTS

 

Section 6.1 Additional Defined Terms. The following additional definitions  are  hereby appended to Section 1.1 of this Agreement:

 

“Borrower Unrestricted Cash” means the aggregate amount of unrestricted cash and cash equivalents of the Borrowers (including any such cash and cash equivalents that are restricted solely as a result of compliance with Section 6.3 of this Agreement) that (a) is held in the name of a Borrower in a Deposit Account or Securities Account that is subject to a Deposit Account Control Agreement or Securities Account Control Agreement, as applicable, in favor of Agent at a depository bank or financial institution located in the United States, (b) is not subject to any Lien (other than Permitted Liens), and (c) are not funds for the payment of a drawn or committed but unpaid draft, ACH or EFT transaction.

 

“Defined Period” means, for purposes of calculating minimum Net Commercial Product Revenue, for any given calendar quarter, the twelve (12) month period ending on the last day of such calendar quarter.

 

“Net Commercial Product Revenue” means, for any period, (a) the consolidated gross revenues of Borrowers and their Subsidiaries generated solely through the commercial sale of the IXINITY product by Borrowers and their Subsidiaries during such period, less (b)(i) trade, quantity and cash discounts allowed by Borrowers, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustments and any other allowances which effectively reduce net selling price and are not reflected in gross revenues,

(iii)product returns and allowances, (iv) allowances for shipping or other distribution expenses, (iv) set- offs and counterclaims by customers, and (v) any other similar and customary deductions made by Borrowers and their Subsidiaries in determining net revenues, all, in respect of (a) and (b), as determined in accordance with GAAP.

 

Section 6.2 Minimum Net Commercial Product Revenue. Borrowers shall not permit consolidated Net Commercial Product Revenue for any Defined Period, as tested quarterly, to be less than the minimum amount set forth on Schedule 6.2 for such Defined Period. A breach of a financial covenant contained in this Section 6.2 shall be deemed to have occurred as of any date of determination by Agent or as of the last day of any specified Defined Period, regardless of when the financial  statements reflecting such breach are delivered to Agent.

 

Section 6.3   Minimum Cash.  Borrower shall not permit the Borrower Unrestricted Cash as of the close of business on any day to be less than $5,000,000.

 

Section 6.4 Evidence of Compliance. Borrowers shall furnish to Agent, together with the  monthly financial reporting required of Borrowers in this Agreement, a Compliance Certificate as evidence of Borrowers’ compliance with the covenants in this Article and evidence that no Event of Default specified in this Article has occurred. The Compliance Certificate shall include, without limitation, (a) a statement and report, on a form reasonably approved by Agent, detailing Borrowers’ calculations, and (b) if requested by Agent, back-up documentation (including, without limitation, bank statements, invoices, receipts and other evidence of costs incurred during such quarter as Agent shall reasonably require) evidencing the propriety of the calculations.

 



55

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


ARTICLE 7 - CONDITIONS

 

Section 7.1    Conditions to Closing.   The obligation of  each Lender  to make the initial Loans on the Closing Date shall be subject to the receipt by Agent of each agreement, document and instrument set forth on the closing checklist attached hereto as Exhibit F, each in form and substance reasonably satisfactory to Agent, and to the satisfaction of the following conditions precedent, each to the reasonable satisfaction of Agent:

 


	
(a)
	
the receipt by Agent of executed counterparts of this Agreement and the other Financing Documents as set forth in the closing checklist provided by Agent to the Borrowers prior to the Closing Date;
	
 




 


	
(b)
	
the payment of all fees, expenses and other amounts due and payable under each Financing Document;
	
 




 


	
(c)
	
since December 31, 2017, the absence of any material adverse change in any aspect of the business, operations, properties, or financial condition of any Credit Party, or any event or condition which would reasonably be expected to result in such a material adverse change;
	
 




 

Each Lender, by delivering its signature page to this Agreement, shall be deemed to have acknowledged receipt of, and consented to and approved, each Financing Document, each additional Operative Document and each other document, agreement and/or instrument required to be approved by Agent, Required Lenders or Lenders, as applicable, on the Closing Date.

 

Section 7.2 Conditions to Each Loan. The obligation of the Lenders to make a Loan or an advance in respect of any Loan, is subject to the satisfaction of the following additional conditions:

 


	
(a)
	
the fact that, immediately before and after such advance, no Default or Event of Default shall have occurred and be continuing;
	
 




 


	
(b)
	
the fact that the representations and warranties of each Credit Party contained in the Financing Documents shall be true, correct and complete on and as of the Closing Date, except to the extent that any such representation or warranty relates to a specific date (in which case such representation or warranty shall be true and correct as of such earlier date); and
	
 




 


	
(c)
	
since the Closing Date, no event has occurred which would be reasonably likely to have a Material Adverse Effect.
	
 




 

Each giving of a Notice of Borrowing hereunder and each acceptance by any Borrower of the proceeds of any Loan made hereunder shall be deemed to be a representation and warranty by each Borrower on the date of such notice or acceptance as to the satisfaction of the conditions specified in this Section.

 

Section 7.3 Searches. Before the Original Closing Date, and thereafter  (as  and  when  determined by Agent in its discretion), Agent shall have the right to perform, all at Borrowers’ reasonable expense, the searches described in clauses (a), (b), and (c) below against Borrowers and any other Credit Party, the results of which are to be consistent with Borrowers’ representations and warranties under this Agreement and the satisfactory results of which shall be a condition precedent to all advances of Loan proceeds: (a) UCC searches with the Secretary of State of the jurisdiction in which the applicable Person is organized; (b) judgment, pending litigation, federal tax lien, personal property tax lien, and corporate and partnership tax lien searches, in each jurisdiction searched under clause (a) above; and (c) searches of

 



56

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


applicable corporate, limited liability company, partnership and related records to confirm the continued existence, organization and good standing of the applicable Person and the exact legal name under which such Person is organized.

 

Section 7.4 Post Closing Requirements. Borrowers shall complete each of the post closing obligations and/or provide to Agent each of the documents, instruments, agreements and information listed on Schedule 7.4 attached hereto on or before the date set forth for each such item thereon (or such later date as Agent may agree in its sole discretion), each of which shall be completed or provided in form and substance reasonably satisfactory to Agent.

 

ARTICLE 8 – REGULATORY MATTERS

 

Section 8.1Reserved.

 

Section 8.2 Representations and Warranties. To induce Agent and Lenders to enter into this Agreement and to make credit accommodations contemplated hereby, Borrowers hereby represent and warrant that all of the information regarding the Borrowers set forth in Schedule 8.2(a) is true, complete and correct, and that, except as disclosed in Schedule 8.2(b), the following statements are true, complete and correct as of the Closing Date, and Borrowers hereby covenant and agree to notify Agent within three

(3)Business Days (but in any event prior to Borrowers submitting any requests for advances of reserves or escrows or fundings of credit facility proceeds under this Agreement) following the occurrence of any facts, events or circumstances known to a Borrower, whether threatened, existing or pending, that would make any of the following representations and warranties materially untrue, incomplete or incorrect (together with such supporting data and information as shall be necessary to fully explain to Agent the scope and nature of the fact, event or circumstance), and shall provide to Agent within two (2) Business Days of Agent’s request, such additional information as Agent shall request regarding such disclosure:

 

(a)Disclosure. All of Borrower’s Products and Regulatory Required Permits are listed on Schedule 8.2(a) (as updated from time to time pursuant to Section 4.15).

 


	
(b)
	
Permits. Borrowers have (i) each material Permit , and have made all material declarations and filings relating to such Permits with, all applicable Governmental Authorities, all self regulatory authorities and all courts and other tribunals necessary to engage in the ownership, management and operation of the business or the assets of any Borrower, and (ii) received no written notice from any Governmental Authority stating that it is limiting, suspending or revoking any such Permit where such limiting, suspending or revoking would reasonably be expected to have a Material Adverse Effect. Borrower has delivered to Agent a copy of all Permits requested by Agent as of the Closing Date or to the extent requested by Agent pursuant to Section 4.17. All such Permits are valid and in full force and effect and Borrowers are in material compliance with the terms and conditions of all such Permits, except where failure to be in such compliance or for a Permit to be valid and in full force and effect would not have a Material Adverse Effect.
	
 




 


	
(c)
	
Regulatory Required Permits. With respect to any Product, (i) Borrower and its Subsidiaries have received, and such Product is the subject of, all Regulatory Required Permits needed to be held by Borrower and its Subsidiaries under applicable Laws in connection with their testing, manufacture, marketing or sale of such Product except where the failure to receive or be the subject of such Regulatory Required Permits would not reasonably be expected to have Material Adverse Effect, and no Borrower has received any written notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is, outside of the normal maintenance or renewal process, conducting an investigation or review of any such Regulatory Required Permit or approval which has disclosed, and notification of which has been provided to Borrower in writing, any
	
 





	
(a)
	

	
 






57

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


material deficiencies or violations of the Regulatory Required Permits, or that any such Regulatory Required Permit has been revoked or withdrawn where such revocation or withdrawal would reasonably be expected to have Material Adverse Effect, nor has any such Governmental Authority issued any written order or recommendation stating that such development, testing, manufacturing, marketing or sales of such Product by Borrower should cease, where such cessation would reasonably be expected to have Material Adverse Effect (ii) to Borrower’s knowledge, such Product is being tested, manufactured, marketed or sold, as the case may be, in material compliance with all applicable Laws and Regulatory Required Permits, and Borrower has not received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or inspection of (A) Borrower’s manufacturing facilities and processes for such Product which have disclosed any material deficiencies or violations of Laws (including Healthcare Laws) and/or the Regulatory Required Permits related to the manufacture of such Product, or (B) (outside of the normal maintenance or renewal process) any such Regulatory Required Permit or that any such Regulatory Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that the development, testing and/or manufacturing of such Product by Borrower should cease and in each case would reasonably be expected to have a Material Adverse Effect.

 


	
 
	
(d)
	
Healthcare and Regulatory Events.




 


	
(i)
	
None of the Borrowers are in violation of any Healthcare Laws, except where any such violation would not reasonably be expected to have a Material Adverse Effect.
	
 




 


	
 
	
(ii)
	
As of the Closing Date, there have been no Regulatory Reporting Events.




 


	
(iii)
	
No Borrower is participating in any Third Party Payor Program, it being understood that agreements to provide discounts or rebates on drugs or biologics reimbursed by Third Party Payors is not participation in a Third Party Payor Program.
	
 




 


	
(iv)
	
None of the Borrower’s officers, directors, employees,  shareholders, their agents or affiliates has made an untrue statement of material fact or fraudulent statement to the FDA or failed to disclose a material fact required to be disclosed to the FDA, committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Regulation 46191 (September 10, 1991).
	
 




 


	
(v)
	
Borrower has not received any written notice that any Governmental Authority, including without limitation the FDA, the Office of the Inspector General of HHS or the United States Department of Justice has commenced or threatened to initiate any material action against a Credit Party, any action to enjoin a Credit Party, their officers, directors, employees, shareholders or their agents and Affiliates, from conducting their businesses at any facility owned or used by them as it may relate to Borrower’s business or for any material civil penalty, injunction, seizure or criminal action.
	
 




 


	
(vi)
	
Borrower has not received from the FDA a Warning Letter, Form FDA- 483, “Untitled Letter,” other correspondence or notice setting forth allegedly objectionable observations or alleged violations of laws and regulations enforced by the FDA or any comparable correspondence from any state or local authority responsible for regulating drug products and establishments, or any comparable correspondence from any foreign counterpart of the FDA or any comparable correspondence from any foreign counterpart of any state or local authority with regard to any Product or the manufacture, processing, packing, or holding thereof, in each case that would reasonably be expected to have a Material Adverse Effect.
	
 





	
(i)
	

	
 






58

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(vii)
	
Borrower has not engaged in any material Recalls, Market Withdrawals, or other forms of product retrieval from the marketplace of any Products.
	
 




 


	
(viii)
	
Each Product (a) is not materially adulterated or misbranded within the meaning of the FDCA; (b) is not an article prohibited from introduction into interstate commerce under the provisions of Section 505 of the FDCA; (c) each Product is being and/or shall be manufactured, imported, possessed, owned, warehoused, marketed, promoted, sold, labeled, furnished, distributed and marketed and in material compliance with all applicable Permits and Laws; and (d) each Product is being and/or shall be manufactured in material compliance with Good Manufacturing Practices.
	
 




 

(e)Proceedings. No Borrower is subject to any proceeding, suit or, to Borrowers’ knowledge, investigation by any federal, state or local government or quasi-governmental body, agency, board or authority or any other administrative or investigative body (including the Office of the Inspector General of the United States Department of Health and Human Services): (i) which may result in the imposition of a fine, alternative, interim or final sanction, which has not been provided for on their respective financial statements, and which would reasonably be expected to have a Material Adverse Effect on any Borrower; or (ii) which could result in the revocation, transfer, surrender, suspension or other impairment of the Permits of Borrower that would reasonably be expected to have a Material Adverse Effect on any Borrower.

 


	
(f)
	
Ancillary Laws. Borrowers have received no written notice, and are not  aware, of any material violation of applicable antitrust laws, employment or landlord-tenant laws of any federal, state or local government or quasi-governmental body, agency, board or other authority with respect to  the Borrowers.
	
 




 

Section 8.3Healthcare Operations.

 

(a)Borrower will timely file or caused to be timely filed (after giving effect to any extension duly obtained), all material notifications, reports, submissions, Permit renewals and reports (other than cost reports as provided in Section 8.3(a)(ii) below) required by Healthcare Laws (which reports will be materially accurate and complete in all respects and not misleading in any material respect and shall not remain open or unsettled).

 


	
(b)
	
Borrower will maintain in full force and effect, and free from restrictions, probations, conditions or known conflicts which would materially impair the use or operation of Borrowers’ business and assets, all material Permits necessary under Healthcare Laws to carry on the business of Borrowers as it is conducted on the Closing Date.
	
 




 


	
 
	
(c)
	
Borrower will not suffer or permit to occur any of the following:




 


	
(i)
	
any transfer of a Permit or rights thereunder to any Person (other than Borrowers or Agent);
	
 




 


	
(ii)
	
any pledge or hypothecation of any Permit as collateral security for any indebtedness other than Debt to Agent and each Lender under this Agreement and the other Financing Documents; or
	
 




 


	
(iii)
	
any rescission, withdrawal, revocation, amendment or modification of or other alteration to the nature, tenor or scope of any material Permit.
	
 





	
(i)
	

	
 






59

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(d)
	
In connection with the development, testing, manufacture, marketing or sale of each and any Product by any Borrower, Borrower shall comply in all material respects with all Regulatory Required Permits at all times issued by any Governmental Authority, specifically including the FDA, with respect to such development, testing, manufacture, marketing or sales of such Product by Borrower as such activities are at any such time being conducted by Borrower.
	
 




 

ARTICLE 9 - SECURITY AGREEMENT

 

Section 9.1 Generally. As security for the payment and performance of the Obligations and without limiting any other grant of a Lien and security interest in any Security Document, Borrowers hereby collateral assign and grant to Agent, for the benefit of itself and Lenders, a continuing first priority Lien on and security interest in, upon, and to the personal property set forth on Schedule 9.1 attached hereto and made a part hereof.

 

Section 9.2Representations and Warranties and Covenants Relating to Collateral.

 


	
(a)
	
The security interest granted pursuant to this Agreement constitutes a valid and, to the extent such security interest is required to be perfected by this Agreement and any other Financing Document, continuing perfected security interest in favor of Agent in all Collateral subject, for the following Collateral, to the occurrence of the following: (i) in the case of all Collateral in which a security interest may be perfected by filing a financing statement under the UCC, the completion of the filings and other actions specified on Schedule 9.2 (which, in the case of all filings and other documents referred to on such schedule, have been delivered to Agent in completed and duly authorized form), (ii) with respect to any Deposit Account, the execution of Deposit Account Control Agreements, (iii) in the case of letter-of-credit rights that are not supporting obligations of Collateral, the execution of a contractual obligation granting control to Agent over such letter-of-credit rights, (iv) in the case of electronic chattel paper, the completion of all steps necessary to grant control to Agent over such electronic chattel paper, (v) in the case of all certificated stock, debt instruments and investment property, the delivery thereof to Agent of such certificated stock, debt instruments and investment property consisting of instruments and certificates, in each case properly endorsed for transfer to Agent or in blank, (vi) in the case of all investment property not in certificated form, the execution of control agreements with respect to such investment property and (vii) in the case of all other instruments and tangible chattel paper that are not certificated stock, debt instructions or investment property,  the delivery thereof to Agent of such instruments and tangible chattel paper. Such security interest shall be prior to all other Liens on the Collateral except for Permitted Liens. Except to the extent not required pursuant to the terms of this Agreement, all actions by each Credit Party necessary or desirable to protect and perfect the Lien granted hereunder on the Collateral have been duly taken.
	
 




 


	
(b)
	
Schedule 9.2 sets forth (i) each chief executive office and principal place of business of each Borrower and each of their respective Subsidiaries, and (ii) all of the addresses (including all warehouses) at which any material portion of the Collateral is located and/or books and records of Borrowers regarding any such Collateral or any of Borrower’s assets, liabilities, business operations or financial condition are kept, which such Schedule 9.2 indicates in each case which Borrower(s) have Collateral and/or books located at such address, and, in the case of any such address not owned by one or more of the Borrowers(s), indicates the nature of such location (e.g.,  leased business location operated by Borrower(s), third party warehouse, consignment location, processor location, etc.) and the name and address of the third party owning and/or operating such location.
	
 




 


	
(c)
	
Without limiting the generality of Section 3.2, except with respect to any rights of any Borrower as a licensee under any license of Intellectual Property owned by another Person, and except for (x) the filing of financing statements under the UCC, (y) any change of ownership filings
	
 





	
(a)
	

	
 






60

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


applications, authorizations, consents or other actions that may be required with respect to Permits and

(z)after the Springing IP Event, the filing of the Intellectual Property Security Agreement, duly completed with scheduled attached, with the United States Patent and Trademark Office and/or the United States Copyright Office (as the case may be), no authorization, approval or other action by, and no notice to or filing with, any Governmental Authority or consent of any other Person is required for (i) the grant by each Borrower to Agent of the security interests and Liens in the Collateral provided for under this Agreement and the other Security Documents (if any), or (ii) the exercise by Agent of its rights and remedies with respect to the Collateral provided for under this Agreement and the other Security Documents or under any applicable Law, including the UCC and neither any such grant  of Liens in favor of Agent or exercise of rights by Agent shall violate or cause a default under any agreement between any Borrower and any other Person relating to any such collateral, including any license constituting Collateral to which a Borrower is a party, whether as licensor or licensee, with respect to any Intellectual Property, whether owned by such Borrower or any other Person.

 


	
(d)
	
As of the Closing Date, no Borrower has any ownership interest in any Chattel Paper (as defined in Article 9 of the UCC), letter of credit rights, commercial tort claims, Instruments, documents or investment property (other than equity interests in any Subsidiaries of such Borrower, and Investments and other investment property disclosed on Schedule 3.4) and Borrowers shall give notice to Agent promptly (but in any event not later than the delivery by Borrowers of the next Compliance Certificate required pursuant to Section 4.1 above) upon the acquisition by any Borrower of any such Chattel Paper, letter of credit rights, commercial tort claims, Instruments, documents, investment property with a value in excess of $100,000. No Person other than Agent or (if applicable) any Lender has “control” (as defined in Article 9 of the UCC) over any Deposit Account, investment property (including Securities Accounts and commodities account), letter of credit rights or electronic chattel paper in which any Borrower has any interest (except for such control arising by operation of law in favor of any bank or securities intermediary or commodities intermediary with whom any Deposit Account, Securities Account or commodities account of Borrowers is maintained).
	
 




 


	
(e)
	
Borrowers shall not, and shall not permit any Credit Party to, take any of the following actions or make any of the following changes unless Borrowers have given at least thirty (30) days prior written notice to Agent of Borrowers’ intention to take any such action (which such written notice shall include an updated version of any Schedule impacted by such change) and have executed any and all documents, instruments and agreements and taken any other actions which Agent may reasonably request after receiving such written notice in order to protect and preserve the Liens, rights and remedies of Agent with respect to the Collateral: (i) change the legal name or organizational identification number of any Borrower as it appears in official filings in the jurisdiction of its organization, (ii) change the jurisdiction of incorporation or formation of any Borrower or Credit Party  or allow any Borrower or Credit Party to designate any jurisdiction as an additional jurisdiction of incorporation for such Borrower or Credit Party, or change the type of entity that it is, or (iii) change its chief executive office, principal place of business, or the location of its books and records or move any Collateral (other than Inventory in transit) to or place any Collateral on any location that is not  then listed on the Schedules and/or establish any business location at any location that is not then listed on the Schedules.
	
 




 


	
(f)
	
Borrowers shall not adjust, settle or compromise the amount or payment of any Account, or release wholly or partly any Account Debtor, or allow any credit or discount thereon (other than adjustments, settlements, compromises, credits and discounts in an amount not to exceed $50,000 individually or $250,000 in the aggregate in any fiscal year) without the prior written consent of Agent. Without limiting the generality of this Agreement or any other provisions of any of the Financing Documents relating to the rights of Agent after the occurrence and during the continuance of an Event of Default, Agent shall have the right at any time after the occurrence and during the continuance of an
	
 





	
(d)
	

	
 






61

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Event of Default to: (i) exercise the rights of Borrowers with respect to the obligation of any Account Debtor to make payment or otherwise render performance to Borrowers and with respect to any property that secures the obligations of any Account Debtor or any other Person obligated on the Collateral, and

(ii) adjust, settle or compromise the amount or payment of such Accounts.

 


	
 
	
(g)
	
Without limiting the generality of Sections 9.2(c) and 9.2(d):




 


	
(i)
	
Borrowers shall deliver to Agent all tangible Chattel Paper and all Instruments and documents, with a value in excess of $100,000, owned by any Borrower and constituting part of the Collateral duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance satisfactory to Agent. Borrowers shall  provide Agent with “control” (as defined in Article 9 of the UCC) of all electronic Chattel Paper, with a value in excess of $100,000 in the aggregate for all such Chattel Paper, owned by any Borrower and constituting part of the Collateral by having Agent identified as the assignee on the records pertaining to the single authoritative copy thereof and otherwise complying with the applicable elements of control set forth in the UCC. Borrowers also shall deliver to Agent all security agreements securing any such Chattel Paper and securing any such Instruments. Borrowers shall comply with all the provisions of Section 5.14 with respect to the Deposit Accounts and Securities Accounts of Borrowers.
	
 




 


	
(ii)
	
Borrowers shall deliver to Agent all letters of credit with a face value in excess of $100,000 on which any Borrower is the beneficiary and which give rise to letter of credit rights owned by such Borrower which constitute part of the Collateral in each case duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to Agent. Borrowers shall take any and all actions as may be necessary or desirable, or that Agent may request, from time to time, to cause Agent to obtain exclusive “control” (as defined in Article 9 of the UCC) of any such letter of credit rights in a manner reasonably acceptable to Agent.
	
 




 


	
(iii)
	
Borrowers shall promptly advise Agent upon any Borrower becoming aware that it has any interests in any commercial tort claims in excess of $100,000 that constitutes part of the Collateral, which such notice shall include descriptions of the events and circumstances giving rise to such commercial tort claim and the dates such events and circumstances occurred, the potential defendants with respect to such commercial tort claim and any court proceedings that have been instituted with respect to such commercial tort claims, and Borrowers shall, with respect to any such commercial tort claim, execute and deliver to Agent such documents as Agent shall request to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to any such commercial tort claim.
	
 




 


	
(iv)
	
Except for Accounts, Inventory in transit and Inventory in an aggregate amount of $100,000, no Accounts or Inventory or other Collateral and no books and records and/or software and equipment of the Borrowers regarding any of the Collateral or any of the Borrower’s assets, liabilities, business operations or financial condition (unless also available at a location subject to a landlord waiver or similar agreement) shall at any time be located at any leased location or in the possession or control of any warehouse, consignee, bailee or any of Borrowers’ agents or processors, without prior written notice to Agent and the receipt by Agent, of warehouse receipts, consignment agreements, landlord waivers, or bailee waivers (as applicable) reasonably satisfactory to Agent prior to the commencement of such lease or of such possession or control (as applicable). Borrower has notified Agent that Collateral and books and records are currently located at the locations set forth on Schedule 9.2. Borrowers shall, upon the reasonable request of Agent, notify any such landlord, warehouse, consignee, bailee, agent or
	
 





	
(i)
	

	
 






62

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


processor of the security interests and Liens in favor of Agent created pursuant to this Agreement and the Security Documents, instruct such Person to hold all such Collateral for Agent’s account subject to Agent’s instructions and shall obtain an acknowledgement from such Person that such Person holds the Collateral for Agent’s benefit.

 


	
(v)
	
Borrowers shall cause all equipment and other tangible personal property other than Inventory to be maintained and preserved in the same condition, repair and in working order as when new, ordinary wear and tear and casualty loss excepted, and shall promptly make or cause to be made all repairs, replacements and other improvements in connection therewith that are necessary or desirable to such end. Upon request of Agent, Borrowers shall promptly deliver to Agent any and all certificates of title, applications for title or similar evidence of ownership of all such tangible Personal Property and shall cause Agent to be named as lienholder on any such certificate of title or other evidence of ownership except with respect to motor vehicles with an aggregate value of less than $100,000. Borrowers shall not permit any such tangible personal property to become fixtures to real estate unless such real estate is subject to a Lien in favor of Agent.
	
 




 


	
(vi)
	
Each Borrower hereby authorizes Agent to file without the signature of such Borrower one or more UCC financing statements relating to liens on personal property relating to all or any part of the Collateral, which financing statements may list Agent as the “secured party” and such Borrower as the “debtor” and which describe and indicate the collateral covered thereby as all or any part of the Collateral under the Financing Documents in such jurisdictions as Agent from time to time determines are appropriate, and to file without the signature of such Borrower any continuations of or corrective amendments to any such financing statements, in any such case in order for Agent to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to the Collateral. Each Borrower also ratifies its authorization for Agent to have filed in any jurisdiction any initial financing statements or amendments thereto if filed prior to the date hereof.
	
 




 


	
(vii)
	
As of the Closing Date, no Borrower holds, and after the Closing Date Borrowers shall promptly notify Agent in writing upon creation or acquisition by any Borrower of, any Collateral which constitutes a claim against any Governmental Authority, including, without limitation, the federal government of the United States or any instrumentality or agency thereof, the assignment of which claim is restricted by any applicable Law, including, without limitation, the federal Assignment of Claims Act and any other comparable Law. Upon the request of Agent, Borrowers shall take such steps as may be necessary or desirable, or that Agent may request, to comply with any such applicable Law in respect of any claim exceeding $50,000 or $250,000 in the aggregate with respect to all such claims.
	
 




 


	
(viii)
	
Borrowers shall furnish to Agent from time to time any statements and schedules further identifying or describing the Collateral and any other information, reports or evidence concerning the Collateral as Agent may reasonably request from time to time.
	
 




 


	
(ix)
	
Notwithstanding anything in this Agreement or any other Financing Document to the contrary, Borrowers shall not be required to take any steps (A) to perfect any security interest in any leasehold interest in real property and (B) to perfect any security interest under the laws of any jurisdiction other than the United States of America (or any state thereof) in those assets as to which Agent determines (in its reasonable discretion) that the cost of obtaining such a security interest or perfection thereof are excessive in relation to the benefit to Lenders of the security to be afforded thereby.
	
 





	
(i)
	

	
 






63

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(x)
	
If any Borrower desires to enter into a Permitted License and the proposed licensee under such Permitted License requests that Agent enter into a non-disturbance agreement (or similar agreement) in connection with such Permitted License, Agent hereby agrees to negotiate in good faith and on a commercially reasonable basis with such Borrower and such licensee to enter into such a non-disturbance and attornment agreement with respect to the proposed Permitted License and the Intellectual Property that is the subject thereof, which shall provide (among other things) (A) that, notwithstanding any exercise of rights and/or remedies by the Agent under this Agreement after a Springing IP Event in respect of the Intellectual Property that is the subject of such Permitted License, such licensee shall continue to have the rights and licenses set forth in its license agreement to the extent that such licensee is in compliance with the terms thereof; provided that in the case of any bankruptcy or insolvency proceeding with respect to such Borrower the rights of such licensee and the Agent shall be determined in accordance with the Bankruptcy Code (or other Laws applicable to such proceeding), (B) an acknowledgement and consent by such licensee of Agent’s security interest in the Collateral (including, to the extent applicable, such Permitted License and the Intellectual Property that is the subject thereof), and (C) that such Permitted License shall attorn to the owner of such Intellectual Property after such exercise of rights and remedies.
	
 




 

ARTICLE 10 - EVENTS OF DEFAULT

 

Section 10.1  Events of Default.  For purposes of the Financing Documents, the occurrence of  any of the following conditions and/or events, whether voluntary or involuntary, by operation of law or otherwise, shall constitute an “Event of Default”:

 


	
(a)
	
(i) any Borrower shall fail to pay any principal or interest under any Financing Document when due or pay any premium, fee or any other amount payable under any Financing Document within three (3) Business Days of when due, or (ii) there shall occur any default in the performance of or compliance with any of the following sections of this Agreement: Section 2.11, Section 4.1, Section 4.2(b), Section 4.4(c), Section 4.6, 4.15, 4.16, 4.17, Article 5, Article 6, Section 7.4 or Article 8;
	
 




 


	
(b)
	
any Credit Party defaults in the performance of or compliance with any term contained in this Agreement or in any other Financing Document (other than occurrences described in other provisions of this Section 10.1 for which a different grace or cure period is specified or for which no grace or cure period is specified and thereby constitute immediate Events of Default) and such default is not remedied by the Credit Party or waived by Agent within twenty (20) days after the earlier of
	
 





	
 
	
(i)
	
receipt by Borrower Representative of notice from Agent or Required Lenders of such default, or





	
 
	
(ii)
	
actual knowledge of any Borrower or any other Credit Party of such default;




 


	
(c)
	
any representation, warranty, certification or statement made by any Credit Party or any other Person in any Financing Document or in any certificate, financial statement or other document delivered pursuant to any Financing Document is incorrect in any respect (or in any material respect if such representation, warranty, certification or statement is not by its terms already qualified as to materiality) when made (or deemed made);
	
 




 


	
(d)
	
(i) failure of any Credit Party to pay when due or within any applicable grace period any principal, interest or other amount on Debt (other than the Loans), or the occurrence of any breach, default, condition or event with respect to any Debt (other than the Loans), if the effect of such failure or occurrence is to cause or to permit the holder or holders of any such Debt, or to cause, Debt or other liabilities having an individual principal amount in excess of $500,000 or having an aggregate principal amount in excess of $500,000 to become or be declared due prior to its stated maturity, or
	
 





	
(a)
	

	
 






64

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


(ii) the occurrence of any breach or default under any terms or provisions of any Subordinated Debt Document or under any agreement subordinating the Subordinated Debt to all or any portion of the Obligations or the occurrence of any event requiring the prepayment of any Subordinated Debt;

 


	
(e)
	
any Credit Party or any Subsidiary of a Borrower shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due, or shall take any corporate action to authorize any of the foregoing;
	
 




 


	
(f)
	
an involuntary case or other proceeding shall be commenced against any Credit Party or any Subsidiary of a Borrower seeking liquidation, reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of sixty (60) days; or an order for relief shall be entered against any Credit Party or any Subsidiary of a Borrower under applicable federal bankruptcy, insolvency or other similar law in respect of (i) bankruptcy, liquidation, winding-up, dissolution or suspension of general operations,
	
 




(ii) composition, rescheduling, reorganization, arrangement or readjustment of, or other relief from, or stay of proceedings to enforce, some or all of the debts or obligations, or (iii) possession, foreclosure, seizure or retention, sale or other disposition of, or other proceedings to enforce security over, all or any substantial part of the assets of such Credit Party or Subsidiary;

 


	
(g)
	
(i) institution of any steps by any Person to terminate a Pension Plan if as a result of such termination any Credit Party or any member of the Controlled Group could be required to make a contribution to such Pension Plan, or could incur a liability or obligation to such Pension Plan, in excess of $500,000, (ii) a contribution failure occurs with respect to any Pension Plan sufficient to give rise to a Lien under Section 303(k) of ERISA or Section 430(k) of the Code or an event occurs that would reasonably be expected to give rise to a Lien securing an amount on excess of $500,000 under Section 4068 of ERISA, or (iii) there shall occur any withdrawal or partial withdrawal from a Multiemployer Plan and the withdrawal liability (without unaccrued interest) to Multiemployer Plans as a result of such withdrawal (including any outstanding withdrawal liability that any Credit Party or any member of the Controlled Group have incurred on the date of such withdrawal) exceeds $500,000;
	
 




 


	
(h)
	
one or more judgments or orders for the payment of money (not paid or fully covered by insurance maintained in accordance with the requirements of this Agreement and as to which the relevant insurance company has acknowledged coverage) aggregating in excess of $500,000 shall be rendered against any or all Credit Parties and either (i) enforcement proceedings shall have been commenced by any creditor upon any such judgments or orders, or (ii) there shall be any period of twenty (20) consecutive days during which a stay of enforcement of any such judgments or orders, by reason of a pending appeal, bond or otherwise, shall not be in effect;
	
 




 


	
(i)
	
any Lien created by any of the Security Documents shall at any time fail to constitute a valid and perfected Lien on all of the Collateral purported to be encumbered thereby, subject to no prior or equal Lien except Permitted Liens (other than as a result of any action or inaction of Agent or Required Lenders provided that such action or inaction is not caused by any Credit Parties failure to comply with the terms of the Financing Documents) or any Credit Party shall so assert;
	
 





	
(a)
	

	
 






65

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(j)
	
the institution by any Governmental Authority of criminal proceedings against any Credit Party;
	
 




 


	
 
	
(k)
	
an event of default occurs under any Guarantee of any portion of the




Obligations;

 


	
(l)
	
any Borrower makes any payment on account of any Debt that has been subordinated to any of the Obligations, other than payments specifically permitted by the terms of such subordination;
	
 




 


	
(m)
	
if any Borrower is or becomes an entity whose equity is registered  with the SEC, and/or is publicly traded on and/or registered with a public securities exchange, such Borrower’s equity fails to remain registered with the SEC in good standing, and/or such equity fails to remain publicly traded on and registered with a public securities exchange;
	
 




 


	
(n)
	
the occurrence of any fact, event or circumstance that would reasonably be expected to result in a Material Adverse Effect;
	
 




 


	
(o)
	
(i) the voluntary withdrawal or institution of any action or proceeding by the FDA or similar Governmental Authority to order the withdrawal of any Product or Product category from the market or to enjoin Borrower, its Subsidiaries or any representative of Borrower or its Subsidiaries from manufacturing, marketing, selling or distributing any Product or Product category, which, in each case, has or would reasonably be expected to result in a Material Adverse Effect, (ii) the institution of any action or proceeding by any FDA, or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict any Regulatory Required Permit held by Borrower, its Subsidiaries or any representative of Borrower or its Subsidiaries, which, in each case, has or would reasonably be expected to result in a Material Adverse Effect, (iii) the commencement of any enforcement action against Borrower, its Subsidiaries or any representative of Borrower or its Subsidiaries (with respect to the business of Borrower or its Subsidiaries) by FDA, or any other Governmental Authority which has or would reasonably be expected to result in a Material Adverse Effect, or (iv) the occurrence of adverse test results in connection with a Product which could result in a Material Adverse Effect; or
	
 




 


	
(p)
	
any Credit Party defaults in any material respect under or breaches in any material respect any Material Contract (after any applicable grace period contained therein), or a Material Contract shall be terminated by a third party or parties party thereto prior to the expiration thereof, or there is a loss of a material right of a Credit Party under any Material Contract to which it is a party, in each case which would reasonably be expected to result in a Material Adverse Effect.
	
 




 

All cure periods provided for in this Section 10.1 shall run concurrently with any cure period provided for in any applicable Financing Documents under which the default occurred.

 

Section 10.2  Acceleration and Suspension or  Termination of Term Loan Commitment.  Upon the occurrence and during the continuance of an Event of Default, Agent may, and shall if requested by Required Lenders, (a) by notice to Borrower Representative suspend or terminate the Term Loan Commitment and the obligations of Agent and the Lenders with respect thereto, in whole or in part (and, if in part, each Lender’s Term Loan Commitment shall be reduced in accordance with its Pro Rata Share), and/or (b) by notice to Borrower Representative declare all or any portion of the Obligations to be, and the Obligations shall thereupon become, immediately due and payable, with accrued interest thereon, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Borrower and Borrowers will pay the same; provided, however, that in the case of any of the Events of

 



66

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Default specified in Section 10.1(e) or 10.1(f) above, without any notice to any Borrower or any other act by Agent or the Lenders, the Term Loan Commitment and the obligations of Agent and the Lenders with respect thereto shall thereupon immediately and automatically terminate and all of the Obligations shall become immediately and automatically due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Borrower and Borrowers will pay the same.

 

Section 10.3UCC Remedies.

 


	
(a)
	
Upon the occurrence of and during the continuance of an Event of Default under this Agreement or the other Financing Documents, Agent, in addition to all other rights, options, and remedies granted to Agent under this Agreement or at law or in equity, may exercise, either directly or through one or more assignees or designees, all rights and remedies granted to it under all Financing Documents and under the UCC in effect in the applicable jurisdiction(s) and under any other applicable law; including, without limitation:
	
 




 


	
(i)
	
the right to take possession of, send notices regarding, and collect directly the Collateral, with or without judicial process;
	
 




 


	
(ii)
	
the right to (by its own means or with judicial assistance) enter any of Borrowers’ premises and take possession of the Collateral, or render it unusable, or to render it usable or saleable, or dispose of the Collateral on such premises in compliance with subsection
	
 




(iii)below and to take possession of Borrowers’ original books and records, to obtain access to Borrowers’ data processing equipment, computer hardware and software relating to the Collateral and to use all of the foregoing and the information contained therein in any manner Agent deems appropriate, without any liability for rent, storage, utilities, or other sums, and Borrowers shall  not resist or interfere with such action (if Borrowers’ books and records are prepared or maintained by an accounting service, contractor or other third party agent, Borrowers hereby irrevocably authorize such service, contractor or other agent, upon notice by Agent to such Person that an Event of Default has occurred and is continuing, to deliver to Agent or its designees such books and records, and to follow Agent’s instructions with respect to further services to be rendered);

 


	
(iii)
	
the right to require Borrowers at Borrowers’ expense to assemble all or any part of the Collateral and make it available to Agent at any place designated by Lender;
	
 




 


	
(iv)
	
the right to notify postal authorities to change the address for delivery of Borrowers’ mail to an address designated by Agent and to receive, open and dispose of all mail addressed to any Borrower; and/or
	
 




 


	
(v)
	
the right to enforce Borrowers’ rights against Account Debtors and other obligors, including, without limitation, (i) the right to collect Accounts directly in Agent’s own name (as agent for Lenders) and to charge the collection costs and expenses, including attorneys’ fees, to Borrowers, and (ii) the right, in the name of Agent or any designee of Agent  or Borrowers, to verify the validity, amount or any other matter relating to any Accounts by mail, telephone, or otherwise, including, without limitation, verification of Borrowers’ compliance with applicable Laws. Borrowers shall cooperate fully with Agent in an effort to facilitate and promptly conclude such verification process. Such verification may include contacts between Agent and applicable federal, state and local regulatory authorities having jurisdiction over the Borrowers’ affairs, all of which contacts Borrowers hereby irrevocably authorize.
	
 





	
(iii)
	

	
 






67

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(b)
	
Each Borrower agrees that a notice received by it at least ten (10) days before the time of any intended public sale, or the time after which any private sale or other disposition of the Collateral is to be made, shall be deemed to be reasonable notice of such sale or other disposition. If permitted by applicable law, any perishable Collateral which threatens to speedily decline in value or which is sold on a recognized market may be sold immediately by Agent without prior notice to Borrowers. At any sale or disposition of Collateral, Agent may (to the extent permitted by applicable law) purchase all or any part of the Collateral, free from any right of redemption by Borrowers, which right is hereby waived and released. Each Borrower covenants and agrees not to interfere with  or  impose any obstacle to Agent’s exercise of its rights and remedies with respect to the Collateral. Agent shall have no obligation to clean-up or otherwise prepare the Collateral for sale. Agent may comply with any applicable state or federal law requirements in connection with a disposition of the Collateral and compliance will not be considered to adversely affect the commercial reasonableness of any sale of the Collateral. Agent may sell the Collateral without giving any warranties as to the Collateral. Agent may specifically disclaim any warranties of title or the like. This procedure will not be considered to adversely affect the commercial reasonableness of any sale of the Collateral. If Agent sells any of the Collateral upon credit, Borrowers will be credited only with payments actually made by the purchaser, received by Agent and applied to the indebtedness of the purchaser. In the event the purchaser fails to pay for the Collateral, Agent may resell the Collateral and Borrowers shall be credited with the proceeds of the sale. Borrowers shall remain liable for any deficiency if the proceeds of any sale or disposition of the Collateral are insufficient to pay all Obligations.
	
 




 


	
(c)
	
Without restricting the generality of the foregoing and for the purposes aforesaid, each Borrower hereby appoints and constitutes Agent its lawful attorney-in-fact with full power of substitution in the Collateral, upon the occurrence and during the continuance of an Event of Default, to (i) use unadvanced funds remaining under this Agreement or which may be reserved, escrowed or set aside for any purposes hereunder at any time, or to advance funds in excess of the face amount of the Notes, (ii) pay, settle or compromise all existing bills and claims, which may be Liens or security interests, or to avoid such bills and claims becoming Liens against the Collateral, (iii) execute  all applications and certificates in the name of such Borrower and to prosecute and defend all actions or proceedings in connection with the Collateral, and (iv) do any and every act which such Borrower might do in its own behalf; it being understood and agreed that this power of attorney in this subsection (c) shall be a power coupled with an interest and cannot be revoked.
	
 




 


	
(d)
	
Agent and each Lender is hereby granted a non-exclusive,  royalty-free license or other right to use, without charge, Borrowers’ labels, mask works, rights of use of any name, any  other Intellectual Property and advertising matter, and any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral pursuant to this Section and, in connection with Agent’s exercise of its rights under this Section, Borrowers’ rights under all licenses (whether as licensor or licensee) and all franchise agreements inure to Agent’s and each Lender’s benefit.
	
 




 

Section 10.4Reserved.

 

Section 10.5 Default Rate of Interest. At the election of Agent or Required Lenders, after the occurrence of an Event of Default and for so long as it continues, the Loans and other Obligations shall bear interest at rates that are three percent (3.0%) per annum in excess of the rates otherwise payable under this Agreement; provided, however, that in the case  of  any  Event  of  Default  specified  in Section 10.1(e) or 10.1(f) above, such default rate shall apply immediately and automatically without the need for any election or action of any kind on the part of Agent or any Lender.

 



68

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 10.6 Setoff Rights. Upon the occurrence and during the continuance of any Event of Default, each Lender is hereby authorized by each Borrower at any time or from time to time, with reasonably prompt subsequent notice to such Borrower (any prior or contemporaneous notice being hereby expressly waived) to set off and to appropriate and to apply any and all (a) balances held by such Lender or any of such Lender’s Affiliates at any of its offices for the account of such Borrower or any of its Subsidiaries (regardless of whether such balances are then due to such Borrower or its Subsidiaries), and (b) other property at any time held or owing by such Lender to or for the credit or for the account of such Borrower or any of its Subsidiaries, against and on account of any of the Obligations; except that no Lender shall exercise any such right without the prior written consent of Agent. Any Lender exercising a right to set off shall purchase for cash (and the other Lenders shall sell) interests in each of such other Lender’s Pro Rata Share of the Obligations as would be necessary to cause all Lenders to share the amount so set off with each other Lender in accordance with their respective Pro Rata Share of the Obligations. Each Borrower agrees, to the fullest extent permitted by law, that any Lender and any of such Lender’s Affiliates may exercise its right to set off with respect to the Obligations as provided in this Section 10.6.

 

Section 10.7Application of Proceeds.

 


	
(a)
	
Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, each Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Agent from or on behalf of such Borrower or any Guarantor of all or any part of the Obligations, and, as between Borrowers on the one hand and Agent and Lenders on the other, Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Agent may deem advisable notwithstanding any previous application by Agent.
	
 




 


	
(b)
	
Following the occurrence and continuance of an Event of Default, but absent the occurrence and continuance of an Acceleration Event, Agent shall apply any and all payments received by Agent in respect of the Obligations, and any and all proceeds of Collateral received by Agent, in such order as Agent may from time to time elect.
	
 




 


	
(c)
	
Notwithstanding anything to the contrary contained in this Agreement, if an Acceleration Event shall have occurred, and so long as it continues, Agent shall apply any and all payments received by Agent in respect of the Obligations, and any and all proceeds of Collateral received by Agent, in the following order: first, to all fees, costs, indemnities, liabilities, obligations and expenses incurred by or owing to Agent with respect to this Agreement, the other Financing Documents or the Collateral; second, to all fees, costs, indemnities, liabilities, obligations and expenses incurred by or owing to any Lender with respect to this Agreement, the other Financing Documents or the Collateral; third, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the Bankruptcy Code, would have accrued on such amounts); fourth, to the principal amount of the Obligations outstanding; and fifth to any other indebtedness or obligations of Borrowers owing to Agent or any Lender under the Financing Documents. Any balance remaining shall be delivered to Borrowers or to whomever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing, (y) amounts received shall be applied  in the numerical order provided until exhausted prior to the application to the next succeeding category, and (z) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its Pro Rata Share of amounts available to be applied pursuant thereto for such category.
	
 





	
(a)
	

	
 






69

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 10.8Waivers.

 


	
(a)
	
Except as otherwise provided for in this Agreement and to the fullest extent permitted by applicable law, each Borrower waives: (i) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment, maturity, release, compromise, settlement, extension or renewal of any or all Financing Documents, the Notes or any other notes, commercial paper, accounts, contracts, documents, Instruments, Chattel Paper and Guarantees at any time held by Lenders on which any Borrower may in any way be liable, and hereby ratifies and confirms whatever Lenders may do in this regard; (ii) all rights to notice and a hearing prior to Agent’s or any Lender’s taking possession or control of, or to Agent’s or any Lender’s replevy, attachment or levy upon, any Collateral or any bond or security which might be required by any court prior to allowing Agent or any Lender to exercise any of its remedies; and (iii) the benefit of all valuation, appraisal and exemption Laws. Each Borrower acknowledges that it has been advised by counsel of its choices and decisions with respect to this Agreement, the other Financing Documents and the transactions evidenced hereby and thereby.
	
 




 


	
(b)
	
Each Borrower for itself and all its successors and assigns, (i) agrees that its liability shall not be in any manner affected by any indulgence, extension of time, renewal, waiver, or modification granted or consented to by Lender; (ii) consents to any indulgences and all extensions of time, renewals, waivers, or modifications that may be granted by Agent or any Lender with respect to the payment or other provisions of the Financing Documents, and to any substitution, exchange or release of the Collateral, or any part thereof, with or without substitution, and agrees to the addition or release of any Borrower, endorsers, guarantors, or sureties, or whether primarily or secondarily liable, without notice to any other Borrower and without affecting its liability hereunder; (iii) agrees that its liability shall be unconditional and without regard to the liability of any other Borrower, Agent or any Lender for any tax on the indebtedness; and (iv) to the fullest extent permitted by law, expressly waives the benefit of any statute or rule of law or equity now provided, or which may hereafter be provided, which would produce a result contrary to or in conflict with the foregoing.
	
 




 


	
(c)
	
To the extent that Agent or any Lender may have acquiesced in any noncompliance with any requirements or conditions precedent to the closing of the Loans or to any subsequent disbursement of Loan proceeds, such acquiescence shall not be deemed to constitute a waiver by Agent or any Lender of such requirements with respect to any future disbursements of Loan proceeds and Agent may at any time after such acquiescence require Borrowers to comply with all such requirements. Any forbearance by Agent or Lender in exercising any right or remedy under any of the Financing Documents, or otherwise afforded by applicable law, including any failure to accelerate the maturity date of the Loans, shall not be a waiver of or preclude the exercise of any right or remedy nor shall it serve as a novation of the Notes or as a reinstatement of the Loans or a waiver of such right of acceleration or the right to insist upon strict compliance of the terms of the Financing Documents. Agent’s or any Lender’s acceptance of payment of any sum secured by any of the Financing Documents after the due date of such payment shall not be a waiver of Agent’s and such Lender’s right to either require prompt payment when due of all other sums so secured or to declare a default for failure to make prompt payment. The procurement of insurance or the payment of taxes or other Liens or charges by Agent as the result of an Event of Default shall not be a waiver of Agent’s right to accelerate the maturity of the Loans, nor shall Agent’s receipt of any condemnation awards, insurance proceeds, or damages under this Agreement operate to cure or waive any Credit Party’s default in payment of sums secured by any of the Financing Documents.
	
 




 


	
(d)
	
Without limiting the generality of anything contained in this Agreement or the other Financing Documents, each Borrower agrees that if an Event of Default is continuing (i) Agent and Lenders shall not be subject to any “one action” or “election of remedies” law or rule, and (ii) all Liens
	
 





	
(a)
	

	
 






70

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


and other rights, remedies or privileges provided to Agent or Lenders shall remain in full force and effect until Agent or Lenders have exhausted all remedies against the Collateral and any other properties owned by Borrowers and the Financing Documents and other security instruments or agreements securing the Loans have been foreclosed, sold and/or otherwise realized upon in satisfaction of Borrowers’ obligations under the Financing Documents.

 


	
(e)
	
Nothing contained herein or in any other Financing Document shall be  construed as requiring Agent or any Lender to resort to any part of the Collateral for the satisfaction of any of Borrowers’ obligations under the Financing Documents in preference or priority to any other  Collateral, and Agent may seek satisfaction out of all of the Collateral or any part thereof, in its absolute discretion in respect of Borrowers’ obligations under the Financing Documents. In addition, Agent shall have the right from time to time to partially foreclose upon any Collateral in any manner and for any amounts secured by the Financing Documents then due and payable as determined by Agent in its sole discretion, including, without limitation, the following circumstances: (i) in the event any Borrower defaults beyond any applicable grace period in the payment of one or more scheduled payments of principal and/or interest, Agent may foreclose upon all or any part of the Collateral to recover such delinquent payments, or (ii) in the event Agent elects to accelerate less than the entire outstanding principal balance of the Loans, Agent may foreclose all or any part of the Collateral to recover so much of the principal balance of the Loans as Lender may accelerate and such other sums secured by one or more of the Financing Documents as Agent may elect. Notwithstanding one or  more  partial foreclosures, any unforeclosed Collateral shall remain subject to the Financing Documents to secure payment of sums secured by the Financing Documents and not previously recovered.
	
 




 


	
(f)
	
To the fullest extent permitted by law, each Borrower, for itself and its successors and assigns, waives in the event of foreclosure of any or all of the Collateral any equitable right otherwise available to any Credit Party which would require the separate sale of any of the Collateral or require Agent or Lenders to exhaust their remedies against any part of the Collateral before proceeding against any other part of the Collateral; and further in the event of such foreclosure each Borrower does hereby expressly consent to and authorize, at the option of Agent, the foreclosure and sale either separately or together of each part of the Collateral.
	
 




 

Section 10.9 Injunctive Relief. The parties acknowledge and agree  that,  in the  event  of  a breach or threatened breach of any Credit Party’s obligations under any Financing Documents, Agent and Lenders may have no adequate remedy in money damages and, accordingly, shall be entitled to an injunction (including, without limitation, a temporary restraining order, preliminary injunction, writ of attachment, or order compelling an audit) against such breach or threatened breach, including, without limitation, maintaining any cash management and collection procedure described herein. However, no specification in this Agreement of a specific legal or equitable remedy shall be construed as a waiver or prohibition against any other legal or equitable remedies in the event of a breach or threatened breach of any provision of this Agreement. Each Credit Party waives, to the fullest extent permitted by law, the requirement of the posting of any bond in connection with such injunctive relief. By joining in the Financing Documents as a Credit Party, each Credit Party specifically joins in this Section as if this Section were a part of each Financing Document executed by such Credit Party.

 

Section 10.10 Marshalling; Payments Set Aside. Neither Agent nor any Lender shall be under any obligation to marshal any assets in payment of any or all of the Obligations. To the extent that Borrower makes any payment or Agent enforces its Liens or Agent or any Lender exercises its right of set-off, and such payment or the proceeds of such enforcement or set-off is subsequently invalidated, declared to be fraudulent or preferential, set aside, or required to be repaid by anyone, then to the extent of such recovery, the Obligations or part thereof originally intended to be satisfied, and all Liens, rights

 



71

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


and remedies therefor, shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or set-off had not occurred.

 

ARTICLE 11 - AGENT

 

Section 11.1 Appointment and Authorization. Each Lender hereby irrevocably appoints and authorizes Agent to enter into each of the Financing Documents to which it is a party (other than this Agreement) on its behalf and to take such actions as Agent on its behalf and to exercise such powers under the Financing Documents as are delegated to Agent by the terms thereof, together with all such powers as are reasonably incidental thereto. Subject to the terms of Section 11.16 and to the terms of the other Financing Documents, Agent is authorized and empowered to amend, modify, or waive any provisions of this Agreement or the other Financing Documents on behalf of Lenders. The provisions of this Article 11 are solely for the benefit of Agent and Lenders and neither any Borrower nor any other Credit Party shall have any rights as a third party beneficiary of any of the provisions hereof. In performing its functions and duties under this Agreement, Agent shall act solely as agent of Lenders and does not assume and shall not be deemed to have assumed any obligation toward or relationship of agency or trust with or for any Borrower or any other Credit Party. Agent may perform any of its duties hereunder, or under the Financing Documents, by or through its agents, servicers, trustees, investment managers or employees.

 

Section 11.2 Agent and Affiliates. Agent shall have the same rights and powers under the Financing Documents as any other Lender and may exercise or refrain from exercising the same as  though it were not Agent, and Agent and its Affiliates may lend money to, invest in and generally engage in any kind of business with each Credit Party or Affiliate of any Credit Party as if it were not Agent hereunder.

 

Section 11.3 Action by Agent. The duties of Agent shall be mechanical and administrative in nature. Agent shall not have by reason of this Agreement a fiduciary relationship in respect of  any Lender. Nothing in this Agreement or any of the Financing Documents is intended to or shall be construed to impose upon Agent any obligations in respect of this Agreement or any of the Financing Documents except as expressly set forth herein or therein.

 

Section 11.4 Consultation with Experts. Agent may consult with legal counsel, independent public accountants and other experts selected by it and shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the advice of such counsel, accountants or experts.

 

Section 11.5 Liability of Agent. Neither Agent nor any of  its  directors,  officers,  agents, trustees, investment managers, servicers or employees shall be liable to any Lender for any action taken or not taken by it in connection with the Financing Documents, except that Agent shall be liable with respect to its specific duties set forth hereunder but only to the extent of its own gross negligence or willful misconduct in the discharge thereof as determined by a final non-appealable judgment of a court  of competent jurisdiction. Neither Agent nor any of its directors, officers, agents, trustees, investment managers, servicers or employees shall be responsible for or have any duty to ascertain, inquire into or verify (a) any statement, warranty or representation made in connection with any Financing Document or any borrowing hereunder; (b) the performance or observance of any of the covenants or agreements specified in any Financing Document; (c) the satisfaction of any condition specified in any Financing Document; (d) the validity, effectiveness, sufficiency or genuineness of any Financing Document, any Lien purported to be created or perfected thereby or any other instrument or writing furnished in connection therewith; (e) the existence or non-existence of any Default or Event of Default; or (f) the financial condition of any Credit Party. Agent shall not incur any liability by acting in reliance upon any notice, consent, certificate, statement, or other writing (which may be a bank wire, facsimile or electronic

 



72

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


transmission or similar writing) believed by it to be genuine or to be signed by the proper party or parties. Agent shall not be liable for any apportionment or distribution of payments made by it in good faith and if any such apportionment or distribution is subsequently determined to have been made in error the sole recourse of any Lender to whom payment was due but not made, shall be to recover from other Lenders any payment in excess of the amount to which they are determined to be entitled (and such other Lenders hereby agree to return to such Lender any such erroneous payments received by them).

 

Section 11.6 Indemnification. Each Lender shall, in accordance with its Pro Rata Share, indemnify Agent (to the extent not reimbursed by Borrowers) upon demand against any cost, expense (including counsel fees and disbursements), claim, demand, action, loss or liability (except such as result from Agent’s gross negligence or willful misconduct as determined by a final non-appealable judgment of a court of competent jurisdiction) that Agent may suffer or incur in connection with the Financing Documents or any action taken or omitted by Agent hereunder or thereunder. If any indemnity furnished to Agent for any purpose shall, in the opinion of Agent, be insufficient or become impaired, Agent may call for additional indemnity and cease, or not commence, to do the acts indemnified against even if so directed by Required Lenders until such additional indemnity is furnished.

 

Section 11.7 Right to Request and Act on Instructions. Agent may at any time request instructions from Lenders with respect to any actions or approvals which by the terms of this Agreement or of any of the Financing Documents Agent is permitted or desires to take or to grant, and if such instructions are promptly requested, Agent shall be absolutely entitled to refrain from taking any action or to withhold any approval and shall not be under any liability whatsoever to any Person for refraining from any action or withholding any approval under any of the Financing Documents until it shall have received such instructions from Required Lenders or all or such other portion of the Lenders as shall be prescribed by this Agreement. Without limiting the foregoing, no Lender shall have any right of action whatsoever against Agent as a result of Agent acting or refraining from acting under this Agreement or any of the other Financing Documents in accordance with the instructions of Required Lenders (or all or such other portion of the Lenders as shall be prescribed by this Agreement) and, notwithstanding the instructions of Required Lenders (or such other applicable portion of the Lenders), Agent shall have no obligation to take any action if it believes, in good faith, that such action would violate applicable Law or exposes Agent to any liability for which it has not received satisfactory indemnification in accordance with the provisions of Section 11.6.

 

Section 11.8 Credit Decision. Each Lender acknowledges that  it  has,  independently  and without reliance upon Agent or any other Lender, and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon Agent or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking any action under the Financing Documents.

 

Section 11.9 Collateral Matters. Lenders irrevocably authorize Agent, at its option and in its discretion, to (a) release any Lien granted to or held by Agent under any Security Document (i) upon termination of the Term Loan Commitment and payment in full of all Obligations; or (ii) constituting property sold or disposed of as part of or in connection with any disposition permitted under any Financing Document (it being understood and agreed that Agent may conclusively rely without further inquiry on a certificate of a Responsible Officer as to the sale or other disposition of property being made in full compliance with the provisions of the Financing Documents); and (b) subordinate any Lien granted to or held by Agent under any Security Document to a Permitted Lien that is allowed to have priority over the Liens granted to or held by Agent pursuant to the definition of “Permitted Liens”. Upon request by Agent at any time, Lenders will confirm Agent’s authority to release and/or subordinate particular types or items of Collateral pursuant to this Section 11.9.

 



73

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 11.10 Agency for Perfection. Agent and each Lender hereby appoint each other Lender as agent for the purpose of perfecting Agent’s security interest in assets which, in accordance with the Uniform Commercial Code in any applicable jurisdiction, can be perfected by possession or control. Should any Lender (other than Agent) obtain possession or control of any such assets, such Lender shall notify Agent thereof, and, promptly upon Agent’s request therefor, shall deliver such assets to Agent or in accordance with Agent’s instructions or transfer control to Agent in accordance with Agent’s instructions. Each Lender agrees that it will not have any right individually to enforce or seek to enforce any Security Document or to realize upon any Collateral for the Loan unless instructed to do so by Agent (or consented to by Agent), it being understood and agreed that such rights and remedies may be exercised only by Agent.

 

Section 11.11 Notice of Default. Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default except with respect to defaults in the payment of principal, interest and fees required to be paid to Agent for the account of Lenders, unless Agent shall have received written notice from a Lender or a Borrower referring to this Agreement, describing such Default or Event of Default and stating that such notice is a “notice of default”. Agent will notify each Lender of  its  receipt of any such notice. Agent shall take such action with respect to such Default or Event of Default  as may be requested by Required Lenders (or all or such other portion of the Lenders as shall be prescribed by this Agreement) in accordance with the terms hereof. Unless and until Agent has received any such request, Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable or in the best interests of Lenders.

 

Section 11.12Assignment by Agent; Resignation of Agent; Successor Agent.

 


	
(a)
	
Agent may at any time assign its rights, powers, privileges and duties hereunder to (i) another Lender or an Affiliate of Agent or any Lender or any Approved Fund, or (ii) any Person to whom Agent, in its capacity as a Lender, has assigned (or will assign, in conjunction with such assignment of agency rights hereunder) 50% or more of its Loan in accordance with Section 11.17(a), in each case without the consent of Lenders or Borrowers. Following any such assignment, Agent shall  give notice to Lenders and Borrowers. Failure to give such notice shall affect such assignment in any way or cause the assignment to be ineffective. An assignment by Agent pursuant to this subsection (a) shall not be deemed a resignation by Agent for purposes of subsection (b) below.
	
 




 


	
(b)
	
Without limiting the rights of Agent to designate an assignee pursuant to subsection (a) above, Agent may at any time give notice of its resignation to the Lenders and Borrowers. Upon receipt of any such notice of resignation, Required Lenders shall have the right to appoint a successor Agent. If no such successor shall have been so appointed by Required Lenders and shall have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice of its resignation, then the retiring Agent may on behalf of Lenders, appoint a successor Agent; provided, however, that if Agent shall notify Borrowers and Lenders that no Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice from Agent that no Person has accepted such appointment and, from and following delivery of such notice, (i) the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Financing Documents, and (ii) all payments, communications and determinations provided to be made by, to or through Agent shall instead be made by or to each Lender directly, until such time as Required Lenders appoint a successor Agent as provided for above in this paragraph.
	
 




 


	
(c)
	
Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a successor’s appointment as Agent pursuant to subsection (b) above, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Agent,
	
 





	
(a)
	

	
 






74

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


and the retiring Agent shall be discharged from all of its duties and obligations hereunder and under the other Financing Documents (if not already discharged therefrom as provided above in this paragraph). The fees payable by Borrowers to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between Borrowers and such successor. After the retiring Agent’s resignation hereunder and under the other Financing Documents, the provisions of this Article and Section 11.12 shall continue in effect for the benefit of such retiring Agent and its sub-agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting or was continuing to act as Agent.

 

Section 11.13Payment and Sharing of Payment.

 


	
 
	
(a)
	
Reserved.




 


	
(b)
	
Term Loan Payments. Payments of principal, interest and fees in respect of the Term Loans will be settled on the date of receipt if received by Agent on the last Business Day of a month or on the Business Day immediately following the date of receipt if received on any day other than the last Business Day of a month.
	
 




 


	
 
	
(c)
	
Return of Payments.




 


	
(i)
	
If Agent pays an amount to a Lender under this Agreement in the belief or expectation that a related payment has been or will be received by Agent from a Borrower and such related payment is not received by Agent, then Agent will be entitled to recover such amount from such Lender on demand without setoff, counterclaim or deduction of any kind, together with interest accruing on a daily basis at the Federal Funds Rate.
	
 




 


	
(ii)
	
If Agent determines at any time that any amount received by Agent under this Agreement must be returned to any Borrower or paid to any other Person pursuant to any insolvency law or otherwise, then, notwithstanding any other term or condition of this Agreement or any other Financing Document, Agent will not be required to distribute any portion thereof to any Lender. In addition, each Lender will repay to Agent on demand any portion of such amount that Agent has distributed to such Lender, together with interest at such rate, if any, as Agent is required to pay to any Borrower or such other Person, without setoff, counterclaim or deduction of any kind.
	
 




 


	
(d)
	
Defaulted Lenders. The failure of any Defaulted Lender to make any payment required by it hereunder shall not relieve any other Lender of its obligations to make payment, but neither any other Lender nor Agent shall be responsible for the failure of any Defaulted Lender to make any payment required hereunder. Notwithstanding anything set forth herein to the contrary, a Defaulted Lender shall not have any voting or consent rights under or with respect to any Financing Document or constitute a “Lender” (or be included in the calculation of “Required Lenders” hereunder) for any voting or consent rights under or with respect to any Financing Document.
	
 




 


	
(e)
	
Sharing of Payments. If any Lender shall obtain any payment or other recovery (whether voluntary, involuntary, by application of setoff or otherwise) on account of any Loan (other than pursuant to the terms of Section 2.8(d)) in excess of its Pro Rata Share of payments  entitled pursuant to the other provisions of this Section 11.13, such Lender shall purchase from the other Lenders such participations in extensions of credit made by such other Lenders (without recourse, representation or warranty) as shall be necessary to cause such purchasing Lender to share the excess payment or other recovery ratably with each of them; provided, however, that if all or any portion of the excess payment  or other recovery is thereafter required to be returned or otherwise recovered from such purchasing
	
 





	
(a)
	

	
 






75

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Lender, such portion of such purchase shall be rescinded and each Lender which has sold a participation to the purchasing Lender shall repay to the purchasing Lender the purchase price to the ratable extent of such return or recovery, without interest. Each Borrower agrees that any Lender so purchasing a participation from another Lender pursuant to this clause (e) may, to the fullest extent permitted by law, exercise all its rights of payment (including pursuant to Section 10.6) with respect to such participation as fully as if such Lender were the direct creditor of Borrowers in the amount of such participation). If under any applicable bankruptcy, insolvency or other similar law, any Lender receives a secured claim in lieu of a setoff to which this clause (e) applies, such Lender shall, to the extent practicable, exercise its rights in respect of such secured claim in a manner consistent with the rights of the Lenders entitled under this clause (e) to share in the benefits of any recovery on such secured claim.

 

Section 11.14 Right to Perform, Preserve and Protect. If any Credit Party fails to perform any obligation hereunder or under any other Financing Document, Agent itself may, but shall not be obligated to, cause such obligation to be performed at Borrowers’ expense. Agent is further authorized by Borrowers and Lenders to make expenditures from time to time which Agent, in its reasonable business judgment, deems necessary or desirable to (a) preserve or protect the business conducted by Borrowers, the Collateral, or any portion thereof, and/or (b) enhance the likelihood of, or maximize the amount of, repayment of the Loan and other Obligations. Each Borrower hereby agrees to reimburse Agent on demand for any and all costs, liabilities and obligations incurred by Agent pursuant to this Section 11.14. Each Lender hereby agrees to indemnify Agent upon demand for any and all costs, liabilities and obligations incurred by Agent pursuant to this Section 11.14, in accordance with the provisions  of Section 11.6.

 

Section 11.15 Additional Titled Agents. Except for rights and powers,  if  any,  expressly reserved under this Agreement to any bookrunner, arranger or to any titled agent named on the  cover page of this Agreement, other than Agent (collectively, the “Additional Titled Agents”), and except for obligations, liabilities, duties and responsibilities, if any, expressly assumed under this Agreement by any Additional Titled Agent, no Additional Titled Agent, in such capacity, has any rights, powers, liabilities, duties or responsibilities hereunder or under any of the other Financing Documents. Without limiting the foregoing, no Additional Titled Agent shall have nor be deemed to have a fiduciary relationship with any Lender. At any time that any Lender serving as an Additional Titled Agent shall have transferred to any other Person (other than any Affiliates) all of its interests in the Loan, such Lender shall be deemed to have concurrently resigned as such Additional Titled Agent.

 

Section 11.16Amendments and Waivers.

 


	
(a)
	
No provision of this Agreement or any other Financing Document may be amended, waived or otherwise modified unless such amendment, waiver or other modification is in writing and is signed or otherwise approved by Borrowers, the Required Lenders and any other  Lender to the extent required under Section 11.16(b); provided, however, the Fee Letter may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto.
	
 




 


	
(b)
	
In addition to the required signatures under Section 11.16(a), no provision of this Agreement or any other Financing Document may be amended, waived or otherwise modified unless such amendment, waiver or other modification is in writing and is signed or otherwise approved by the following Persons:
	
 




 

(i)if any amendment, waiver or other modification would increase a Lender’s funding obligations in respect of any Loan, by such Lender; and/or

 


	
 
	
(ii)
	
if the rights or duties of Agent are affected thereby, by Agent;





	
 
	
(i)
	







76

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


provided, however, that, in each of (i) and (ii) above, no such amendment, waiver or other modification shall,  unless  signed  or  otherwise  approved  in  writing  by  all  the  Lenders  directly  affected  thereby,

(A)reduce the principal of, rate of interest on or any fees with respect to any Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Loan;

(B)postpone the date fixed for, or waive, any payment (other than any mandatory prepayment pursuant to Section 2.1(b)(ii)) of principal of any Loan, or of interest on any Loan (other than default interest) or any fees provided for hereunder (other than late charges) or postpone the date of termination of any commitment of any Lender hereunder; (C) change the definition of the term Required Lenders or the percentage of Lenders which shall be required for Lenders to take any action hereunder; (D) release all or substantially all of the Collateral, authorize any Borrower to sell or otherwise dispose of all or substantially all of the Collateral, release any Guarantor of all or any portion of the Obligations or its Guarantee obligations with respect thereto, or consent to a transfer of any of the Intellectual Property, except, in each case with respect to this clause (D), as otherwise may be provided in this Agreement  or the  other  Financing  Documents  (including  in  connection  with  any  disposition  permitted hereunder);

(E)amend, waive or otherwise modify this Section 11.16(b) or the definitions of the terms used in this Section 11.16(b) insofar as the definitions affect the substance of this Section 11.16(b); (F) consent to the assignment, delegation or other transfer by any Credit Party of any of its rights and obligations under any Financing Document or release any Borrower of its payment obligations under any Financing Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; or (G) amend any of the provisions of Section 10.7 or amend any of the definitions of Pro Rata Share, Term Loan Commitments, or Term Loan Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder. It is hereby understood and agreed that all Lenders shall be deemed  directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F) and (G) of the preceding sentence.

 

Section 11.17Assignments and Participations.

 


	
 
	
(a)
	
Assignments.




 


	
(i)
	
Any Lender may at any time assign to one or more Eligible Assignees all or any portion of such Lender’s Loan together with all related obligations of such Lender hereunder. Except as Agent may otherwise agree, the amount of any such  assignment (determined as of the date of the applicable Assignment Agreement or, if a “Trade Date” is specified in such Assignment Agreement, as of such Trade Date) shall be in a minimum aggregate amount equal to $1,000,000 or, if less, the assignor’s entire interests in the outstanding Loan; provided, however, that, in connection with simultaneous assignments to two or more related Approved Funds, such Approved Funds shall be treated as one assignee for purposes of determining compliance with the minimum assignment size referred to above. Borrowers and Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned to an Eligible Assignee until Agent shall have received and accepted an effective Assignment Agreement executed, delivered and fully completed by the applicable parties thereto and a processing fee of $3,500 to be paid by the assigning Lender; provided, however, that only one processing fee shall be payable in connection with simultaneous assignments to two or more related Approved Funds.
	
 




 


	
(ii)
	
From and after the date on which the conditions described above have been met, (A) such Eligible Assignee shall be deemed automatically to have become a party hereto and, to the extent of the interests assigned to such Eligible Assignee pursuant to such Assignment Agreement, shall have the rights and obligations of a Lender hereunder, and (B) the assigning Lender, to the extent that rights and obligations hereunder have been assigned by it
	
 





	
(i)
	

	
 






77

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


pursuant to such Assignment Agreement, shall be released from its rights and obligations hereunder (other than those that survive termination pursuant to Section 12.1). Upon the request of the Eligible Assignee (and, as applicable, the assigning Lender) pursuant to an effective Assignment Agreement, each Borrower shall execute and deliver to Agent for delivery to the Eligible Assignee (and, as applicable, the assigning Lender) Notes in the aggregate principal amount of the Eligible Assignee’s Loan (and, as applicable, Notes in the principal amount of that portion of the principal amount of the Loan retained by the assigning Lender). Upon receipt by the assigning Lender of such Note, the assigning Lender shall return to Borrower Representative any prior Note held by it.

 

(iii)Agent, acting solely for this purpose as an agent of Borrower, shall maintain at the office of its servicer located in Bethesda, Maryland a copy of each Assignment Agreement delivered to it and a register for the recordation of the names and addresses of each Lender, and the commitments of, and principal amount of the Loan owing to, such Lender pursuant to the terms hereof (the “Register”). The entries in such Register shall be conclusive, absent manifest error, and Borrower, Agent and Lenders shall treat each Person whose name is recorded therein pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. Such Register shall be available for inspection by Borrower and any Lender, at any reasonable time upon reasonable prior notice to Agent. Each Lender that sells a participation shall, acting solely for this purpose as an agent of Borrower maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant’s interest in the Obligations (each, a “Participant Register”). The entries in the Participant Registers shall be conclusive, absent manifest error. Each Participant Register shall be available for inspection by Borrower and Agent at any reasonable time upon reasonable prior notice to the applicable Lender; provided, that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant's interest in any commitments, loans, letters of credit or its other obligations under any Financing Document) to any Person (including Borrower) except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. For the avoidance of doubt, Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register.

 


	
(iv)
	
Notwithstanding the foregoing provisions of this Section 11.17(a) or any other provision of this Agreement, any Lender may at any time pledge or assign a security  interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided, however, that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a  party hereto.
	
 




 


	
(v)
	
Notwithstanding the foregoing provisions of this Section 11.17(a) or any other provision of this Agreement, Agent has the right, but not the obligation, to effectuate assignments of Loan via an electronic settlement system acceptable to Agent as designated in writing from time to time to Lenders by Agent (the “Settlement Service”). At any time when Agent elects, in its sole discretion, to implement such Settlement Service, each such assignment shall be effected by the assigning Lender and proposed assignee pursuant to the procedures then in effect under the Settlement Service, which procedures shall be consistent with the other provisions of this Section 11.17(a). Each assigning Lender and proposed Eligible Assignee shall comply with the requirements of the Settlement Service in connection with effecting any assignment of Loan pursuant to the Settlement Service. With the prior written approval of Agent,
	
 





	
(i)
	

	
 






78

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Agent’s approval of such Eligible Assignee shall be deemed to have been automatically granted with respect to any transfer effected through the Settlement Service. Assignments and assumptions of the Loan shall be effected by the provisions otherwise set forth herein until Agent notifies Lenders of the Settlement Service as set forth herein.

 


	
(b)
	
Participations. Any Lender may at any time, without the consent of,  or  notice to, any Borrower or Agent, sell to one or more Persons (other than any Borrower or any Borrower’s Affiliates) participating interests in its Loan, commitments or other interests hereunder (any such Person, a “Participant”). In the event of a sale by a Lender of a participating interest to a Participant, (i) such Lender’s obligations hereunder shall remain unchanged for all purposes, (ii) Borrowers and Agent shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations hereunder, and (iii) all amounts payable by each Borrower shall be determined as if such Lender had not sold such participation and shall be paid directly to such Lender. Each Borrower agrees that if amounts outstanding under this Agreement are due and payable (as a result of acceleration or otherwise), each Participant shall be deemed to have the right of set-off in respect of its participating interest in amounts owing under this Agreement to the same extent as if the amount of its participating interest were owing directly to it as a Lender under this Agreement; provided, however, that such right of set-off shall be subject to the obligation of each Participant to share with Lenders, and Lenders agree to share with each Participant, as provided in Section 11.5.
	
 




 


	
(c)
	
Replacement of Lenders. Within thirty (30) days after: (i) receipt by Agent of notice and demand from any Lender for payment of additional costs as provided in Section 2.8(d), which demand shall not have been revoked, (ii) any Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.8(a), (iii) any Lender is a Defaulted Lender, and the circumstances causing such status shall not have been cured or waived; or (iv) any failure by any Lender to consent to a requested amendment, waiver or modification to any Financing Document in which Required Lenders have already consented to such amendment, waiver or modification but the consent of each Lender, or each Lender affected thereby, is required with respect thereto (each relevant Lender in the foregoing clauses (i) through (iv) being an “Affected Lender”) each of Borrower Representative and Agent may, at its option, notify such Affected Lender and, in the case of Borrowers’ election, Agent, of such Person’s intention to obtain, at Borrowers’ expense, a replacement Lender (“Replacement Lender”) for such Lender, which Replacement Lender shall be an Eligible Assignee and, in the event the Replacement Lender is to replace an Affected Lender described in the preceding clause (iv), such Replacement Lender consents to the requested amendment, waiver or modification making the replaced Lender an Affected Lender. In the event Borrowers or Agent, as applicable, obtains a Replacement Lender within ninety (90) days following notice of its intention to do so, the Affected Lender shall sell, at par, and assign all of its Loan and funding commitments hereunder to such Replacement Lender in accordance with the procedures set forth in Section 11.17(a); provided, however, that (A) Borrowers shall have reimbursed such Lender for its increased costs and additional payments for which it is entitled to reimbursement under Section 2.8(a) or Section 2.8(d), as applicable, of this Agreement through the date of such sale and assignment, and
	
 




(B) Borrowers shall pay to Agent the $3,500 processing fee in respect of such assignment. In the event that a replaced Lender does not execute an Assignment Agreement pursuant to Section 11.17(a) within five (5) Business Days after receipt by such replaced Lender of notice of replacement pursuant to this Section 11.17(c) and presentation to such replaced Lender of an Assignment Agreement evidencing an assignment pursuant to this Section 11.17(c), such replaced Lender shall be deemed to have consented to the terms of such Assignment Agreement, and any such Assignment Agreement executed by Agent, the Replacement Lender and, to the extent required pursuant to Section 11.17(a), Borrowers, shall be effective for purposes of this Section 11.17(c) and Section 11.17(a). Upon any such assignment and payment, such replaced Lender shall no longer constitute a “Lender” for purposes hereof, other than with respect to such rights and obligations that survive termination as set forth in Section 12.1.

 



79

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 



	
(d)
	
Credit Party Assignments. No Credit Party may assign, delegate or otherwise transfer any of its rights or other obligations hereunder or under any other Financing Document without the prior written consent of Agent and each Lender.
	
 




 

Section 11.18 Funding and Settlement Provisions Applicable When  Non-Funding  Lenders Exist. So long as Agent has not waived the conditions to the funding of Loans set forth in Section 7.2 or Section 2.1, any Lender may deliver a notice to Agent stating that such Lender shall not fund the Term Loan due to the non-satisfaction of one or more conditions to funding Loans set forth in Section 7.2 or Section 2.1, and specifying any such non-satisfied conditions. Any Lender delivering any such notice shall become a non-funding Lender (a “Non-Funding Lender”) for purposes of this Agreement commencing on the Business Day following receipt by Agent of such notice, and shall cease to be a Non- Funding Lender on the date on which such Lender has either revoked the effectiveness of such notice or acknowledged in writing to each of Agent the satisfaction of the condition(s) specified in such notice, or Required Lenders waive the conditions to the funding of such Loans giving rise to such notice by Non- Funding Lender. Each Non-Funding Lender shall remain a Lender for purposes of this Agreement to the extent that such Non-Funding Lender has Term Loans outstanding in excess of $0; provided, however, that during any period of time that any Non-Funding Lender exists, and notwithstanding any provision to the contrary set forth herein, the following provisions shall apply:

 


	
 
	
(a)
	
[reserved].




 


	
(b)
	
Except as provided in clause (a) above, Term Loan Commitment Amount of each Non-Funding Lender shall be deemed to be $0.
	
 




 


	
 
	
(c)
	
[reserved].




 


	
(d)
	
The Term Loan Commitment at any date of determination during such period shall be deemed to be equal to the sum of (i) the aggregate Term Loan Commitment Amounts of all Lenders, other than the Non-Funding Lenders as of such date plus (ii) the aggregate principal amount outstanding under the Term Loans of all Non-Funding Lenders as of such date.
	
 




 

Section 11.19Reserved.

 

Section 11.20 Definitions. As used in this Article 11, the following terms have the following meanings:

 

“Approved Fund” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the Ordinary Course of Business, or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender, or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.

 

“Assignment Agreement” means an assignment agreement in form and substance acceptable to

Agent.

 

“Defaulted Lender” means any Lender that (a) has failed, within two (2) Business Days of the date required to be funded or paid, to (i) fund any portion of its Loans, or (ii) pay over to any Credit Party any other amount required to be paid by it hereunder, unless, in the case of clause (i) above, such Lender notifies Agent and Borrower Representative in writing that such failure is the result of such Lender's good

 



80

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


faith determination that a condition precedent to funding (specifically identified and including the particular default, if any) has not been satisfied, (b) has notified any Borrower or any Credit Party in writing, or has made a public statement to the effect, that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement indicates that such position is based on such Lender's good faith determination that a condition precedent (specifically identified and including the particular default, if any) to funding a Loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to extend credit, (c) has failed, within three (3) Business Days after request by a Credit Party or the Borrower Representative, acting in good faith, to provide a certification in writing from an authorized officer of such Lender that it will comply with its obligations (and is financially able to meet such obligations) to fund prospective Loans under this Agreement, provided that such Lender shall cease to be a Defaulted Lender pursuant to this clause (c) upon such Credit Party’s receipt of such certification in form and substance satisfactory to it and the Agent, or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any bankruptcy, insolvency or other similar law, or (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets. Any determination by Agent that a Lender is a Defaulted Lender under any one or more of clauses (a) through (d) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulted Lender upon delivery of written notice of such determination to Borrower Representative and each Lender.

 

“Eligible Assignee” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and

(d) any other Person (other than a natural person) approved by Agent; provided, however, that notwithstanding the foregoing, (x) “Eligible Assignee” shall not include (i) any Borrower or any of a Borrower’s Affiliates or (ii) unless an Event of Default has occurred and is continuing, (A) any hedge fund or private equity fund that is primarily and directly engaged in the business of purchasing distressed debt or (B) any direct competitor of Credit Parties, in each case, as determined by Agent in its reasonable discretion, and (y) no proposed assignee intending to assume any unfunded portion of the Term Loan Commitment shall be an Eligible Assignee unless such proposed assignee either already holds a portion of such Term Loan Commitment, or has been approved as an Eligible Assignee by Agent.

 

“Federal Funds Rate” means, for any day, the rate of interest per annum (rounded upwards, if necessary, to the nearest whole multiple of 1/100 of 1%) equal to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day, provided, however, that (a) if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day, and

(b)if no such rate is so published on such next preceding Business Day, the Federal Funds Rate for such day shall be the average rate quoted to Agent on such day on such transactions as determined by Agent.

 

ARTICLE 12 - MISCELLANEOUS

 

Section 12.1 Survival. All agreements, representations and  warranties  made  herein and in  every other Financing Document shall survive the execution and delivery of this Agreement and the other Financing Documents and the other Operative Documents. The provisions of Section 2.10 and  Articles 11 and 12 shall survive the payment of the Obligations (both with respect to any Lender and all Lenders collectively) and any termination of this Agreement and any judgment with respect to any Obligations, including any final foreclosure judgment with respect to any Security Document, and no unpaid or unperformed, current or future, Obligations will merge into any such judgment.

 

Section 12.2 No Waivers. No failure or delay by Agent or any Lender in exercising any right, power or privilege under any Financing Document shall operate as a waiver thereof nor shall any single

 



81

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein and therein provided shall be cumulative and not exclusive of any rights or remedies provided by law. Any reference in any Financing Document to the “continuing” nature of any Event of Default shall not be construed as establishing or otherwise indicating that any Borrower or any other Credit Party has the independent right to cure any such Event of Default, but is rather presented merely for convenience should such Event of Default  be waived in accordance with the terms of the applicable Financing Documents.

 

Section 12.3Notices.

 


	
(a)
	
All notices, requests and other communications to any party hereunder shall be in writing (including prepaid overnight courier, facsimile transmission or similar writing) and shall be given to such party at its address, facsimile number or e-mail address set forth on the signature pages hereof (or, in the case of any such Lender who becomes a Lender after the date hereof, in an assignment agreement or in a notice delivered to Borrower Representative and Agent by the assignee Lender forthwith upon such assignment) or at such other address, facsimile number or e-mail address as such party may hereafter specify for the purpose by notice to Agent and Borrower Representative; provided, however, that notices, requests or other communications shall be permitted by electronic means only in accordance with the provisions of Section 12.3(b) and (c). Each such notice, request or other communication shall be effective (i) if given by facsimile, when such notice is transmitted to the facsimile number specified by this Section and the sender receives a confirmation of transmission from the sending facsimile machine, or (ii) if given by mail, prepaid overnight courier or any other means, when received or when receipt is refused at the applicable address specified by this Section 12.3(a).
	
 




 


	
(b)
	
Notices and other communications to the parties hereto may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved from time to time by Agent, provided, however, that the foregoing shall not apply to notices sent directly to any Lender if such Lender has notified Agent that it is incapable of receiving notices by electronic communication. Agent or Borrower Representative may, in their discretion, agree to accept notices and other communications to them hereunder by electronic communications pursuant to procedures approved by it, provided, however, that approval of such procedures may be limited to particular notices or communications.
	
 




 


	
(c)
	
Unless Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgment from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgment), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor, provided, however, that if any such notice or other communication is not sent or posted during normal business hours, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day.
	
 




 

Section 12.4 Severability. In case any provision of or obligation under this Agreement or any other Financing Document shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

Section 12.5  Headings.   Headings and captions used in the Financing Documents (including   the Exhibits, Schedules and Annexes hereto and thereto) are included for convenience of reference only and shall not be given any substantive effect.

 



82

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


Section 12.6Confidentiality.

 


	
 
	
(a)
	
[Reserved].




 


	
(b)
	
Agent and each Lender shall hold all non-public information regarding the Credit Parties and their respective businesses and obtained by Agent or any Lender pursuant to the requirements hereof in accordance with such Person’s customary procedures for handling information of such nature, except that disclosure of such information may be made (i) to their respective agents, employees, Subsidiaries, Affiliates, attorneys, auditors, professional consultants, rating agencies, insurance industry associations and portfolio management services, (ii) to prospective transferees or purchasers of any interest in the Loans, Agent or a Lender, provided, however, that any such Persons are bound by obligations of confidentiality, (iii) as required by Law, subpoena, judicial order or similar  order and in connection with any litigation, (iv) as may be required in connection with the examination, audit or similar investigation of such Person, and (v) to a Person that is a trustee, investment advisor or investment manager, collateral manager, servicer, noteholder or secured party in a Securitization (as hereinafter defined) in connection with the administration, servicing and reporting on the assets serving as collateral for such Securitization. For the purposes of this Section, “Securitization” shall mean (A) the pledge of the Loans as collateral security for loans to a Lender, or (B) a public or private offering by a Lender or any of its Affiliates or their respective successors and assigns, of securities which represent an interest in, or which are collateralized, in whole or in part, by the Loans. Confidential information shall include only such information identified as such at the time provided to Agent and shall not include information that either: (y) is in the public domain, or becomes part of the public  domain  after disclosure to such Person through no fault of such Person, or (z) is disclosed to such Person by a Person other than a Credit Party, provided, however, Agent does not have actual knowledge that such Person is prohibited from disclosing such information. The obligations  of  Agent  and  Lenders  under  this Section 12.6 shall supersede and replace the obligations of Agent and Lenders under any confidentiality agreement in respect of this financing executed and delivered by Agent or any Lender prior to the date hereof.
	
 




 

Section 12.7 Waiver of Consequential and Other Damages. To the fullest extent permitted by applicable law, no Borrower shall assert, and each Borrower hereby waives, any claim against any Indemnitee (as defined below), on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of this Agreement, any other Financing Document or any agreement or instrument contemplated hereby or thereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. No Indemnitee shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Financing Documents or the transactions contemplated hereby or thereby.

 

Section 12.8GOVERNING LAW; SUBMISSION TO JURISDICTION.

 


	
(a)
	
THIS AGREEMENT, EACH NOTE AND EACH OTHER FINANCING DOCUMENT, AND ALL DISPUTES AND OTHER MATTERS RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.
	
 




 


	
(b)
	
EACH BORROWER HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED IN THE STATE OF NEW YORK IN THE CITY OF
	
 





	
(a)
	

	
 






83

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


NEW YORK, BOROUGH OF MANHATTAN, AND IRREVOCABLY AGREES THAT, SUBJECT TO AGENT’S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER FINANCING DOCUMENTS SHALL BE LITIGATED IN SUCH COURTS. EACH BORROWER EXPRESSLY SUBMITS AND CONSENTS TO THE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS. EACH BORROWER HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS AND AGREES THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE UPON  SUCH BORROWER BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, ADDRESSED TO SUCH BORROWER AT THE ADDRESS SET FORTH IN THIS AGREEMENT AND SERVICE SO MADE SHALL BE COMPLETE TEN (10) DAYS AFTER THE SAME  HAS BEEN POSTED.

 


	
(c)
	
Each Borrower, Agent and each Lender agree that each Loan (including those made on the Closing Date) shall be deemed to be made in, and the transactions contemplated hereunder and in any other Financing Document shall be deemed to have been performed in, the State of Maryland. Nothing in this Section 12.8(c) shall amend or modify Sections 12.8(a) or (b) in any respect.
	
 




 

Section 12.9 WAIVER OF JURY TRIAL. EACH BORROWER, AGENT AND THE LENDERS HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THE FINANCING DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. EACH BORROWER, AGENT AND EACH LENDER ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THE OTHER FINANCING DOCUMENTS, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED FUTURE DEALINGS. EACH BORROWER, AGENT AND EACH LENDER WARRANTS AND REPRESENTS THAT IT HAS HAD THE OPPORTUNITY OF REVIEWING THIS JURY WAIVER WITH LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS.

 

Section 12.10Publication; Advertisement.

 


	
(a)
	
Publication. No Credit Party will directly or indirectly publish, disclose or otherwise use in any advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of MCF or any of its Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case except (i) as required by Law, subpoena or judicial or  similar order, in which case the applicable Credit Party shall, to the extent legally permitted to do so, give Agent prior written notice of such publication or other disclosure, or (ii) with MCF’s prior written consent.
	
 




 


	
(b)
	
Advertisement. Each Lender and each Credit Party hereby authorizes MCF to publish the name of such Lender and Credit Party, the existence of the financing arrangements referenced under this Agreement, the primary purpose and/or structure of those arrangements, the amount of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of the financing evidenced hereby in any “tombstone”, comparable advertisement or press release which MCF elects to submit for publication. In addition, each Lender and each Credit Party agrees that MCF may provide lending industry trade organizations with information necessary and customary for inclusion in league table measurements after the Closing Date. With respect to any of the foregoing, MCF shall provide Borrowers with an opportunity to review and confer with MCF regarding
	
 





	
(a)
	

	
 






84

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


the contents of any such tombstone, advertisement or information, as applicable, prior to its submission for publication and, following such review period, MCF may, from time to time, publish such information in any media form desired by MCF, until such time that Borrowers shall have requested MCF cease any such further publication.

 

Section 12.11 Counterparts; Integration. This Agreement and the other Financing Documents may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Signatures by facsimile or by electronic mail delivery of an electronic version of any executed signature page shall bind the parties hereto. This Agreement and the other Financing Documents constitute the entire agreement and understanding among the parties hereto and supersede any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.

 

Section 12.12 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

 

Section 12.13 Lender Approvals. Unless expressly provided herein to the  contrary,  any approval, consent, waiver or satisfaction of Agent or Lenders with respect to any matter that is the subject of this Agreement, the other Financing Documents may be granted or withheld by Agent and Lenders in their sole and absolute discretion and credit judgment.

 

Section 12.14Expenses; Indemnity

 


	
(a)
	
Borrowers hereby agree to promptly pay (i) all reasonable costs and expenses of Agent (including, without limitation, the fees, costs and expenses of counsel to, and independent appraisers and consultants retained by Agent) in connection with the examination, review, due diligence investigation, documentation, negotiation, closing and syndication of the transactions contemplated by the Financing Documents, in connection with the performance by Agent of its rights and remedies under the Financing Documents and in connection with the continued administration of the Financing Documents including (A) any amendments, modifications, consents and waivers to and/or under any and all Financing Documents, and (B) any periodic public record searches conducted by or at the request of Agent (including, without limitation, title investigations, UCC searches, fixture filing searches, judgment, pending litigation and tax lien searches and searches of applicable corporate, limited liability, partnership and related records concerning the continued existence, organization and good standing of certain Persons); (ii) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with the creation, perfection and maintenance of Liens pursuant to the Financing Documents;
	
 





	
 
	
(iii)
	
without limitation of the preceding clause (i), all costs and expenses of Agent in connection with




(A) protecting, storing, insuring, handling, maintaining or selling any Collateral, (B) any litigation, dispute, suit or proceeding relating to any Financing Document, and (C) any workout, collection, bankruptcy, insolvency and other enforcement proceedings under any and all of the Financing Documents; (iv) without limitation of the preceding clause (i), all reasonable costs and expenses of Agent in connection with Agent’s reservation of funds in anticipation of the funding of the initial Loans to be made hereunder; and (v) all costs and expenses incurred by Lenders in connection with any litigation, dispute, suit or proceeding relating to any Financing Document and in connection with any workout, collection, bankruptcy, insolvency and other enforcement proceedings under any and all Financing Documents, whether or not Agent or Lenders are a party thereto. If Agent or any Lender uses in-house counsel for any of these purposes, Borrowers further agree that the Obligations include

 



85

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


reasonable charges for such work commensurate with the fees that would otherwise be charged by outside legal counsel selected by Agent or such Lender for the work performed.

 


	
(b)
	
Each Borrower hereby agrees to indemnify, pay and hold harmless Agent and Lenders and the officers, directors, employees, trustees, agents, investment advisors and investment managers, collateral managers, servicers, and counsel of Agent and Lenders (collectively called the “Indemnitees”) from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnitee) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnitee shall be designated a party thereto and including any such proceeding initiated by or on behalf of a Credit Party, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated hereby, which may be imposed on, incurred by or asserted against such Indemnitee as a result of or in connection with the transactions contemplated hereby or by the other Operative Documents (including (i)(A) as a direct or indirect result of the presence on or under, or escape, seepage, leakage, spillage, discharge, emission or release from, any property now or previously owned, leased or operated by Borrower, any Subsidiary or any other Person of any Hazardous Materials, (B) arising out of or relating to the offsite disposal of any materials generated or present on any such property, or (C) arising out of or resulting from the environmental condition of any such property or the applicability of any governmental requirements relating to Hazardous Materials, whether or not occasioned wholly or in part by any condition, accident or event caused by any act or omission of Borrower or any Subsidiary, and
	
 




(ii)proposed and actual extensions of credit under this Agreement) and the use or intended use of the proceeds of the Loans, except that Borrower shall have no obligation hereunder to an Indemnitee with respect to any liability resulting from the gross negligence or willful misconduct of such Indemnitee, as determined by a final non-appealable judgment of a court of competent jurisdiction. To the extent that the undertaking set forth in the immediately preceding sentence may be unenforceable, Borrower shall contribute the maximum portion which it is permitted to pay and satisfy under applicable Law to the payment and satisfaction of all such indemnified liabilities incurred by the Indemnitees or any of them.

 


	
(c)
	
Notwithstanding any contrary provision in this Agreement, the obligations of Borrowers under this Section 12.14 shall survive the payment in full of the Obligations and the termination of this Agreement. NO INDEMNITEE SHALL BE RESPONSIBLE OR LIABLE TO THE BORROWERS OR TO ANY OTHER PARTY TO ANY FINANCING DOCUMENT, ANY SUCCESSOR, ASSIGNEE OR THIRD PARTY BENEFICIARY OR ANY OTHER PERSON ASSERTING CLAIMS DERIVATIVELY THROUGH SUCH PARTY, FOR INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES WHICH MAY BE ALLEGED AS A RESULT  OF CREDIT HAVING BEEN EXTENDED, SUSPENDED OR TERMINATED UNDER THIS AGREEMENT OR ANY OTHER FINANCING DOCUMENT OR AS A RESULT OF ANY OTHER TRANSACTION CONTEMPLATED HEREUNDER OR THEREUNDER.
	
 




 

Section 12.15RESERVED.

 

Section 12.16 Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition or other proceeding be filed by or against any Credit Party for liquidation or reorganization, should any Credit Party become insolvent or make an assignment for the benefit of any creditor or creditors or should an interim receiver, receiver, receiver and manager or trustee be appointed for all or any significant part of any Credit Party’s assets, and shall continue to be effective or to be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored

 



86

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


or returned by any obligee of the Obligations, whether as a fraudulent preference reviewable transaction or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

 

Section 12.17 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of Borrowers and Agent and each Lender and their respective successors and permitted assigns.

 

Section 12.18 USA PATRIOT Act Notification. Agent (for itself and not on behalf of any Lender) and each Lender hereby notifies Borrowers that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record certain information and documentation that identifies Borrowers, which information includes the name and address of Borrower and such other information that will allow Agent or such Lender, as applicable, to identify Borrowers in accordance with the USA PATRIOT Act.

 

Section 12.19Existing Agreements Superseded; Exhibits and Schedules.

 


	
(a)
	
The Original Credit Agreement, including the schedules thereto, is superseded by this Agreement, including the schedules hereto, which has been executed in amendment, restatement and modification of, but not in novation or extinguishment of, the obligations under the Original Credit Agreement. It is the express intention of the parties hereto to reaffirm the indebtedness created under the Original Credit Agreement, as amended and restated hereby, which is secured by the Collateral. Any and all outstanding amounts under the Original Credit Agreement including, but not limited to principal, accrued interest, fees (except as otherwise provided herein) and other charges, as of the Closing Date shall be carried over and deemed outstanding under this Agreement.
	
 




 


	
(b)
	
Each Borrower reaffirms its obligations under each Financing Document to which it is a party, including but not limited to the Security Documents and the schedules thereto.
	
 




 


	
(c)
	
Each Borrower acknowledges and confirms that (i) the Liens and security interests granted pursuant to the Financing Documents secure the indebtedness, liabilities and obligations of the Borrowers to Agent and the Lenders under the Original Credit Agreement, as amended and restated hereby, and that the term “Obligations” as used in the Financing Documents (or any other term used therein to describe or refer to the indebtedness, liabilities and obligations of the Borrowers to Agent and the Lenders) includes, without limitation, the indebtedness, liabilities and obligations of the Borrowers under this Agreement and the Notes to be delivered hereunder, if any, and under the Original Credit Agreement, as amended and restated hereby, as the same further may be amended, restated, supplemented and/or modified from time to time, and (ii) the grants of Liens under and pursuant to the Financing Documents shall continue unaltered, and each other Financing Document shall continue in full force and effect in accordance with its terms unless otherwise amended by the parties thereto, and the parties hereto hereby ratify and confirm the terms thereof as being in full force and effect and unaltered by this Agreement and all references in the any of the Financing Documents to the “Credit Agreement” shall be deemed to refer to this Amended and Restated Credit Agreement.
	
 




 

 

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]

 



87

MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 

 
 


IN WITNESS WHEREOF, intending to be legally bound, and intending that this Agreement constitute an agreement executed under seal, each of the parties have caused this Agreement to be executed under seal the day and year first above mentioned. 

 


	
BORROWER REPRESENTATIVE:

 
	
APTEVO THERAPEUTICS INC.




By:/s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer

	
 
	
Address:

2401 4th Avenue, Suite 1050
Seattle, WA 98121

Attn:  General Counsel
Facsimile:  206.838.0503
E-Mail:  jlamothe@apvo.com




 

 

 



 



 







MidCap I Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

 
 



	
BORROWERS 

 
	
APTEVO THERAPEUTICS INC.




By:/s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer

Aptevo BioTherapeutics LLC

 

By:/s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer

Aptevo Research and Development LLC




By:/s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer

 




 







MidCap / Aptevo Therapeut ics / Amended and Restated Credit and Security Agreement

 
 



	
AGENT:
	
 

MIDCAP FINANCIAL TRUST

 

By: Apollo Capital Management, L.P., 

its investment manager

 

By: Apollo Capital Management GP, LLC, 

its general partner

 

 

By: /s/Maurice Amsellem

Name: Maurice Amsellem

Title:   Authorized Signatory

 

 

Address:

 

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attn:  Account Manager for Aptevo transaction
Facsimile:  301-941-1450

E-mail:  notices@midcapfinancial.com

 

with a copy to:

 

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attn:  General Counsel
Facsimile:  301-941-1450

E-mail:  legalnotices@midcapfinancial.com

 

 

	
 
	
Payment Account Designation:

SunTrust Bank, N.A. 
ABA #:  061000104
Account Name:  MidCap Financial Trust – Collections
Account #:  1000113400435

Attention:  Aptevo Therapeutics

 




 







MidCap / Aptevo T herapeutics / Amended and Restated Credi t and Secu rity Agreeme nt

 
 



	
LENDER:
	
APOLLO INVESTMENT CORPORATION

 

By: Apollo Investment Management, L.P., as Advisor

By: ACC Management, LLC, as its General Partner

By: /s/ Tanner Powell

Name: Tanner Powell

Title: Authorized Signatory

 

 

Address:

 

Apollo Investment Corporation
9 West 57th Street, 37th Floor
New York, New York 10019
Attn: Howard Widra
E-mail: hwidra@apolloLP.com

with a copy to:

Apollo Investment Corporation
730 Fifth Avenue, 11th Floor
New York, New York 10019
Attn: Sheriff Ibrahim, Jonathan Krain
Facsimile: 602-680-4108
E-mail: RealEstateOps@apolloLP.com,
16026804108@tls.ldsprod.com






M1dCap I Aptcvo ThaapcUllc::i / Amended and Rcs1a1cd Crcdi1 nnd Sccurily Agrccmcnl

 
 



	

LENDER:
	
ELM 2016-1 TRUST 

 

 

By: MidCap Financial Services Capital Management, LLC, as Servicer 

 

By:_/s/John O’Dea
Name: John O’Dea
Title: Authorized Signatory

 

 

Address:

 

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attn:  Account Manager for Aptevo transaction
Facsimile:  301-941-1450

E-mail:  notices@midcapfinancial.com

 

with a copy to:

 

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attn:  General Counsel
Facsimile:  301-941-1450

E-mail:  legalnotices@midcapfinancial.com

 




 







M1dCap I Aptcvo ThaapcUllc::i / Amended and Rcs1a1cd Crcdi1 nnd Sccurily Agrccmcnl

 
 



	

LENDER:
	
FLEXPOINT MCLS SPV LLC

 

 

By: /s/ Daniel Edelman

Name:  Daniel Edelman

Title: Vice President

 

 

Address:

 

Flexpoint MCLS SPV, LLC

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attn:  Account Manager for Aptevo transaction
Facsimile:  301-941-1450

E-mail:  notices@midcapfinancial.com

 

with a copy to:

 

Flexpoint MCLS SPV, LLC

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200
Bethesda, Maryland 20814
Attn:  General Counsel
Facsimile:  301-941-1450

E-mail:  legalnotices@midcapfinancial.com

 




 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MidCap / Aptevo Therapeutics/ Amended and Restated Credit and Security Agreement

 

 



ANNEXES, EXHIBITS AND SCHEDULES

 

ANNEXES

 

Annex ACommitment Annex

 

 

EXHIBITS

 

Exhibit A[Reserved]

Exhibit BForm of Compliance Certificate

Exhibit C[Reserved]

Exhibit DForm of Notice of Borrowing

Exhibit EForm of Payment Notification

Exhibit FForm of Closing Checklist

 

 

SCHEDULES

 

Schedule 2.1Scheduled Principal Payments for Term Loan

Schedule 3.1Existence, Organizational ID Numbers, Foreign Qualification, Prior Names Schedule 3.4Capitalization

Schedule 3.6Litigation

Schedule 3.17Material Contracts Schedule 3.18Environmental Compliance Schedule 3.19Intellectual Property

Schedule 4.9Litigation, Governmental Proceedings and Other Notice Events Schedule 5.1Debt; Contingent Obligations

Schedule 5.2Liens

Schedule 5.7Permitted Investments

Schedule 5.8Affiliate Transactions

Schedule 5.11Business Description

Schedule 5.14Deposit Accounts and Securities Accounts Schedule 6.2Net Commercial Product Revenue Schedule 7.4Post-Closing Obligations

Schedule 8.2(a)Licensing and Products

Schedule 8.2(b)Exceptions to Healthcare Representations and Warranties Schedule 9.1Collateral

Schedule 9.2Location of Collateral

 



MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 
 


Annex A to Credit Agreement (Commitment Annex)

 

 

 



 

 

 

Lender





Term Loan Commitment Amount





Term Loan Commitment Percentage





 



ELM 2016-1

Trust

Apollo Investment Corporation

Flexpoint MCLS SPV LLC





$10,285,714.2951.43%

 

$8,571,428.5742.86%

 

$1,142,857.145.71%



 

TOTALS$20,000,000.00100%

 



MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 
 


Exhibit A to Credit Agreement (Reserved)

 



MidCap / Aptevo Therapeutics / Amended and Restated Credit and Security Agreement

\\DC - 036639/000031 - 12505399

 

 
 


Exhibit B to Credit Agreement (Form of Compliance Certificate)

 

COMPLIANCE CERTIFICATE

 

This  Compliance  Certificate  is given by , a Responsible Officer of Aptevo Therapeutics Inc. (the “Borrower Representative”), pursuant to that certain Amended and Restated Credit and Security Agreement dated as of August 6, 2018 among Borrower Representative, Aptevo Biotherapeutics LLC, Aptevo Research and Development LLC, and any additional Borrower that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.

 

The undersigned Responsible Officer hereby certifies to Agent and Lenders that:

 

(a)the financial statements delivered with this certificate in accordance with Section 4.1 of the Credit Agreement fairly present in all material respects the results of operations and financial condition of Borrowers and their Consolidated Subsidiaries as of the dates and the accounting period covered by such financial statements, subject, in the case of interim financial statements, to year end reconciliation and the absence of footnotes;

 

(b)I have reviewed the terms of the Credit Agreement and have made, or caused to be made under my supervision, a review in reasonable detail of the transactions and conditions of Borrowers and their Consolidated Subsidiaries during the accounting period covered by such financial statements, and such review has not disclosed the existence during or at the end of such accounting period, and I have no knowledge of the existence as of the date hereof, of any condition or event that constitutes a Default or an Event of Default, except as set forth in Schedule 1 hereto, which includes a description of the nature and period of existence of such Default or an Event of Default and what action Borrowers have taken, are undertaking and propose to take with respect thereto;

 

(c)except as noted on Schedule 2 attached hereto, Schedule 9.2 to the Credit Agreement contains a complete and accurate list of all business locations of Borrowers and Guarantors and all names under which Borrowers and Guarantors currently conduct business; Schedule 2 specifically notes any changes in the names under which any Borrower or Guarantors conduct business;

 

(d)except as noted on Schedule 3 attached hereto, the undersigned has no knowledge of (i) any federal or state tax liens having been filed against any Borrower, Guarantor or any Collateral, or (ii) any failure of any Borrower or any Guarantors to make required payments of withholding or other tax obligations of any Borrower or any Guarantors during the accounting period to which the attached statements pertain or any subsequent period;

 

(e)except as noted on Schedule 4 attached hereto, Schedule 5.14 to the Credit Agreement contains a complete and accurate statement of all deposit accounts or investment accounts maintained by Borrowers and Guarantors;

 

(f)except as noted on Schedule 5 attached hereto and Schedule 3.6 to the Credit Agreement, the undersigned has no knowledge of any current, pending or threatened: (i) litigation against the Borrowers or any Guarantors, (ii) material inquiries, investigations or proceedings concerning the

(a)



Exhibit B – Page 1

 
 


business affairs, practices, licensing or reimbursement entitlements of Borrowers or any Guarantors, or


	
 
	
(iii)
	
material default by Borrowers or any Guarantors under any Material Contract to which it is a party;




 

(g)except as noted on Schedule 6 attached hereto, no Borrower or Guarantor has acquired, by purchase, by the approval or granting of any application for registration (whether or not such application was previously disclosed to Agent by Borrowers) or otherwise, any Intellectual Property that is registered with any United States or foreign Governmental Authority, or has filed with any such United States or foreign Governmental Authority, any new application for the registration of any Intellectual Property, or acquired rights under a license as a licensee with respect to any such registered Intellectual Property (or any such application for the registration of Intellectual Property) owned by another Person, that has not previously been reported to Agent on Schedule 3.17 to the Credit Agreement or any  Schedule 6 to any previous Compliance Certificate delivered by Borrower to Agent;

 

(h)except as noted on Schedule 7 attached hereto, no Borrower or Guarantor has acquired, by purchase or otherwise, any Chattel Paper, Letter of Credit Rights, Instruments, Documents or Investment Property that has not previously been reported to Agent on any Schedule 7 to any previous Compliance Certificate delivered by Borrower Representative to Agent;

 

(i)except as noted on Schedule 8 attached hereto, no Borrower or Guarantor is aware of any commercial tort claim that has not previously been reported to Agent on any Schedule 8 to any previous Compliance Certificate delivered by Borrower Representative to Agent; and

 

(j)Borrowers and Guarantor are in compliance with the covenants contained in Article 6 of the Credit Agreement, and in any Guarantee constituting a part of the Financing Documents, as demonstrated by the calculation of such covenants below, except as set forth below; in determining such compliance, the following calculations have been made: [See attached worksheets]. Such calculations  and the certifications contained therein are true, correct and complete1.

 

The foregoing certifications and computations are made as of , 201 (end of month) and as of , 201 .

 

Sincerely,

 

Aptevo Therapeutics Inc.

 

By: Name: Title: 

 

 

 

 

 

 

 

 

 

 



1 Note to draft: to be included only with quarterly compliance certificates.

 



Exhibit B – Page 2

 
 


Exhibit C to Credit Agreement (Reserved)

 

 



Exhibit D to Credit Agreement (Form of Notice of Borrowing)

 

NOTICE OF BORROWING

 

This  Notice  of  Borrowing  is  given  by , a Responsible Officer of Aptevo Therapeutics Inc. (the “Borrower Representative”), pursuant to that certain Amended and Restated Credit and Security Agreement dated as of August 6, 2018 among Borrower Representative, Aptevo Biotherapeutics LLC, Aptevo Research and Development LLC, and any additional Borrower that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.

 

The undersigned Responsible Officer hereby gives notice to Agent of Borrower Representative’s request to borrow $ of Term Loans on , 201 .

 

The undersigned officer hereby certifies that, both before and after giving effect to the request above (a) each of the conditions precedent set forth in Section 7.2 have been satisfied, (b) all of the representations and warranties contained in the Credit Agreement and the other Financing Documents are true, correct and complete in all material respects as of the date hereof, except to the extent such representation or warranty relates to a specific date, in which case such representation or warranty is true, correct and complete as of such earlier date; provided, however, in each case, such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof, and (c) no Default or Event of Default has occurred and is continuing on  the date hereof.

 

IN WITNESS WHEREOF, the undersigned officer has executed and delivered this Notice of Borrowing this         day of , 201 .

 

Sincerely,

 

Aptevo Therapeutics Inc.

 

By: Name: Title: 

 

 



Exhibit E to Credit Agreement (Form of Payment Notification)

 

PAYMENT NOTIFICATION

 

This Payment Notification is given by , a Responsible Officer of Aptevo Therapeutics Inc. (the “Borrower Representative”), pursuant to that certain Amended and Restated Credit and Security Agreement dated as August 6, 2018among Borrower Representative, Aptevo Biotherapeutics LLC, Aptevo Research and Development LLC, and the other Borrowers signatory thereto and any additional Borrower that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”). Capitalized terms  used herein without definition shall have the meanings set forth in the Credit Agreement.

 

Please be advised that funds in the amount of $ will be wire transferred to Agent on , 201_. Such funds shall constitute [an optional] [a mandatory] prepayment of the Term Loans, with such prepayments to be applied in the manner specified in Section 2.1(a)(iii). [Such mandatory prepayment is being made pursuant to Section of the Credit Agreement.]

 

Fax to MCF Operations 301-941-1450 no later than noon Eastern time.

 

Note: Funds must be received in the Payment Account by no later than noon Eastern time for same day application

 

IN WITNESS WHEREOF, the undersigned officer has executed and delivered this Payment Notification this         day of , 201 .

 

Sincerely,

 

Aptevo Therapeutics Inc.

 

By: Name: Title: 

 

 



Exhibit F to Credit Agreement (Form of Closing Checklist)

 

 









 

 

 
APTEVO THERAPUETICS INC.
 

$20,000,000 TERM LOAN

by MIDCAP FINANCIAL TRUST

 

 

 

 

 

CLOSING CHECKLIST

Key:

 

BBorrower – Aptevo Therapeutics Inc. and certain of its direct and indirect Subsidiaries BCBorrower’s Counsel – Morgan Lewis

LLenders – MidCap Financial Trust and Others LCMCF’s Counsel – Hogan Lovells US LLP

 


	
	
 

Closing Item

	
 

	
I.TERM SHEET/COMMITMENT

LETTER/CREDIT

	
A.Term Sheet

B.Credit Committee Memorandum

C.Pre-Closing Memo

	
II. TERM LOAN DOCUMENTS

	
A.Perfection Certificate

B.A&R Credit and Security Agreement

(i)Schedules

(ii)Exhibits

C.UCC-1 Financing Statements

D.Reaffirmation Agreement

E.Third A&R Fee Letter

F.Updated IP Security Agreement Schedules

G.Solvency Certificate

H.Wells Fargo Securities Account Control Agreement Reaffirmation

I.Legal Opinion

	
III. ORGANIZATIONAL DOCUMENTS

	
A.General Certificate of Secretary of each Credit Party, with Exhibits:

•Formation Document/Articles

•Governing Agreement/Bylaws

•Incumbency Certificate

•Authorizing Resolutions




 

MidCap / Aptevo Therapeutics / Closing Checklist

 







\\DC - 036639/000031 - 12505755 v8

 
 



	
	
	
•Good Standing Certificates

•Foreign Qualification to Do Business

	
IV. FINANCIAL, LIEN AND OTHER MISC. DILIGENCE

	
A.UCC, Lien and Litigation Searches

B.Intellectual Property searches

C.Certified Financial Statements and other financial diligence

D.Background Checks on Principals

	
V. LOAN AND LEASE DILIGENCE AND

OTHER MATERIAL CONTRACTS

	
A.Material Contracts, material licenses and any related legal diligence

B.Updated Insurance Certificates

C.KYC diligence and any other diligence

	
VI. POST CLOSING

	
A.Post-Closing UCC Searches

B.Closing Binder




 



\\DC - 036639/000031 - 12505755 v8

 

2

 
 


Exhibit G to Credit Agreement (Form of Intellectual Property Security Agreement)

 

 



INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This   Intellectual   Property   Security   Agreement   is   entered   into   as of  the day of

 , by and among MIDCAP FINANCIAL TRUST, a Delaware statutory trust (“Agent”) and APTEVO THERAPEUTICS INC., a Delaware corporation (“Aptevo Therapeutics”), APTEVO BIOTHERAPEUTICS LLC, a Delaware limited liability company (“Aptevo BioTherapeutics”), and APTEVO RESEARCH AND DEVELOPMENT LLC, a Delaware limited liability company (“Aptevo R&D, and Aptevo R&D together with Aptevo Therapeutics, Aptevo BioTherapeutics and any other Person that joins this agreement as a Grantor, each a “Grantor” and collectively, the “Grantors”).

 

RECITALS

 

A.The Lenders made and have agreed to make certain advances of money and to extend certain financial accommodation to the Grantors (the “Credit Extensions”) in the amounts and manner set forth in that certain Amended and Restated Credit and Security Agreement by and between Agent, the Lenders and the Grantors dated as of August 6, 2018 (as the same may be amended, modified or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein without definition are used as defined in the Credit Agreement). The Lenders are willing to continue to make the Credit Extensions to the Grantors, but only upon the condition, among others, that the Grantors shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of the Grantors under the Credit Agreement.

 

B.Pursuant to the terms of the Credit Agreement, each Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of such Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, each Grantor hereby represents, warrants, covenants and agrees as follows:

 

AGREEMENT

 

To secure its obligations under the Credit Agreement, each Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of such Grantor's right, title and interest in, to and under its Intellectual Property other than any Excluded Property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following (except, in each case, to the extent constituting Excluded Property):

 

(a)Any and all copyright rights, copyright applications, copyright registrations  and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

 


	
(b)
	
Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;
	
 





	
(a)
	

	
 






MidCap / Aptevo / IP Security Agreement

\\DC - 036639/000031 - 10307000

 

 
 


(c)Any and all design rights that may be available to such Grantor now or hereafter existing, created, acquired or held;

 


	
(d)
	
All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of  the  same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);
	
 




 

(e)Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

 


	
(f)
	
All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);
	
 




 


	
(g)
	
Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
	
 




 


	
(h)
	
All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;
	
 




 


	
 
	
(i)
	
All amendments, extensions, renewals and extensions of any of the Copyrights,




Trademarks, Patents, or Mask Works; and

 

(j)All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

 

The security interest granted under this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement and the other Financing Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement or any of the Financing Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement or any of the other Financing Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

 

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT AND ALL DISPUTES AND OTHER MATTERS RELATING HERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

 



2

 

MidCap / Aptevo / IP Security Agreement

\\DC - 036639/000031 - 10307000

 

 
 


This Intellectual Property Security Agreement may be signed in any number of counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same instrument. Delivery of an executed counterpart of this Intellectual Property Security Agreement by facsimile or by electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed signature page shall be effective as delivery of an original executed counterpart hereof and shall bind the parties hereto.

 

[Signature page follows.]

 



3

 

MidCap / Aptevo / IP Security Agreement

\\DC - 036639/000031 - 10307000

 

 
 


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

 

 

GRANTORS:                                                                      APTEVO THERAPEUTICS INC.





	

	
   By: /s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer




Aptevo BioTherapeutics LLC

 


	

	
By: /s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer




Aptevo Research and 

Development LLC


By: /s/Jeff Lamothe
Name: Jeff Lamothe
Title: Treasurer

 



MidCap / Aptevo / IP Security Agreement

 
 


 

AGENT:MIDCAP FINANCIAL TRUST

 

By: Apollo Capital Management, L.P., 

its investment manager

 

By: Apollo Capital Management GP, LLC, 

its general partner

 

 

By: /s/Maurice Amsellem

Name: Maurice Amsellem

Title:   Authorized Signatory

 

 



MidCap / Aptevo / IP Security Agreement

 
 


EXHIBIT A

 

Copyrights

 

 

 



DescriptionRegistration/

Application Number





Registration/ Application Date



 

None.

 

 



EXHIBIT B

 

Patents

 

 

 



DescriptionRegistration/

Application Number





Registration/ Application Date



 

[See attached.]

 

 



 

Dated: July 30, 2018

 


	
 
	
A.
	
Patents




 

 

 

 

 


									
	
FIX rPROTEIN

	
Method of producing biologically active vitamin K dependent proteins by recombinant methods

	
APVO.40900

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40900
	
US
	
3
	
CON
	
Pending
	
15/875,373
	
19-Jan-2018
	
 
	
 




 

 


									
	
METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS

	
APVO.40901

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40901
	
US
	
2
	
CON
	
Granted
	
14/475,881
	
03-Sep-2014
	
9,587,008
	
07-Mar-2017




 

 


		
	
 
	
STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE

	
 
	
APVO.40902




 

 



 


									
	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40902
	
US
	
2
	
CON
	
Pending
	
16/028,736
	
06-July-2018
	
 
	
 




 

 


									
	
RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME

	
APVO.40903

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40903
	
US
	
1
	
CON
	
Pending
	
14/860,042
	
21-Sep-2015
	
 
	
 




 

 

 

 

 

 


									
	
BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS

	
APVO.80011a

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80011a
	
US
	
1
	
CON
	
Granted
	
11/088693
	
23-Mar-2005
	
8,106,161
	
31-Jan-2012

	
APVO.80011a
	
US
	
10
	
CON
	
Granted
	
12/901,297
	
08-Oct-2010
	
8,197,810
	
12-Jun-2012

	
APVO.80011a
	
US
	
11
	
CON
	
Granted
	
13/451,641
	
20-Apr-2012
	
9,005,612
	
14-Apr-2015

	
APVO.80011a
	
US
	
9
	
CON
	
Granted
	
12/901295
	
08-Oct-2010
	
8,188,237
	
29-May-2012




 

 



 


									
	
BINDING CONSTRUCTS AND METHODS FOR USE THEREOF

	
APVO.80011c

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80011c
	
US
	
 
	
PRI
	
Granted
	
10/627,556
	
26-Jul-2003
	
7,829,084
	
09-Nov-2010

	
APVO.80011c
	
US
	
1
	
PCT
	
Expired
	
10/566,409
	
24-Aug-2006
	
7,754,209
	
13-Jul-2010




 

 


									
	
BINDING CONSTRUCTS AND METHODS FOR USE THEREOF

	
APVO.80011b

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80011b
	
US
	
1
	
CON
	
Granted
	
12/541,062
	
13-Aug-2009
	
8,147,835
	
03-Apr-2012

	
APVO.80011b
	
US
	
4
	
DIV
	
Granted
	
13/396,147
	
14-Feb-2012
	
8,853,366
	
04-Oct-2014




 

 


									
	
B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES

	
APVO.80100

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80100
	
US
	
 
	
ORD
	
Pending
	
11/493,132
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
US
	
3
	
CON
	
Pending
	
13/836,103
	
15-Mar-2013
	
 
	
 




 

 



 


									
	
SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION

	
APVO.80102

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80102
	
US
	
1
	
PCT
	
Granted
	
12/304,562
	
22-Jul-2010
	
8,409,577
	
02-Apr-2013

	
APVO.80102
	
US
	
3
	
CON
	
Pending
	
15/617,833
	
8-June-2017
	
 
	
 




 

 

 

 


									
	
CD86 Antagonist Multi-Target Binding Proteins

	
APVO.80116

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80116
	
US
	
 
	
PCT
	
Granted
	
13/122,383
	
02-Oct-2009
	
9,493,564
	
15-Nov-2016

	
APVO.80116
	
US
	
 
	
CON
	
Pending
	
15/281,441
	
30-Sep-2016
	
 
	
 




 

 


									
	
TCR Complex Immunotherapeutics

	
APVO.80117

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80117
	
US
	
2
	
CON
	
Pending
	
15/040,744
	
10-Feb-2016
	
 
	
 




 

 



 


									
	
CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF

	
APVO.80120

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80120
	
US
	
 
	
ORD
	
Granted
	
12/422,780
	
13-Apr-2009
	
9,101,609
	
11-Aug-2015

	
APVO.80120
	
US
	
1
	
PCT
	
Granted
	
12/678,857
	
15-Jul-2010
	
8,333,966
	
18-Dec-2012




 

 


									
	
Heterodimer Binding Proteins and Uses Thereof

	
APVO.80121

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80121
	
US
	
2
	
CON
	
Pending
	
15/802,636
	
03-Nov-2017
	
 
	
 




 

 


									
	
RTCC Constructs

	
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods

	
APVO.80124

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80124
	
US
	
 
	
CON
	
Granted
	
15/585,921
	
03-May-2017
	
9,782,478
	
10-Oct-2017

	
APVO.80124
	
US
	
 
	
CON
	
Pending
	
15/699,474
	
8-Sep-2017
	
 
	
 




 

 



 


									
	
CD3 BINDING POLYPEPTIDES

	
APVO.80126

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80126
	
US
	
 
	
PCT
	
Pending
	
14/395,689
	
18-Apr-2013
	
 
	
 




 

 


									
	
Cell Line-Based Redirected T-Cell Cytotoxicity Assay

	
APVO.80135

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80135
	
US
	
 
	
PCT
	
Pending
	
15/126,922
	
16-Sep-2016
	
 
	
 




 

 

 

 


									
	
Compositions and Methods for Combination Therapy with Prostate-Specific Membrane Antigen Binding Proteins

	
APVO.80137

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80137
	
US
	
 
	
PCT
	
Pending
	
15/550,143
	
10-Aug-2017
	
 
	
 




 

 


									
	
CD3 Binding Polypeptides

	
APVO.80138

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date




 

 



 


									
	
APVO.80138
	
US
	
 
	
PCT
	
Pending
	
15/761,499
	
21-Sep-2016
	
 
	
 




 

 

 

 

 

 


									
	
CD123 Binding Proteins and Related Compositions and Methods

	
APVO.80141

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80141
	
PCT
	
 
	
PCT
	
Pending
	
PCT/US2017/052808
	
21-Sep-2017
	
 
	
 

	
APVO.80141
	
US
	
 
	
ORD
	
Pending
	
15/933,324
	
22-March-2018
	
 
	
 




 

 

 

 

 

 


									
	
Oncofetal Antigen Binding Proteins and Related Compositions and Methods

	
APVO.142 (Co-owned with Alligator Bioscience)

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80142
	
US
	
 
	
PRO
	
Pending
	
62/575,820
	
23-Oct-2017
	
 
	
 

	
APVO.80142
	
US
	
 
	
PRO
	
Pending
	
62/648,072
	
26-Mar-2018
	
 
	
 

	
APVO.80142
	
PCT
	
 
	
PRI
	
Pending
	
 
	
20-July-2018
	
 
	
 

	
APVO.80142
	
US
	
 
	
ORD
	
Pending
	
16/041,309
	
20-July-2018
	
 
	
 




 

 



 

 

 


									
	
Protein Therapeutics For Cytokine Delivery

	
APVO.80144

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80144
	
US
	
 
	
PRO
	
Pending
	
62/667,404
	
04-May-2018
	
 
	
 




 

 


									
	
Formulations Of Protein Therapeutics

	
APVO.80145

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80145
	
US
	
 
	
PRO
	
Pending
	
62/667,402
	
04-May-2018
	
 
	
 




 

 



EXHIBIT C

 

Trademarks

 

 

 



DescriptionRegistration/

Application Number





Registration/ Application Date



 

[See Attached.]

 

 



 


	
 
	
B.
	
Trademarks




 


							
	
ADAPTIR

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
ADAPTIR
	
Allowed
	
86/974,244
	
13-Apr-2016
	
 
	
 




 

 

 

 


							
	
APTEVO BIOTHERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
APTEVO BIOTHERAPEUTICS
	
Allowed
	
86/859161
	
28-Dec-2015
	
 
	
 




 

 


							
	
APTEVO RESEARCH AND DEVELOPMENT

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
APTEVO RESEARCH AND DEVELOPMENT
	
Allowed
	
86/859,136
	
28-Dec-2015
	
 
	
 




 

 


							
	
APTEVO THERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
APTEVO THERAPEUTICS
	
Pending
	
86/768,978
	
25-Sep-2015
	
 
	
 




 

 



 

 

 


							
	
APTEVO LOGO

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
APTEVO_Logo
	
Registered
	
86/823,176
	
17-Nov-2015
	
5,370,601
	
02-Jan- 2018




 

 

 

 


							
	
IXINITY

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
IXINITY
	
Registered
	
85/220,714
	
19-Jan-2011
	
4597459
	
02-Sep-2014

	
US
	
IXINITY (STYLIZED)
	
Registered
	
86/322,323
	
27-June-2014
	
4788624
	
11-Aug-2015




 

 


							
	
IXPERIENCE

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
IXPERIENCE
	
Registered
	
86/322,313
	
27-June-2014
	
4923507
	
22-Mar-2016




 

 

 

 


							
	
VYDAPTIV

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
VYDAPTIV
	
Pending
	
86/972,975
	
21-April-2106
	
 
	
 




 

 



 

 

 

 

 


							
	
VYDAPTIV BIOTHERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
 

US
	
 

VYDAPTIV BIOTHERAPEUTICS
	
 

 

Under Opposition
	
 

86/972,988
	
 

12-April-2106
	
 
	
 




 

 


							
	
VYDAPTIV THERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
 

US
	
 

VYDAPTIV THERAPEUTICS
	
 

 

Under Opposition
	
 

86/972,981
	
 

12-April-2106
	
 
	
 




 

 

 

 


				
	
Trademark Clearinghouse Registrations (TMCH)

	
US
	
IXINITY Trademark Clearinghouse

Registration
	
Active
	
00170514158981891415

	
US
	
ADAPTIR Trademark Clearinghouse

Registration
	
Active
	
00170513892841101389




 

 



EXHIBIT D

 

Mask Works

 

 

 



DescriptionRegistration/

Application Number





Registration/ Application Date



 

None.

 

 



Schedule 2.1 - Amortization

 

Commencing on the Applicable Amortization Start Date and continuing on the first day of each calendar month thereafter, Borrower shall pay to Agent as a principal payment on the Term Loans an amount equal to the Applicable Amortization Payment Amount. Notwithstanding the foregoing, the entire remaining outstanding principal balance under each of the Term Loans shall mature and be due and payable upon the Termination Date.

 

For purposes hereof of this Schedule 2.1 the following terms shall have the following meanings: “Applicable Amortization Start Date” means:


	
 
	
(a)
	
If Borrower has not satisfied the Initial Extension Conditions, February 1, 2020; or




 


	
 
	
(b)
	
If Borrower has satisfied the Initial Extension Conditions, August 1, 2020; provided that, if for any of the Defined Periods ending on March 31, 2020 or June 30, 2020, respectively, Borrower fails to deliver a Compliance Certificate in accordance with Section 6.4 demonstrating to Agent’s reasonable satisfaction that Borrower’s Net Commercial Product Revenue for such Defined Period is greater than or equal $32,000,000, then the Applicable Amortization Start Date shall be deemed to have occurred on the first day of the calendar month following the end of such Defined Period and Borrower shall immediately pay to Agent true up principal payments in the amount of the Applicable Amortization Payment Amount for (i) the month in which the Applicable Amortization Start date was deemed to have occurred and (ii) each month commencing thereafter and prior to the date on which such Compliance Certificate was delivered (such true up payments shall, for the avoidance of doubt, be in addition to the Applicable Amortization Payment Amounts that shall be due and payable for each month commencing after the delivery of the applicable Compliance Certificate in accordance with the terms hereof).
	
 




 

“Applicable Amortization Payment Amount” means, with respect to the Applicable Amortization Start Date, an amount equal to (a) the principal balance of Term Loans outstanding on the Applicable Amortization Start Date divided by (b) the total number of Payment Dates remaining through and including the Maturity Date.

 

“Initial Extension Conditions” means: (a) Borrower shall have delivered, by January 31, 2020, management prepared, unaudited financial reporting for the Defined Period ending on December 31, 2019, certified by a Responsible Officer of Borrower, that demonstrates to Agent’s reasonable satisfaction that Borrowers’ Net Commercial Product Revenue for such Defined Period is greater than or equal to

$32,000,000 (it being understood that such financial reporting shall be subject to correction by Borrowers, as necessary, in connection with Borrower’s delivery of its financial statements in accordance with Section 4.1(a) for the Defined Period ending December 31, 2019) and (b) no Default or Event of Default has occurred and is continuing as of February 1, 2020.

 

“Payment Dates” means, collectively, the Applicable Amortization Start Date and the first day of each calendar month thereafter.

 

 



 

Schedule 3.1 – Existence, Organizational ID Numbers, Foreign Qualification, Prior Names

 

 

 


									
	
Borrower
	
Prior Names
	
Type of Entity / State of Formation
	
States Qualified
	
State Org. ID Number
	
Federal Tax ID Number
	
Location of Borrower (address)

	
Aptevo Therapeutics Inc
	
N/A
	
DE Corporation
	
WA
	
5833686
	
81-1567056
	
2401 4th Ave, Suite 1050, Seattle, WA

98121

	
Aptevo Research and
	
Emergent Product
	
DE Limited
	
WA
	
4858233
	
52-2385898
	
2401 4th Ave, Suite 1050, Seattle, WA

98121

	
Development LLC
	
Development
	
Liability
	
 
	
 
	
 

	
 
	
Seattle LLC
	
Company
	
 
	
 
	
 

	
 
	
Trubion
	
 
	
 
	
 
	
 

	
 
	
Pharmaceuticals,
	
 
	
 
	
 
	
 

	
 
	
Inc.
	
 
	
 
	
 
	
 

	
Aptevo BioTherapeutics LLC
	
N/A
	
DE Limited Liability Company
	
AL AZ CA CO FL GA IL IN KY
	
LA ME MI MN MO NV NJ NM NY NC
	
OH PA SC TN TX UT WA
	
5937234
	
81-1429784
	
2401 4th Ave, Suite 1050, Seattle, WA

98121




 



[Schedule 3.1]

 
 


 

Schedule 3.4 – Capitalization

 

 

 


					
	
Credit Party
	
Authorized Equity
	
Holder(s) of Issued and Outstanding Equity
	
Equity Held
	
Percentage of Ownership

	
 

 

Aptevo Therapeutics Inc.
	
500,000,000 shares of Common Stock

15,000,000 shares of Preferred Stock
	
 

 

Public Shareholders
	
 

 

All outstanding stock
	
 

 

100%

	
Aptevo Research and Development LLC
	
Membership interests
	
Aptevo Therapeutics Inc.
	
All membership interests
	
100%

	
Aptevo BioTherapeutics LLC
	
Membership interests
	
Aptevo Therapeutics Inc.
	
All membership interests
	
100%

	
Aptevo Europe Limited
	
5,000 Ordinary Shares
	
Aptevo Therapeutics Inc.
	
1 ordinary share
	
100%




 



[Schedule 3.4]

 
 


Schedule 3.6 – Litigation

None.

 



[Schedule 3.6]

 
 


Schedule 3.15 – Brokers, Finders or Other Intermediaries

Piper Jaffray

 



[Schedule 3.15]

 
 


Schedule 3.17 – Material Contracts


	
 
	
1.
	
Manufacturing Services Agreement, dated May 27, 2015, by and between Aptevo BioTherapeutics LLC and Patheon UK Limited
	
 





	
 
	
2.
	
Development and Technical Transfer Services Agreement dated December 21, 2009, by and between Patheon UK Limited and Inspiration Biopharmaceuticals, Inc.
	
 





	
 
	
3.
	
Addendum to Development and Technical Transfer Services Agreement dated December 21, 2009, dated October 7, 2013, by and between Patheon UK Limited and CNJ Holdings Inc.
	
 





	
 
	
4.
	
Non-Exclusive License Agreement, dated July 21, 2008, by between Trubion Pharmaceuticals and Hospital Clinic I Provincial de Barcelona
	
 





	
 
	
5.
	
Exclusive License Agreement, dated December 12, 2011, by and between University of Washington and Emergent Product Development Seattle LLC
	
 





	
 
	
6.
	
Commercial Platform License Agreement, dated January 8, 2016, by and between Open Monoclonal Technology, Inc. and Emergent Product Development Seattle, LLC
	
 





	
 
	
7.
	
License Agreement, dated December 13, 2013, by and between Lonza Sales AG and Emergent Product Development Seattle, LLC
	
 





	
 
	
8.
	
License Agreement, dated April 10, 2018 by and between Lonza Sales AG and Aptevo Research and Development LLC
	
 





	
 
	
9.
	
Amendment No. 1 dated May 10, 2018, to the License Agreement dated April 10, 2018, by and between Lonza Sales AG and Aptevo Research and Development LLC
	
 





	
 
	
10.
	
Research Evaluation Agreement, dated December 10, 2003, by and between Lonza Biologics PLC and Trubion Pharmaceuticals, Inc.
	
 





	
 
	
11.
	
Amended and Restated License Agreement, dated as of November 28, 2008, by and between Cangene Corporation (as successor-in-interest to Inspiration Biopharmaceuticals, Inc.) and The University of North Carolina at Chapel Hill, as amended on June 14, 2012
	
 





	
 
	
12.
	
Consent letter regarding Amended and Restated License Agreement dated as of November 28, 2008, dated July 23, 2012, by and between The University of North Carolina at Chapel Hill and Inspiration Biopharmaceuticals Inc.
	
 





	
 
	
13.
	
Lease, dated November 19, 2011, by and between Brandywine Operating Partnership, L.P. and Cangene Biopharma, Inc.
	
 





	
 
	
14.
	
First Amendment, dated April 2, 2017, by and between Brandywine Operating Partnership, L.P. and Aptevo BioTherapeutics LLC
	
 





	
 
	
15.
	
Second Amendment, dated November 30, 2017 by and between Brandywine Operating Partnership, L.P. and Aptevo BioTherapeutics LLC
	
 





	
 
	
1.
	

	
 






[Schedule 3.17]

 
 


 


	
 
	
16.
	
Fourth and Battery Office Lease, dated as of April 28, 2003, by and between Emergent Product Development Seattle, LLC (as successor-in-interest to Trubion Pharmaceuticals, Inc. and Genecraft, Inc.) and Selig Real Estate Holdings Eight L.L.C. (the “Seattle Office Lease”)
	
 





	
 
	
17.
	
First Amendment to Seattle Office Lease, dated December 8, 2004




 


	
 
	
18.
	
Second Amendment to Seattle Office Lease, dated February 1, 2006




 


	
 
	
19.
	
Third Amendment to Seattle Office Lease, dated February 2, 2007




 


	
 
	
20.
	
Fourth Amendment to Seattle Office Lease, dated June 7, 2010




 


	
 
	
21.
	
Fifth Amendment to Seattle Office Lease, dated December 21, 2010




 


	
 
	
22.
	
Sixth Amendment to Seattle Office Lease, dated July 17, 2012




 


	
 
	
23.
	
Seventh Amendment to Seattle Office Lease, dated December 5, 2014




 


	
 
	
24.
	
Amended and Restated Commercial Supply Agreement, dated June 16, 2017, between CMC ICOS Biologics, Inc. (AGC Biologics) and Aptevo BioTherapeutics LLC.
	
 





	
 
	
25.
	
Medicare Coverage Gap Discount Program Agreement, Contract No. P1325, effective May 2, 2016
	
 





	
 
	
26.
	
Medicare Coverage Gap Discount Program Data Agreement, Contract No. P1325, with an initial effective date of January 1, 2013.
	
 





	
 
	
27.
	
Life Technologies DG44 Commercial Production License Agreement, dated July 28, 2016, by and between Life Techonologies Corporation and Emergent BioSolutions Inc.
	
 





	
 
	
28.
	
Collaboration and Option Agreement, dated as of July 20, 2017, by and between Aptevo Research and Development LLC, and Alligator Bioscience AB.
	
 





	
 
	
29.
	
Antibody Library Subscription Agreement, dated March 14, 2016, by and between Distributed Bio Inc. and Emergent Product Development Seattle LLC.
	
 




 


	
 
	
30.
	
Amendment No. 1 to the Antibody Library Subscription Agreement, dated May 25, 2018.





	
 
	
1.
	







[Schedule 3.17]

 
 


Schedule 3.18 – Environmental Compliance

None.

 



[Schedule 3.18]

 
 


 

Schedule 3.19 – Registered Intellectual Property


	
 
	
A.
	
Patents




 


									
	
FIX rPROTEIN

	
Method of producing biologically active vitamin K dependent proteins by recombinant methods

	
APVO.40900

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40900
	
AT
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
673396
	
18-Jun-2014

	
APVO.40900
	
AU
	
 
	
ORD
	
Granted
	
2006331501
	
21-Dec-2006
	
2006331501
	
19-Dec-2013

	
APVO.40900
	
AU
	
1
	
DIV
	
Granted
	
2013211534
	
02-Aug-2013
	
2013211534
	
16-Jun-2016

	
APVO.40900
	
BE
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
41661-BE-U
	
18-Jun-2014

	
APVO.40900
	
BG
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
CA
	
 
	
ORD
	
Pending
	
2,633,661
	
21-Dec-2006
	
 
	
 

	
APVO.40900
	
CH
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
CY
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
CY2014220002
	
16-Sep-2014

	
APVO.40900
	
CZ
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
E214840
	
18-Jun-2014

	
APVO.40900
	
DE
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
DK
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014




 



[Schedule 3.19]

 
 


 


									
	
APVO.40900
	
EE
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
E009452
	
18-Jun-2014

	
APVO.40900
	
ES
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
300136771
	
18-Jun-2014

	
APVO.40900
	
FI
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
FR
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
GB
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
GR
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
60 2006 041 992.9
	
18-Jun-2014

	
APVO.40900
	
HK
	
1
	
REP
	
Pending
	
12104533.2
	
21-Dec-2006
	
 
	
 

	
APVO.40900
	
HU
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
E06848864
	
18-Jun-2014

	
APVO.40900
	
IE
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
IS
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
IT
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
502014000000502.00
	
18-Jun-2014

	
APVO.40900
	
JP
	
 
	
ORD
	
Granted
	
2008-547588
	
21-Dec-2006
	
5526332
	
25-Apr-2014

	
APVO.40900
	
LI
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
LT
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
LU
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
LV
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
MC
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
NL
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
500114787
	
18-Jun-2014




 



[Schedule 3.19]

 
 


 


									
	
APVO.40900
	
PL
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
PT
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
201400000472409.00
	
18-Jun-2014

	
APVO.40900
	
RO
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
3908
	
18-Jun-2014

	
APVO.40900
	
SE
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
SI
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1969127
	
18-Jun-2014

	
APVO.40900
	
SK
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
1000011882
	
18-Jun-2014

	
APVO.40900
	
TR
	
 
	
EPC
	
Granted
	
6848864.2
	
21-Dec-2006
	
2014/10859
	
18-Jun-2014

	
APVO.40900
	
US
	
3
	
CON
	
Pending
	
15/875,373
	
19-Jan-2018
	
 
	
 




 

 

 

 

 

 

 

 


									
	
METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS

	
APVO.40901

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40901
	
EP
	
 
	
PCT
	
Allowed
	
10827499.4
	
28-Oct-2010
	
2494040
	
 

	
APVO.40901
	
HK
	
 
	
REP
	
Published
	
13102606.7
	
28-Oct-2010
	
 
	
 

	
APVO.40901
	
JP
	
 
	
PCT
	
Granted
	
2012-537082
	
28-Oct-2010
	
5851410
	
11-Dec-2015




 



[Schedule 3.19]

 
 


 


									
	
APVO.40901
	
US
	
2
	
CON
	
Granted
	
14/475,881
	
03-Sep-2014
	
9,587,008
	
07-Mar-2017




 

 


									
	
STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE

	
APVO.40902

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40902
	
AT
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
AU
	
 
	
PCT
	
Granted
	
2008340304
	
16-Dec-2008
	
2008340304
	
16-Jun-2016

	
APVO.40902
	
BE
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
BR
	
 
	
PCT
	
Pending
	
PI0821591-0
	
16-Dec-2008
	
 
	
 

	
APVO.40902
	
CA
	
1
	
DIV
	
Pending
	
2,991,162
	
16-Dec-2008
	
 
	
 

	
APVO.40902
	
CH
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
CN
	
1
	
DIV
	
Pending
	
2015106594510
	
16-Dec-2008
	
 
	
 

	
APVO.40902
	
DE
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
DK
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
EP
	
1
	
DIV
	
Pending
	
13165012.9
	
16-Dec-2008
	
2633860
	
 

	
APVO.40902
	
ES
	
 
	
EPP
	
Granted
	
088864646.8
	
16-Dec-2008
	
22222315
	
24-Apr-2013

	
APVO.40902
	
FI
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
FR
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013




 



[Schedule 3.19]

 
 


 


									
	
APVO.40902
	
GB
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
HK
	
 
	
REP
	
Pending
	
14101930.5
	
16-Dec-2008
	
 
	
 

	
APVO.40902
	
HK
	
 
	
REP
	
Pending
	
16106932.0
	
16-Dec-2008
	
 
	
 

	
APVO.40902
	
IE
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
IN
	
 
	
PCT
	
Pending
	
1530/MUMNP/2010
	
16-Dec-2008
	
 
	
 

	
APVO.40902
	
IT
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
JP
	
 
	
PCT
	
Granted
	
2010-539710
	
16-Dec-2008
	
5649451
	
21-Dec-2014

	
APVO.40902
	
LU
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
MC
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
NL
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
PT
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
RU
	
 
	
PCT
	
Granted
	
2010122379
	
16-Dec-2008
	
2481823
	
20-May-2013

	
APVO.40902
	
SE
	
 
	
EPP
	
Granted
	
08864646.8
	
16-Dec-2008
	
2222315
	
24-Apr-2013

	
APVO.40902
	
US
	
2
	
CON
	
Pending
	
16/028,736
	
06-Jul-2018
	
 
	
 




 

 


									
	
RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME

	
APVO.40903

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date




 



[Schedule 3.19]

 
 


 


									
	
APVO.40903
	
AU
	
1
	
DIV
	
Granted
	
2014202989
	
28-Apr-2008
	
2014202989
	
20-Oct-2016

	
APVO.40903
	
AU
	
2
	
DIV
	
Pending
	
2016238889
	
28-Apr-2008
	
 
	
 

	
APVO.40903
	
CA
	
 
	
PCT
	
Pending
	
2,683,423
	
28-Apr-2008
	
 
	
 

	
APVO.40903
	
HK
	
 
	
REP
	
Pending
	
13105065.4
	
28-Apr-2008
	
 
	
 

	
APVO.40903
	
JP
	
 
	
PCT
	
Granted
	
2010-506563
	
28-Apr-2008
	
6050927
	
02-Dec-2016

	
APVO.40903
	
JP
	
1
	
DIV
	
Granted
	
2014-246477
	
28-Apr-2008
	
6223319
	
13-Oct-2017

	
APVO.40903
	
US
	
1
	
CON
	
Pending
	
14/860,042
	
21-Sep-2015
	
 
	
 




 

 


									
	
Cells expressing vitamin K epoxide reductase and use thereof

	
APVO.40904

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40904
	
AT
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
AU
	
 
	
PCT
	
Granted
	
2004275828
	
23-Sep-2004
	
2004275828
	
29-Apr-2010

	
APVO.40904
	
BE
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
CA
	
 
	
PCT
	
Granted
	
2,539,434
	
23-Sep-2004
	
2539434
	
18-Mar-2014

	
APVO.40904
	
CH
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
CH 2380985
	
13-Jan-2010

	
APVO.40904
	
DE
	
 
	
EPP
	
Granted
	
7109353.8
	
23-Sep-2004
	
1842920
	
13-Jan-2010

	
APVO.40904
	
DE
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
13-Jan-2010




 



[Schedule 3.19]

 
 


 


									
	
APVO.40904
	
DK
	
 
	
EPP
	
Granted
	
7109353.8
	
23-Sep-2004
	
1842920
	
13-Jan-2010

	
APVO.40904
	
DK
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
13-Jan-2010

	
APVO.40904
	
ES
	
 
	
EPP
	
Granted
	
07109358.3
	
23-Sep-2004
	
1842920
	
13-Jan-2010

	
APVO.40904
	
ES
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
13-Jan-2010

	
APVO.40904
	
FR
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
13-Jan-2010

	
APVO.40904
	
GB
	
 
	
EPP
	
Granted
	
71093538
	
23-Sep-2004
	
1,842,920
	
13-Jan-2010

	
APVO.40904
	
GB
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
13-Jan-2010

	
APVO.40904
	
HK
	
 
	
DIV
	
Granted
	
61140030
	
23-Sep-2004
	
1093223
	
 

	
APVO.40904
	
IE
	
 
	
ORD
	
Granted
	
71093538
	
23-Sep-2004
	
1,842,920
	
13-Jan-2010

	
APVO.40904
	
IE
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
IT
	
 
	
EPP
	
Granted
	
7109353.8
	
23-Sep-2004
	
1842920
	
13-Jan-2010

	
APVO.40904
	
IT
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
JP
	
2
	
ORD
	
Granted
	
2012054537
	
23-Sep-2004
	
5840539
	
20-Nov-2015

	
APVO.40904
	
LU
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
MC
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Mar-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
NL
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
PL
	
 
	
EPP
	
Granted
	
7109353.8
	
23-Sep-2004
	
1842920
	
13-Jan-2010

	
APVO.40904
	
PT
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014




 



[Schedule 3.19]

 
 


 


									
	
APVO.40904
	
SE
	
 
	
EPP
	
Granted
	
71093538
	
23-Sep-2004
	
1,842,920
	
13-Jan-2010

	
APVO.40904
	
SE
	
1
	
EPP
	
Granted
	
11156979.4
	
23-Sep-2004
	
2380985
	
01-Jan-2014

	
APVO.40904
	
TR
	
 
	
EPP
	
Granted
	
7109353.8
	
23-Sep-2004
	
1842920
	
13-Jan-2010

	
APVO.40904
	
US
	
1
	
CON
	
Granted
	
11/516,229
	
06-Sep-2006
	
7,524,665
	
28-Apr-2009

	
APVO.40904
	
US
	
10
	
CON
	
Allowed
	
14/490,244
	
18-Sep-2014
	
 
	
 

	
APVO.40904
	
US
	
2
	
CON
	
Granted
	
11/699,930
	
30-Jan-2007
	
7,482,141
	
27-Jan-2009

	
APVO.40904
	
US
	
3
	
CIP
	
Granted
	
11/787,072
	
13-Apr-2007
	
7,645,602
	
12-Jan-2010

	
APVO.40904
	
US
	
4
	
CON
	
Pending
	
16/020,731
	
27-Jun-2018
	
 
	
 




 

 


									
	
METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS

	
APVO.40905

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.40905
	
CA
	
 
	
PCT
	
Granted
	
2601574
	
15-Mar-2005
	
2601574
	
02-Dec-2014

	
APVO.40905
	
US
	
1
	
CON
	
Granted
	
12/612,154
	
04-Nov-2009
	
8,603,823
	
10-Dec-2013

	
APVO.40905
	
US
	
2
	
CON
	
Published
	
14/496,801
	
25-Sep-2014
	
9,828,588
	
28-Nov-2017

	
APVO.40905
	
US
	
3
	
CON
	
Pending
	
15/794,788
	
26-Oct-2017
	
 
	
 

	
APVO.40905
	
US
	
4
	
CON
	
Pending
	
16/001,476
	
6-Jun-2018
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS

	
EPDS.80011a

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80011a
	
AU
	
 
	
PCT
	
Granted
	
2002241922
	
17-Jan-2002
	
2002241922
	
07-Feb-2008

	
APVO.80011a
	
AU
	
1
	
DIV
	
Granted
	
2008200400
	
17-Jan-2002
	
2008200400
	
20-Sep-2012

	
APVO.80011a
	
CA
	
 
	
PCT
	
Granted
	
2433877
	
17-Jan-2002
	
2433877
	
18-Nov-2014

	
APVO.80011a
	
CN
	
 
	
PCT
	
Granted
	
02803820.7
	
17-Jan-2002
	
ZL02803820.7
	
09-Aug-2006

	
APVO.80011a
	
CN
	
1
	
DIV
	
Granted
	
200610093692.4
	
17-Jan-2002
	
ZL200610093692. 4
	
29-May-2013

	
APVO.80011a
	
KR
	
 
	
PCT
	
Granted
	
10-2003-7009474
	
17-Jan-2002
	
10-0927261
	
10-Nov-2009

	
APVO.80011a
	
MX
	
 
	
PCT
	
Granted
	
PA/a/2003/006358
	
17-Jan-2002
	
282451
	
05-Jan-2011

	
APVO.80011a
	
MX
	
2
	
DIV
	
Granted
	
MX/a/2011/000016
	
17-Jan-2002
	
303607
	
21-Sep-2012

	
APVO.80011a
	
NZ
	
 
	
PCT
	
Granted
	
527591
	
17-Jan-2002
	
527591
	
10-Aug-2006

	
APVO.80011a
	
RU
	
 
	
PCT
	
Granted
	
2003125266
	
17-Jan-2002
	
2420537
	
28-Nov-2011

	
APVO.80011a
	
US
	
1
	
CON
	
Granted
	
11/088,693
	
23-Mar-2005
	
8,106,161
	
31-Jan-2012

	
APVO.80011a
	
US
	
10
	
CON
	
Granted
	
12/901,297
	
08-Oct-2010
	
8,197,810
	
12-Jun-2012

	
APVO.80011a
	
US
	
11
	
CON
	
Granted
	
13/451,641
	
20-Apr-2012
	
9,005,612
	
14-Apr-2015

	
APVO.80011a
	
US
	
9
	
CON
	
Granted
	
12/901,295
	
08-Oct-2010
	
8,188,237
	
29-May-2012

	
APVO.80011a
	
ZA
	
 
	
PCT
	
Granted
	
2003/05098
	
17-Jan-2002
	
2003/05098
	
29-Dec-2004




 



[Schedule 3.19]

 
 


 

 

 


									
	
BINDING CONSTRUCTS AND METHODS FOR USE THEREOF

	
APVO.80011c

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80011c
	
SG
	
 
	
PCT
	
Granted
	
200600553-2
	
24-Dec-2003
	
119455
	
29-Feb-2008

	
APVO.80011c
	
US
	
 
	
PRI
	
Granted
	
10/627,556
	
26-Jul-2003
	
7829084
	
09-Nov-2010

	
APVO.80011c
	
ZA
	
 
	
PCT
	
Granted
	
2006/01653
	
24-Dec-2003
	
2006/01653
	
30-May-2007




 

 


									
	
BINDING CONSTRUCTS AND METHODS FOR USE THEREOF

	
APVO.80011b

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80011b
	
US
	
1
	
CON
	
Granted
	
12/541,062
	
13-Aug-2009
	
8,147,835
	
03-Apr-2012

	
APVO.80011b
	
US
	
4
	
DIV
	
Granted
	
13/396,147
	
14-Feb-2012
	
8,853,366
	
07-Oct-2014




 

 


									
	
B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES

	
APVO.80100

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80100
	
AE
	
 
	
PCT
	
Pending
	
73/2008
	
25-Jul-2006
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80100
	
AL
	
 
	
EPP
	
Granted
	
AL/P/2014/000099
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
AL
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
AT
	
 
	
EPP
	
Granted
	
AT E 651839
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
AT
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
AU
	
 
	
PCT
	
Granted
	
2006272555
	
25-Jul-2006
	
2006272555
	
21-Jun-2012

	
APVO.80100
	
AU
	
1
	
DIV
	
Granted
	
2012203322
	
25-Jul-2006
	
2012203322
	
23-Oct-2014

	
APVO.80100
	
BA
	
 
	
EPP
	
Granted
	
E01403
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
BA
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
BE
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
BE
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
BG
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
BG
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
BR
	
 
	
PCT
	
Pending
	
PI0614184-6
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
CA
	
 
	
PCT
	
Granted
	
2616395
	
25-Jul-2006
	
2616395
	
04-Oct-2016

	
APVO.80100
	
CH
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
CH
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
CN
	
 
	
PCT
	
Granted
	
200680027227.9
	
25-Jul-2006
	
ZL20068002722 7.9
	
29-Apr-2015




 



[Schedule 3.19]

 
 


 


									
	
APVO.80100
	
CN
	
1
	
DIV
	
Granted
	
201510137983.8
	
26-Mar-2015
	
ZL20151013798 3.8
	
22-Jun-2018

	
APVO.80100
	
CO
	
 
	
PCT
	
Granted
	
08003675
	
25-Jul-2006
	
08003675
	
17-Oct-2013

	
APVO.80100
	
CR
	
 
	
PCT
	
Granted
	
9761
	
25-Jul-2006
	
3051
	
07-May-2014

	
APVO.80100
	
CY
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
CY
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
CZ
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
CZ
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
DE
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
DE
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
DK
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
DK/EP 1912675T3
	
12-Feb-2014

	
APVO.80100
	
DK
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
EE
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
EE
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
ES
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
ES 20406517T3
	
12-Feb-2014

	
APVO.80100
	
ES
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
FI
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
FI
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015




 



[Schedule 3.19]

 
 


 


									
	
APVO.80100
	
FR
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
FR
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
GB
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
GB
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
GR
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
GR
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
GT
	
 
	
ORD
	
Granted
	
A-20080004
	
23-Jan-2008
	
5617/412/19
	
11-Nov-2011

	
APVO.80100
	
HK
	
 
	
REP
	
Granted
	
08111578.9
	
25-Jul-2006
	
1115820
	
01-Aug-2014

	
APVO.80100
	
HK
	
1
	
RCN
	
Granted
	
09102857.9
	
25-Jul-2006
	
1125288
	
20-Nov-2015

	
APVO.80100
	
HK
	
2
	
REP
	
Granted
	
11110031.7
	
25-Jul-2006
	
1155761
	
31-Dec-2015

	
APVO.80100
	
HK
	
4
	
REP
	
Pending
	
13110586.4
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
HR
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
HR
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
HU
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
HU
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
ID
	
 
	
PCT
	
Pending
	
W-00200800171
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
IE
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
IE
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015




 



[Schedule 3.19]

 
 


 


									
	
APVO.80100
	
IL
	
 
	
PCT
	
Granted
	
188345
	
25-Jul-2006
	
188345
	
31-Jul-2015

	
APVO.80100
	
IN
	
 
	
PCT
	
Granted
	
197/DELNP/2008
	
25-Jul-2006
	
270418
	
18-Dec-2015

	
APVO.80100
	
IS
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
IS
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
IT
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
IT
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
JP
	
 
	
PCT
	
Granted
	
2008-524109
	
25-Jul-2006
	
5740076
	
01-May-2015

	
APVO.80100
	
KR
	
 
	
PCT
	
Granted
	
10-2008-7003703
	
25-Jul-2006
	
10-1251157
	
29-Mar-2013

	
APVO.80100
	
LI
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
LI
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
LT
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
LT
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
LU
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
LU
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
LV
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
LV
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
MC
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
MC
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015




 



[Schedule 3.19]

 
 


 


									
	
APVO.80100
	
MK
	
 
	
EPP
	
Granted
	
2014/136
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
MK
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
MX
	
 
	
PCT
	
Granted
	
MX/a/2008/001131
	
25-Jul-2006
	
314397
	
21-Oct-2013

	
APVO.80100
	
NI
	
 
	
PCT
	
Granted
	
2008-0032I
	
25-Jul-2006
	
2446 RPI
	
29-Jan-2016

	
APVO.80100
	
NL
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
NL
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
NO
	
 
	
PCT
	
Pending
	
20080217
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
NZ
	
1
	
DIV
	
Granted
	
594275
	
26-Jul-2011
	
594274
	
30-Jul-2013

	
APVO.80100
	
NZ
	
2
	
DIV
	
Granted
	
606294
	
25-Jan-2013
	
606294
	
06-Jan-2015

	
APVO.80100
	
PL
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
PL
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
PT
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
PT
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
RO
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
RO
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
RS
	
 
	
EPP
	
Granted
	
P-2014/0232
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
RS
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
RU
	
 
	
PCT
	
Granted
	
2008106893
	
25-Jul-2006
	
2423381
	
10-Jul-2011




 



[Schedule 3.19]

 
 


 


									
	
APVO.80100
	
SE
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
SE
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
SG
	
2
	
DIV
	
Granted
	
201009615-4
	
25-Jul-2006
	
168530
	
15-Sep-2014

	
APVO.80100
	
SI
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
SI
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
SK
	
 
	
EPP
	
Granted
	
06788565.7
	
25-Jul-2006
	
1912675
	
12-Feb-2014

	
APVO.80100
	
SK
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
TR
	
 
	
EPP
	
Granted
	
20140400893
	
25-Jul-2006
	
TR 201404796TR
	
12-Feb-2014

	
APVO.80100
	
TR
	
1
	
EDV
	
Granted
	
10181126.3
	
25-Jul-2006
	
2298815
	
11-Mar-2015

	
APVO.80100
	
UA
	
 
	
PCT
	
Granted
	
200802255
	
25-Jul-2006
	
97469
	
25-Nov-2011

	
APVO.80100
	
US
	
 
	
ORD
	
Pending
	
11/493,132
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
US
	
3
	
CON
	
Pending
	
13/836,103
	
15-Mar-2013
	
 
	
 

	
APVO.80100
	
VN
	
 
	
PCT
	
Pending
	
1-2008-00373
	
25-Jul-2006
	
 
	
 

	
APVO.80100
	
ZA
	
 
	
PCT
	
Granted
	
2008/00692
	
25-Jul-2006
	
2008/00692
	
26-Oct-2011




 

 


									
	
SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION

	
APVO.80102

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date




 



[Schedule 3.19]

 
 


 


									
	
APVO.80102
	
AU
	
 
	
PCT
	
Granted
	
2007257692
	
12-Jun-2007
	
2007257692
	
27-Feb-2014

	
APVO.80102
	
AU
	
1
	
DIV
	
Granted
	
2014200661
	
06-Feb-2014
	
2014200661
	
13-Oct-2016

	
APVO.80102
	
AU
	
1
	
DIV
	
Pending
	
2016231617
	
23-Sep-2016
	
 
	
 

	
APVO.80102
	
BR
	
 
	
PCT
	
Pending
	
PI0713000-7
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
CA
	
 
	
PCT
	
Pending
	
2654317
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
CN
	
1
	
DIV
	
Pending
	
201610169942.1
	
23-Mar-2016
	
 
	
 

	
APVO.80102
	
EP
	
 
	
PCT
	
Pending
	
07784422.3
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
EP
	
1
	
PCT
	
Pending
	
11182404.1
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
HK
	
 
	
REP
	
Pending
	
09108900.3
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
HK
	
2
	
REP
	
Pending
	
12107631.6
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
IL
	
 
	
PCT
	
Granted
	
195739
	
12-Jun-2007
	
195739
	
01-Mar-2016

	
APVO.80102
	
JP
	
1
	
DIV
	
Granted
	
2014-222591
	
29-Oct-2014
	
6038858
	
11-Nov-2016

	
APVO.80102
	
JP
	
2
	
DIV
	
Pending
	
2016-214734
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
KR
	
 
	
PCT
	
Granted
	
10-2009-7000622
	
12-Jun-2007
	
10-1571027
	
17-Nov-2015

	
APVO.80102
	
MX
	
 
	
PCT
	
Granted
	
MX/a/2008/015524
	
12-Jun-2007
	
312426
	
16-Aug-2013

	
APVO.80102
	
MX
	
1
	
DIV
	
Pending
	
MX/a/2013/009517
	
16-Aug-2013
	
 
	
 

	
APVO.80102
	
MY
	
 
	
PCT
	
Granted
	
PI20085024
	
12-Jun-2007
	
162131
	
31-May-2017

	
APVO.80102
	
NO
	
 
	
PCT
	
Pending
	
20085253
	
12-Jun-2007
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80102
	
NZ
	
 
	
PCT
	
Granted
	
573646
	
12-Jun-2007
	
573646
	
06-Aug-2012

	
APVO.80102
	
NZ
	
1
	
DIV
	
Granted
	
596865
	
12-Jun-2007
	
596865
	
30-Oct-2013

	
APVO.80102
	
NZ
	
2
	
DIV
	
Granted
	
612319
	
17-Jun-2007
	
612319
	
28-Jul-2015

	
APVO.80102
	
PH
	
 
	
PCT
	
Granted
	
1-2008-502612
	
12-Jun-2007
	
1-2008-502512
	
10-Sep-2015

	
APVO.80102
	
RU
	
 
	
PCT
	
Granted
	
2009100153
	
12-Jun-2007
	
2487888
	
20-Jun-2013

	
APVO.80102
	
SG
	
1
	
DIV
	
Granted
	
201104275-1
	
12-Jun-2007
	
172698
	
25-Nov-2014

	
APVO.80102
	
US
	
1
	
PCT
	
Granted
	
12/304,562
	
22-Jul-2010
	
8,409,577
	
02-Apr-2013

	
APVO.80102
	
US
	
3
	
CON
	
Pending
	
15/617,833
	
08-Jun-2017
	
 
	
 

	
APVO.80102
	
VN
	
 
	
PCT
	
Granted
	
1-2009-00069
	
12-Jun-2007
	
18920
	
04-Apr-2018

	
APVO.80102
	
ZA
	
 
	
PCT
	
Allowed
	
2009/00056
	
12-Jun-2007
	
 
	
 

	
APVO.80102
	
ZA
	
1
	
DIV
	
Granted
	
2013/03003
	
24-Apr-2013
	
2013/03003
	
25-Jun-2014




 

 


									
	
Glyco-Variants

	
APVO.80105a

	
APVO.80105a
	
US
	
1
	
CIP
	
Granted
	
12/082,497
	
11-Apr-2008
	
7,846,434
	
07-Dec-2010

	
APVO.80105a
	
US
	
2
	
DIV
	
Granted
	
12/909,769
	
21-Oct-2010
	
8,383,106
	
26-Feb-2013




 



CD86 Antagonist Multi-Target Binding Proteins

 
 
 



[Schedule 3.19]

 
 


 


									
	
APVO.80116

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80116
	
AT
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
AU
	
 
	
PCT
	
Granted
	
2009298131
	
02-Oct-2009
	
2009298131
	
27-Oct-2016

	
APVO.80116
	
AU
	
3
	
DIV
	
Pending
	
2018203491
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
BE
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
BR
	
 
	
PCT
	
Pending
	
PI0920749-0
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
CA
	
 
	
PCT
	
Pending
	
2,739,460
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
CH
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
CN
	
1
	
DIV
	
Pending
	
201710294122.X
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
CY
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
DE
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
DK
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
EA
	
 
	
PCT
	
Granted
	
201170443
	
02-Oct-2009
	
024877
	
31-Oct-2016

	
APVO.80116
	
EP
	
 
	
DIV
	
Pending
	
17192769.2
	
02-Oct-2009
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80116
	
ES
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
FI
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
FR
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
GB
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
GR
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
HK
	
 
	
REP
	
Published
	
11112650.3
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
HK
	
 
	
RCN
	
Pending
	
18102489.4
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
HR
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
IE
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
IN
	
 
	
PCT
	
Pending
	
1806/KOLNP/2011
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
JP
	
 
	
PCT
	
Granted
	
2011-530279
	
02-Oct-2009
	
5840494
	
20-Nov-2015

	
APVO.80116
	
IS
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
IT
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
JP
	
2
	
DIV
	
Pending
	
2016-153405
	
02-Oct-2009
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80116
	
KR
	
 
	
PCT
	
Pending
	
10-2011-7010004
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
KR
	
2
	
DIV
	
Pending
	
10-2017-7021715
	
02-Oct-2009
	
 
	
 

	
APVO.80116
	
LT
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
LU
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
LV
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
MC
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
MK
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
MT
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
MX
	
 
	
PCT
	
Granted
	
MX/a/2011/003611
	
02-Oct-2009
	
338825
	
03-May-

2016

	
APVO.80116
	
MX
	
1
	
PCT
	
Pending
	
MX/a/2015/004490
	
06-Apr-2015
	
 
	
 

	
APVO.80116
	
NL
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
NO
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
NZ
	
 
	
PCT
	
Granted
	
592420
	
02-Oct-2009
	
59240
	
22-Mar-2013

	
APVO.80116
	
PL
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-




 



[Schedule 3.19]

 
 


 


									
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
2017

	
APVO.80116
	
PT
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
SE
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
SG
	
 
	
PCT
	
Granted
	
201102375-1
	
02-Oct-2009
	
170262
	
14-Oct-2013

	
APVO.80116
	
SI
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
TR
	
 
	
EPC
	
Granted
	
09793296.6
	
02-Oct-2009
	
2344540
	
29-Nov-

2017

	
APVO.80116
	
US
	
 
	
PCT
	
Granted
	
13/122,383
	
02-Oct-2009
	
9,493,564
	
15-Nov-2016

	
APVO.80116
	
US
	
 
	
CON
	
Pending
	
15/281,441
	
30-Sep-2016
	
 
	
 

	
APVO.80116
	
ZA
	
 
	
PCT
	
Granted
	
2011/02637
	
02-Oct-2009
	
2011/02637
	
28-Sep-2016




 

 


									
	
TCR Complex Immunotherapeutics

	
APVO.80117

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80117
	
AU
	
 
	
PCT
	
Granted
	
2009303318
	
09-Oct-2009
	
2009303318
	
13-Oct-2016

	
APVO.80117
	
BR
	
 
	
PCT
	
Pending
	
PI0920573-0
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
CA
	
 
	
PCT
	
Pending
	
2740098
	
09-Oct-2009
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80117
	
CN
	
1
	
DIV
	
Pending
	
201510679112.9
	
19-Oct-2015
	
 
	
 

	
APVO.80117
	
EA
	
 
	
PCT
	
Pending
	
201170475
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
EP
	
 
	
PCT
	
Pending
	
09740584.9
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
HK
	
 
	
REP
	
Published
	
11112849.5
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
HK
	
1
	
RCN
	
Pending
	
12105515.1
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
IN
	
 
	
PCT
	
Pending
	
1934/KOLNP/2011
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
JP
	
1
	
DIV
	
Granted
	
2014-179868
	
04-Sep-2014
	
5955913
	
24-Jun-2016

	
APVO.80117
	
KR
	
 
	
PCT
	
Pending
	
10-2011-7010643
	
09-Oct-2009
	
 
	
 

	
APVO.80117
	
NZ
	
 
	
PCT
	
Granted
	
592611
	
09-Oct-2009
	
592611
	
30-Apr-2013

	
APVO.80117
	
NZ
	
1
	
DIV
	
Granted
	
603623
	
09-Oct-2009
	
603623
	
02-Sep-2014

	
APVO.80117
	
SG
	
 
	
PCT
	
Pending
	
201102560-8
	
09-Oct-2009
	
172754
	
03-Jan-2018

	
APVO.80117
	
US
	
2
	
CON
	
Pending
	
15/040,744
	
10-Feb-2016
	
 
	
 

	
APVO.80117
	
ZA
	
 
	
PCT
	
Pending
	
2011/02681
	
09-Oct-2009
	
 
	
 




 

 


									
	
CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF

	
APVO.80118

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80118
	
HK
	
 
	
REP
	
Published
	
12100725.8
	
13-Nov-2009
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80118
	
IL
	
 
	
PCT
	
Granted
	
212834
	
13-Nov-2009
	
212834
	
01-Oct-2016

	
APVO.80118
	
MX
	
 
	
PCT
	
Granted
	
MX/a/2011/00498
	
13-Nov-2009
	
324189
	
07-Oct-2014

	
APVO.80118
	
NZ
	
1
	
DIV
	
Granted
	
602407
	
13-Nov-2009
	
602407
	
02-Dec-2014

	
APVO.80118
	
NZ
	
2
	
DIV
	
Granted
	
620326
	
13-Nov-2009
	
620326
	
03-Nov-2015

	
APVO.80118
	
RU
	
 
	
PCT
	
Granted
	
2011123879
	
13-Nov-2009
	
2526156
	
20-Aug-2014




 

 


									
	
CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF

	
APVO.80120

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80120
	
AL
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
3791
	
22-Jun-2011

	
APVO.80120
	
AT
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
E513856
	
22-Jun-2011

	
APVO.80120
	
AU
	
 
	
PCT
	
Granted
	
2009234277
	
11-Apr-2009
	
2009234277
	
19-Mar-2015

	
APVO.80120
	
BA
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
BAP/EP2132228
	
31-Mar-2014

	
APVO.80120
	
BE
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
BG
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
BR
	
 
	
PCT
	
Pending
	
PI0911377-0
	
11-Apr-2009
	
 
	
 

	
APVO.80120
	
CA
	
 
	
PCT
	
Granted
	
2719924
	
11-Apr-2009
	
2719924
	
03-Oct-2017

	
APVO.80120
	
CH
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011




 



[Schedule 3.19]

 
 


 


									
	
APVO.80120
	
CN
	
1
	
DIV
	
Pending
	
201510609700.5
	
22-Sep-2015
	
 
	
 

	
APVO.80120
	
CY
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
CY20111100815
	
22-Jun-2011

	
APVO.80120
	
CZ
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
DE
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
602009001618.0
	
22-Jun-2011

	
APVO.80120
	
DK
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
EE
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
ES
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
FI
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
FR
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
GB
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
GR
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2011-002821
	
22-Jun-2011

	
APVO.80120
	
HK
	
 
	
REP
	
Granted
	
10103762.8
	
11-Apr-2009
	
1137767
	
11-Jan-2013

	
APVO.80120
	
HK
	
1
	
REP
	
Published
	
12101244.8
	
08-Feb-2012
	
 
	
 

	
APVO.80120
	
HR
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
P20110619
	
22-Jun-2011

	
APVO.80120
	
HU
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
E012589
	
22-Jun-2011

	
APVO.80120
	
IE
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
IL
	
 
	
PCT
	
Pending
	
208566
	
11-Apr-2009
	
 
	
 

	
APVO.80120
	
IN
	
 
	
PCT
	
Pending
	
7230/CHENP/2010
	
11-Apr-2009
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80120
	
IS
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
IT
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
JP
	
 
	
PCT
	
Granted
	
2011-504229
	
11-Apr-2009
	
6013733
	
30-Sep-2016

	
APVO.80120
	
LT
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
LU
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
LV
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
MC
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
MK
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
904060
	
08-May-2012

	
APVO.80120
	
MT
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
EP00367/213222 8
	
22-Jun-2011

	
APVO.80120
	
MX
	
 
	
PCT
	
Granted
	
MX/a/2010/011057
	
11-Apr-2009
	
298052
	
11-Apr-2012

	
APVO.80120
	
MX
	
1
	
DIV
	
Granted
	
MX/a/2012/001458
	
11-Apr-2009
	
340204
	
30-Jun-2016

	
APVO.80120
	
NL
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
NO
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
NZ
	
 
	
PCT
	
Granted
	
588671
	
11-Apr-2009
	
588671
	
01-Mar-2013

	
APVO.80120
	
NZ
	
1
	
DIV
	
Granted
	
603059
	
11-Apr-2009
	
603059
	
29-Oct-2014

	
APVO.80120
	
NZ
	
2
	
DIV
	
Granted
	
621443
	
26-Feb-2014
	
621443
	
06-Jan-2016

	
APVO.80120
	
PL
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011




 



[Schedule 3.19]

 
 


 


									
	
APVO.80120
	
PT
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
RO
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
RS
	
 
	
EPC
	
Granted
	
P-2011/0408
	
11-Apr-2009
	
51975
	
22-Jun-2011

	
APVO.80120
	
RU
	
 
	
PCT
	
Granted
	
2010145917
	
11-Apr-2009
	
2531754
	
27-Oct-2014

	
APVO.80120
	
SE
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
SG
	
 
	
PCT
	
Granted
	
201007096-9
	
11-Apr-2009
	
165063
	
30-Apr-2013

	
APVO.80120
	
SI
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
SK
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
2132228
	
22-Jun-2011

	
APVO.80120
	
TR
	
 
	
EPC
	
Granted
	
09707110.4
	
11-Apr-2009
	
TR20110859T4
	
22-Jun-2011

	
APVO.80120
	
US
	
 
	
ORD
	
Granted
	
12/422,780
	
13-Apr-2009
	
9,101,609
	
11-Aug-2015

	
APVO.80120
	
US
	
1
	
PCT
	
Granted
	
12/678,857
	
15-Jul-2010
	
8,333,966
	
18-Dec-2012

	
APVO.80120
	
ZA
	
 
	
PCT
	
Granted
	
2010/07570
	
11-Apr-2009
	
2010/07570
	
28-Mar-2012




 

 


									
	
Heterodimer Binding Proteins and Uses Thereof

	
APVO.80121

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80121
	
AL
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
AT
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016




 



[Schedule 3.19]

 
 


 


									
	
APVO.80121
	
AU
	
 
	
PCT
	
Granted
	
2010343057
	
29-Dec-2010
	
2010343057
	
08-Jun-2017

	
APVO.80121
	
BA
	
 
	
EPC
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
BE
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
BG
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
BR
	
 
	
PCT
	
Pending
	
112012 0161350
	
29-Dec-2010
	
 
	
 

	
APVO.80121
	
CA
	
 
	
PCT
	
Pending
	
2,784,814
	
29-Dec-2010
	
 
	
 

	
APVO.80121
	
CH
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
CN
	
1
	
DIV
	
Pending
	
201610086074.0
	
15-Feb-2016
	
 
	
 

	
APVO.80121
	
CY
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
CZ
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
DE
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
DK
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
EA
	
 
	
PCT
	
Granted
	
201290568
	
29-Dec-2010
	
023674
	
30-Jun-2016

	
APVO.80121
	
EE
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
ES
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
FI
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
FR
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
GB
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016




 



[Schedule 3.19]

 
 


 


									
	
APVO.80121
	
GR
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
HK
	
 
	
REP
	
Granted
	
12111376.7
	
29-Dec-2010
	
1170741
	
29-Jun-2016

	
APVO.80121
	
HK
	
1
	
RCN
	
Pending
	
13109776.6
	
29-Dec-2010
	
 
	
 

	
APVO.80121
	
HR
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
HU
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
IE
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
IL
	
 
	
PCT
	
Granted
	
220398
	
29-Dec-2010
	
220398
	
01-Apr-2018

	
APVO.80121
	
IN
	
 
	
PCT
	
Pending
	
1608/KOLNP/2012
	
29-Dec-2010
	
 
	
 

	
APVO.80121
	
IS
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
IT
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
JP
	
 
	
PCT
	
Granted
	
2012-547282
	
29-Dec-2010
	
5851419
	
11-Dec-2015

	
APVO.80121
	
KR
	
 
	
PCT
	
Pending
	
10-2012-7019837
	
29-Dec-2010
	
 
	
 

	
APVO.80121
	
LI
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
LT
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
LU
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
LV
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
MC
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
ME
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016




 



[Schedule 3.19]

 
 


 


									
	
APVO.80121
	
MK
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
MT
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
MX
	
 
	
PCT
	
Granted
	
MX/a/2012/007533
	
29-Dec-2010
	
341796
	
02-Sep-2016

	
APVO.80121
	
NL
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
NO
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
NZ
	
 
	
PCT
	
Granted
	
600820
	
29-Dec-2010
	
600820
	
25-Mar-2015

	
APVO.80121
	
PL
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
PT
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
RO
	
 
	
EPP
	
Abandoned
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
RS
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
SE
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
SG
	
 
	
PCT
	
Granted
	
201204741-1
	
29-Dec-2010
	
181952
	
26-Apr-2017

	
APVO.80121
	
SI
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
SK
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
SM
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
TR
	
 
	
EPP
	
Granted
	
10803713.6
	
29-Dec-2010
	
2519543
	
29-Jun-2016

	
APVO.80121
	
US
	
2
	
Con
	
Pending
	
15/802,636
	
03-Nov-2017
	
 
	
 

	
APVO.80121
	
ZA
	
 
	
PCT
	
Pending
	
2012/04797
	
29-Dec-2010
	
 
	
 




 



[Schedule 3.19]

 
 


 

 

 

 

 


									
	
RTCC Constructs

	
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods

	
APVO.80124

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80124
	
CA
	
 
	
PCT
	
Pending
	
2,833,019
	
20-Apr-2012
	
 
	
 

	
APVO.80124
	
US
	
 
	
CON
	
Granted
	
15/585,921
	
03-May-2017
	
9,782,478
	
10-Oct-2017

	
APVO.80124
	
US
	
 
	
CON
	
Pending
	
15/699,474
	
08-Sep-2017
	
 
	
 




 

 


									
	
CD3 BINDING POLYPEPTIDES

	
APVO.80126

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80126
	
AE
	
 
	
PCT
	
Pending
	
1137/2014
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
AU
	
 
	
DIV
	
Pending
	
2017228643
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
BR
	
 
	
PCT
	
Pending
	
112014025830 9
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
CA
	
 
	
PCT
	
Pending
	
2,870,545
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
CN
	
 
	
PCT
	
Pending
	
2013800271098
	
18-Apr-2013
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80126
	
EG
	
 
	
PCT
	
Pending
	
PCT/US2014/1655
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
EP
	
 
	
PCT
	
Pending
	
13778209.0
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
HK
	
 
	
REP
	
Published
	
15108038.0
	
19-Aug-2015
	
 
	
 

	
APVO.80126
	
HK
	
1
	
RCN
	
Pending
	
15109147.6
	
17-Sep-2015
	
 
	
 

	
APVO.80126
	
ID
	
 
	
PCT
	
Pending
	
P00201407140
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
IL
	
 
	
PCT
	
Pending
	
235093
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
IN
	
 
	
PCT
	
Pending
	
2293|/MUMNP/2014
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
JP
	
 
	
PCT
	
Pending
	
2015-507169
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
JP
	
1
	
DIV
	
Pending
	
2018-080199
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
KR
	
 
	
PCT
	
Pending
	
10-2014-7032216
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
MX
	
 
	
PCT
	
Pending
	
MX/a/2014/012578
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
MY
	
 
	
PCT
	
Pending
	
PI 2014002979
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
NZ
	
 
	
DIV
	
Pending
	
731297
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
RU
	
 
	
PCT
	
Pending
	
2014142166
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
SG
	
 
	
DIV
	
Pending
	
10201608307W
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
UA
	
 
	
PCT
	
Pending
	
a 2014 12306
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
US
	
 
	
PCT
	
Pending
	
14/395,689
	
18-Apr-2013
	
 
	
 

	
APVO.80126
	
VN
	
 
	
PCT
	
Pending
	
1-2014-03790
	
18-Apr-2013
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80126
	
ZA
	
 
	
PCT
	
Pending
	
2014/08449
	
18-Apr-2013
	
 
	
 




 

 

 

 


									
	
Cell Line-Based Redirected T-Cell Cytotoxicity Assay

	
APVO.80135

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80135
	
EP
	
 
	
PCT
	
Pending
	
EP15765747.9
	
18-Mar-2015
	
 
	
 

	
APVO.80135
	
US
	
 
	
PCT
	
Pending
	
15/126,922
	
18-Mar-2015
	
 
	
 




 

 

 

 


									
	
Compositions and Methods for Combination Therapy with Prostate-Specific Membrane Antigen Binding Proteins

	
APVO.80137

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80137
	
CA
	
 
	
PCT
	
Pending
	
2976360
	
11-Feb-2016
	
 
	
 

	
APVO.80137
	
EP
	
 
	
PCT
	
Pending
	
EP16749890.6
	
11-Feb-2016
	
 
	
 

	
APVO.80137
	
US
	
 
	
PCT
	
Pending
	
15/550,143
	
11-Feb-2016
	
 
	
 




 



APVO.80138

CD3 Binding Polypeptides

 

 
 
 



[Schedule 3.19]

 
 


 


									
	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80138
	
AU
	
 
	
PCT
	
Pending
	
2016326449
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
BR
	
 
	
PCT
	
Pending
	
112018005573-5
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
CA
	
 
	
PCT
	
Pending
	
2999138
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
CN
	
 
	
PCT
	
Pending
	
2016800548403
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
CO
	
 
	
PCT
	
Pending
	
NC2018/0004094
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
EA
	
 
	
PCT
	
Pending
	
201890613
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
EP
	
 
	
PCT
	
Pending
	
16849533.1
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
ID
	
 
	
PCT
	
Pending
	
P00201802864
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
IL
	
 
	
PCT
	
Pending
	
258202
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
IN
	
 
	
PCT
	
Pending
	
201827013403
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
JP
	
 
	
PCT
	
Pending
	
2018-513821
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
KR
	
 
	
PCT
	
Pending
	
10-2018-7009336
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
MY
	
 
	
PCT
	
Pending
	
PI2018701059
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
MX
	
 
	
PCT
	
Pending
	
MX/a/2018/003292
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
NZ
	
 
	
PCT
	
Pending
	
740365
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
PH
	
 
	
PCT
	
Pending
	
1-2018-500520
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
SG
	
 
	
PCT
	
Pending
	
11201801773S
	
21-Sep-2016
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
APVO.80138
	
UA
	
 
	
PCT
	
Pending
	
a 2018 03341
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
US
	
 
	
PCT
	
Pending
	
15/761,499
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
VN
	
 
	
PCT
	
Pending
	
1-2018-01678
	
21-Sep-2016
	
 
	
 

	
APVO.80138
	
ZA
	
 
	
PCT
	
Pending
	
2018/02440
	
21-Sep-2016
	
 
	
 




 

 


									
	
CD123 Binding Proteins and Related Compositions and Methods

	
APVO.80141

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80141
	
US
	
 
	
ORD
	
Pending
	
15/933,324
	
22-Mar-2018
	
 
	
 

	
APVO.80141
	
WO
	
 
	
PRI
	
Pending
	
PCT/US2017/052808
	
21-Sep-2017
	
 
	
 




 

 

 

 


									
	
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods

	
MRPH.80124

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
MPHS.80124
	
AE
	
 
	
PCT
	
Pending
	
1130/2013
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
AU
	
 
	
PCT
	
Granted
	
2012245260
	
20-Apr-2012
	
2012245260
	
22-Dec-2016

	
MPHS.80124
	
BA
	
 
	
PCT
	
Pending
	
12773598.3
	
20-Apr-2012
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
MPHS.80124
	
BR
	
 
	
PCT
	
Pending
	
112013 027224 4
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
CN
	
 
	
PCT
	
Pending
	
201280030553.0
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
EG
	
 
	
PCT
	
Pending
	
PCT 1621/2013
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
EP
	
 
	
PCT
	
Pending
	
12773598.3
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
HK
	
 
	
REP
	
Pending
	
14106738.8
	
03-Jul-2014
	
 
	
 

	
MPHS.80124
	
HK
	
1
	
RCN
	
Pending
	
14107298.8
	
17-Jul-2014
	
 
	
 

	
MPHS.80124
	
ID
	
 
	
PCT
	
Granted
	
W00201305397
	
20-Apr-2012
	
IDP 000042371
	
15-Aug-2016

	
MPHS.80124
	
IL
	
 
	
PCT
	
Pending
	
228991
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
IN
	
 
	
PCT
	
Pending
	
8648/CHENP/2013
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
JP
	
 
	
DIV
	
Pending
	
2017-023634
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
ME
	
 
	
PCT
	
Pending
	
12773598.3
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
MX
	
 
	
PCT
	
Pending
	
MX/a/2013/012127
	
20-Apr-2012
	
355908
	
04-May-2018

	
MPHS.80124
	
MX
	
1
	
DIV
	
Pending
	
MX/a/2018/005604
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
MY
	
 
	
PCT
	
Pending
	
PI2013003838
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
NZ
	
 
	
PCT
	
Granted
	
616481
	
20-Apr-2012
	
616481
	
01-Dec-2015

	
MPHS.80124
	
RU
	
 
	
PCT
	
Pending
	
2013142600
	
20-Apr-2012
	
2632647
	
06-Oct-2017

	
MPHS.80124
	
SG
	
 
	
PCT
	
Granted
	
201307708-6
	
20-Apr-2012
	
194510
	
15-Aug-2016

	
MPHS.80124
	
UA
	
 
	
PCT
	
Pending
	
a201313177
	
20-Apr-2012
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
MPHS.80124
	
VN
	
 
	
PCT
	
Pending
	
1-2013-03660
	
20-Apr-2012
	
 
	
 

	
MPHS.80124
	
ZA
	
 
	
PCT
	
Pending
	
2013/07559
	
20-Apr-2012
	
 
	
 




 

 

 

 


									
	
Oncofetal Antigen Binding Proteins And Related Compositions And Methods

	
APVO.80142 (Co-owned with Alligator)

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80142
	
US
	
 
	
PRO
	
Pending
	
62/575,820
	
23-Oct-2017
	
 
	
 

	
APVO.80142
	
US
	
 
	
PRO
	
Pending
	
62/648,072
	
26-Mar-2018
	
 
	
 

	
APVO.80142
	
PCT
	
 
	
PRI
	
Pending
	
PCT/EP2018/069850
	
20-July-2018
	
 
	
 

	
APVO.80142
	
US
	
 
	
ORD
	
Pending
	
16/041,309
	
20-July-2018
	
 
	
 




 

 

 

 


									
	
Protein Therapeutics For Cytokine Delivery

	
APVO.80144

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.80144
	
US
	
 
	
PRO
	
Pending
	
62/667,404
	
04-May-2018
	
 
	
 




 



[Schedule 3.19]

 
 


 


									
	
Formulations Of Protein Therapeutics

	
APVO.80145

	
Docket Number
	
Country
	
Subcase
	
Case Type
	
Application Status
	
Application Number
	
Filing Date
	
Patent Number
	
Issue Date

	
APVO.
	
US
	
 
	
PRO
	
Pending
	
62/667,402
	
04-May-2018
	
 
	
 




 

 

 

 

 

 

 


	
 
	
B.
	
Trademarks




 


							
	
ADAPTIR

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
AU
	
ADAPTIR
	
Registered
	
1535279
	
07-Aug-2012
	
1535279
	
24-Sep-2014

	
CN
	
ADAPTIR
	
Registered
	
12166130
	
07-Aug-2012
	
12166130
	
28-Jul-2014

	
CN
	
ADAPTIR
	
Registered
	
12166129
	
07-Aug-2012
	
12166129
	
28-Jul-2014

	
EM
	
ADAPTIR
	
Registered
	
011481851
	
07-Aug-2012
	
011481851
	
07-Jun-2013

	
IN
	
ADAPTIR
	
Registered
	
2460333
	
07-Aug-2012
	
2460333
	
14-Jan-2013

	
JP
	
ADAPTIR
	
Registered
	
2013-004108
	
07-Aug-2012
	
5598630
	
12-Jul-2013

	
SG
	
ADAPTIR
	
Registered
	
T1300692I
	
07-Aug-2012
	
T1300692I
	
11-Jan-2013

	
US
	
ADAPTIR
	
Allowed
	
86/974,244
	
13-Apr-2016
	
 
	
 




 



[Schedule 3.19]

 
 


 

 

 


							
	
APTEVO

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
BR
	
APTEVO
	
Published
	
910765901
	
16-Mar-2016
	
 
	
 

	
BR
	
APTEVO
	
Published
	
910765944
	
16-Mar-2016
	
 
	
 

	
CA
	
APTEVO
	
Pending
	
1,772,702
	
16-Mar-2016
	
 
	
 

	
EG
	
APTEVO
	
Pending
	
332268
	
16-Sep-2015
	
 
	
 

	
EG
	
APTEVO
	
Pending
	
332269
	
16-Sep-2015
	
 
	
 

	
EM
	
APTEVO
	
Registered
	
015221261
	
16-Sep-2015
	
015221261
	
09-Jan-2018

	
HK
	
APTEVO
	
Registered
	
303714291
	
16-Sep-2015
	
30371429
	
16-Mar-2016

	
IQ
	
APTEVO
	
Published
	
71869
	
16-Mar-2016
	
 
	
 

	
JP
	
APTEVO
	
Registered
	
2016-029238
	
16-Mar-2016
	
5855830
	
03-Jun-2016

	
KW
	
APTEVO
	
Registered
	
178411
	
16-Mar-2016
	
149700
	
16-Oct-2017

	
KW
	
APTEVO
	
Registered
	
178412
	
16-Mar-2016
	
149701
	
16-Oct-2017

	
MY
	
APTEVO
	
Pending
	
2016054448
	
16-Sep-2015
	
 
	
 

	
MY
	
APTEVO
	
Registered
	
2016054450
	
16-Sep-2015
	
201654450
	
16-Dec-2016

	
NI
	
APTEVO
	
Published
	
TBD
	
16-Sep-2015
	
 
	
 

	
PK
	
APTEVO
	
Pending
	
413897
	
16-Sep-2015
	
 
	
 




 



[Schedule 3.19]

 
 


 


							
	
APTEVO

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
PK
	
APTEVO
	
Pending
	
413898
	
16-Sep-2015
	
 
	
 

	
UA
	
APTEVO
	
Registered
	
m201605321
	
16-Sep-2015
	
232123
	
25-Sep-2017

	
UY
	
APTEVO
	
Pending
	
472611
	
16-Sep-2015
	
 
	
 




 

 


							
	
APTEVO BIOTHERAPEUTICS

	
US
	
APTEVO BIOTHERAPEUTICS
	
Allowed
	
86/859161
	
28-Dec-2015
	
 
	
 

	
AU
	
APTEVO BIOTHERAPEUTICS
	
Registered
	
1865781
	
14-Aug-2017
	
1865781
	
13-Mar-2018

	
BR
	
APTEVO BIOTHERAPEUTICS
	
Pending
	
913215953
	
15-Aug-2017
	
 
	
 

	
BR
	
APTEVO BIOTHERAPEUTICS
	
Pending
	
913215910
	
15-Aug-2017
	
 
	
 

	
CA
	
APTEVO BIOTHERAPEUTICS
	
Pending
	
1,788,036
	
21-Jun-2016
	
 
	
 

	
EM
	
APTEVO BIOTHERAPEUTICS
	
Under Opposition
	
015568157
	
22-Jun-2016
	
 
	
 

	
HK
	
APTEVO BIOTHERAPEUTICS
	
Pending
	
304241628
	
15-Aug-2017
	
 
	
 

	
IN
	
APTEVO
	
Registered
	
3612484
	
14-Aug-2017
	
3612484
	
14-Aug-2017




 



[Schedule 3.19]

 
 


 


							
	
 
	
BIOTHERAPEUTICS
	
 
	
 
	
 
	
 
	
 

	
JP
	
APTEVO BIOTHERAPEUTICS
	
Pending
	
2017-106073
	
14-Aug-2017
	
 
	
 




 

 


							
	
APTEVO RESEARCH AND DEVELOPMENT

	
US
	
APTEVO RESEARCH AND DEVELOPMENT
	
Allowed
	
86/859,136
	
28-Dec-2015
	
 
	
 




 

 


							
	
APTEVO THERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
AU
	
APTEVO THERAPEUTICS
	
Registered
	
1865780
	
14-Aug-2017
	
1865780
	
13-Mar-2018

	
BR
	
APTEVO THERAPEUTICS
	
Published
	
913215902
	
15-Aug-2017
	
 
	
 

	
BR
	
APTEVO THERAPEUTICS
	
Published
	
913215821
	
15-Aug-2017
	
 
	
 

	
CA
	
APTEVO THERAPEUTICS
	
Pending
	
TBD
	
25-Sep-2015
	
 
	
 

	
CN
	
APTEVO THERAPEUTICS
	
Pending
	
26252801
	
06-Sept-2017
	
 
	
 

	
CN
	
APTEVO THERAPEUTICS
	
Pending
	
26252800
	
06-Sept-2017
	
 
	
 




 



[Schedule 3.19]

 
 


 


							
	
APTEVO THERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
CO
	
APTEVO THERAPEUTICS
	
Registered
	
SD2017/0065041
	
23-Aug-2017
	
594655
	
26-May-2018

	
EG
	
APTEVO THERAPEUTICS
	
Pending
	
355400
	
15-Aug-2017
	
 
	
 

	
EG
	
APTEVO THERAPEUTICS
	
Pending
	
355401
	
15-Aug-2017
	
 
	
 

	
EM
	
APTEVO THERAPEUTICS
	
Under Opposition
	
015281959
	
25-Sep-2015
	
 
	
 

	
HK
	
APTEVO THERAPEUTICS
	
Pending
	
304241619
	
15-Aug-2017
	
 
	
 

	
IN
	
APTEVO THERAPEUTICS
	
Published
	
3612482
	
14-Aug-2017
	
 
	
 

	
JP
	
APTEVO THERAPEUTICS
	
Pending
	
2017-106072
	
14-Aug-2017
	
 
	
 

	
KW
	
APTEVO THERAPEUTICS
	
Allowed
	
192998
	
15-Aug-2017
	
 
	
 

	
KW
	
APTEVO THERAPEUTICS
	
Allowed
	
192999
	
15-Aug-2017
	
 
	
 

	
MY
	
APTEVO THERAPEUTICS
	
Pending
	
2017065771
	
16-Aug-2017
	
 
	
 

	
MY
	
APTEVO THERAPEUTICS
	
Pending
	
2017065773
	
16-Aug-2017
	
 
	
 




 



[Schedule 3.19]

 
 


 


							
	
APTEVO THERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
MX
	
APTEVO THERAPEUTICS
	
Registered
	
1932722
	
15-Aug-2017
	
1817711
	
08-Nov-2017

	
MX
	
APTEVO THERAPEUTICS
	
Registered
	
1932726
	
15-Aug-2017
	
1817712
	
08-Nov-2017

	
NO
	
APTEVO THERAPEUTICS
	
Registered
	
201711429
	
30-Aug-2017
	
296390
	
16-Feb-2018

	
KR
	
APTEVO THERAPEUTICS
	
Registered
	
40-2017-0102884
	
14-Aug-2017
	
40-1353643
	
24-Apr-2018

	
RU
	
APTEVO THERAPEUTICS
	
Allowed
	
2017733207
	
15-Aug-2017
	
 
	
 

	
ZA
	
APTEVO THERAPEUTICS
	
Pending
	
2017/23208
	
14-Aug-2017
	
 
	
 

	
ZA
	
APTEVO THERAPEUTICS
	
Pending
	
2017/23209
	
14-Aug-2017
	
 
	
 

	
CH
	
APTEVO THERAPEUTICS
	
Registered
	
60107/2017
	
14-Aug-2017
	
712186
	
24-Jan-2018

	
TR
	
APTEVO THERAPEUTICS
	
Registered
	
2017/72729
	
14-Aug-2017
	
201772729
	
05-Mar-2018

	
UY
	
APTEVO THERAPEUTICS
	
Published
	
486802
	
16-Aug-2017
	
 
	
 

	
US
	
APTEVO THERAPEUTICS
	
Pending
	
86/768,978
	
25-Sep-2015
	
 
	
 




 



[Schedule 3.19]

 
 


 

 

 


							
	
APTEVO LOGO

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
AU
	
APTEVO_Logo
	
Registered
	
1790478
	
13-May-2016
	
1790478
	
13-May-2016

	
BR
	
APTEVO_Logo
	
Published
	
911049290
	
17-May-2016
	
 
	
 

	
BR
	
APTEVO_Logo
	
Published
	
91104931
	
17-May-2016
	
 
	
 

	
CA
	
APTEVO_Logo
	
Allowed
	
1,782,515
	
16-May-2016
	
 
	
 

	
CH
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
CN
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
CN
	
APTEVO_Logo
	
Pending
	
1306007
	
13-May-2016
	
 
	
 

	
CO
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
EG
	
APTEVO_Logo
	
Pending
	
1306007
	
13-May-2016
	
 
	
 

	
EM
	
APTEVO_Logo
	
Pending
	
1306007
	
13-May-2016
	
 
	
 

	
HK
	
APTEVO_Logo
	
Registered
	
303775816
	
16-May-2016
	
303775816
	
16-May-2016

	
IN
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
3345080
	
16-May-2016

	
IN
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
 
	
 

	
IQ
	
APTEVO_Logo
	
Allowed
	
72213
	
17-May-2016
	
 
	
 

	
IR
	
APTEVO_Logo
	
Registered
	
A0058870
	
13-May-2016
	
1306007
	
13-May-2016




 



[Schedule 3.19]

 
 


 


							
	
APTEVO LOGO

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
KR
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
KW
	
APTEVO_Logo
	
Registered
	
180380
	
16-May-2016
	
150024
	
01-Nov-2017

	
KW
	
APTEVO_Logo
	
Registered
	
180381
	
16-May-2016
	
150025
	
01-Nov-2017

	
MX
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
MX
	
APTEVO_Logo
	
Pending
	
1306007
	
13-May-2016
	
 
	
 

	
MY
	
APTEVO_Logo
	
Registered
	
2016058867
	
16-May-2016
	
2016058867
	
06-Jul-2017

	
MY
	
APTEVO_Logo
	
Registered
	
2016058869
	
17-Nov-2015
	
2016058869
	
28-Jun-2017

	
NI
	
APTEVO_Logo
	
Registered
	
2016-001909
	
16-May-2016
	
2017118458LM
	
06-Apr-2017

	
NO
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
PK
	
APTEVO_Logo
	
Pending
	
421013
	
16-May-2016
	
 
	
 

	
PK
	
APTEVO_Logo
	
Pending
	
421014
	
16-May-2016
	
 
	
 

	
RU
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
TN
	
APTEVO_Logo
	
Pending
	
1306007
	
13-May-2016
	
 
	
 

	
TR
	
APTEVO_Logo
	
Pending
	
1306007
	
13-May-2016
	
 
	
 

	
UA
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016

	
US
	
APTEVO_Logo
	
Registered
	
86/823,176
	
17-Nov-2015
	
5,370,601
	
02-Jan- 2018




 



[Schedule 3.19]

 
 


 


							
	
APTEVO LOGO

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
UY
	
APTEVO_Logo
	
Published
	
474195
	
17-May-2016
	
 
	
 

	
JP
	
APTEVO_Logo
	
Registered
	
1306007
	
13-May-2016
	
1306007
	
13-May-2016




 

 

 

 


							
	
IXINITY

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
AR
	
IXINITY
	
Registered
	
3165116
	
17-May-2012
	
2596265
	
07-Oct-2013

	
AU
	
IXINITY
	
Registered
	
1480170
	
14-Mar-2012
	
1480170
	
14-Mar-2012

	
BR
	
IXINITY
	
Pending
	
904637328
	
23-Mar-2012
	
 
	
 

	
CA
	
IXINITY
	
Published
	
1568455
	
13-Mar-2012
	
 
	
 

	
CH
	
IXINITY
	
Registered
	
627391
	
14-Mar-2012
	
627391
	
22-Mar-2012

	
CL
	
IXINITY
	
Registered
	
999711
	
23-Mar-2012
	
1056965
	
14-Nov-2013

	
CN
	
IXINITY
	
Registered
	
10645298
	
20-Mar-2012
	
10645298
	
21-May-2013

	
CO
	
IXINITY
	
Registered
	
12079796
	
15-Mar-2012
	
477717
	
30-Aug-2013

	
EM
	
IXINITY
	
Registered
	
9671249
	
19-Jan-2011
	
9671249
	
27-Jun-2011

	
ID
	
IXINITY
	
Pending
	
D002012013996
	
07-Mar-2012
	
IDM000422137
	
27-Mar-2012




 



[Schedule 3.19]

 
 


 


							
	
IXINITY

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
IL
	
IXINITY
	
Registered
	
245198
	
14-Mar-2012
	
245198
	
04-Feb-2014

	
IN
	
IXINITY
	
Published
	
2299289
	
14-Mar-2012
	
 
	
 

	
JP
	
IXINITY
	
Registered
	
2012-019936
	
15-Mar-2012
	
5519002
	
31-Aug-2012

	
KR
	
IXINITY
	
Registered
	
4020120020248
	
27-Mar-2012
	
40-0960235
	
25-Mar-2013

	
KW
	
IXINITY
	
Registered
	
128765
	
27-Mar-2012
	
113202
	
27-Mar-2012

	
KZ
	
IXINITY
	
Registered
	
57589
	
26-Mar-2012
	
41032
	
19-Jun-2013

	
MX
	
IXINITY
	
Registered
	
1258399
	
15-Mar-2012
	
1302878
	
09-Aug-2012

	
NO
	
IXINITY
	
Registered
	
201202805
	
14-Mar-2012
	
266290
	
06-Jul-2012

	
NZ
	
IXINITY
	
Registered
	
955543
	
14-Mar-2012
	
955543
	
18-Sep-2012

	
PE
	
IXINITY
	
Registered
	
487424
	
21-Mar-2012
	
190646
	
15-Aug-2012

	
RU
	
IXINITY
	
Registered
	
2012707588
	
15-Mar-2012
	
489113
	
07-Jun-2013

	
SA
	
IXINITY
	
Registered
	
180225
	
27-Mar-2012
	
143305340
	
05-Nov-2013

	
SG
	
IXINITY
	
Registered
	
T1203502H
	
15-Mar-2012
	
T1203520H
	
15-Mar-2012

	
TH
	
IXINITY
	
Registered
	
841121
	
27-Mar-2012
	
TM379750
	
27-May-2014

	
TW
	
IXINITY
	
Registered
	
101017402
	
02-Apr-2012
	
1538533
	
01-Oct-2012

	
UA
	
IXINITY
	
Registered
	
m201204919
	
22-Mar-2012
	
169569
	
25-Apr-2013




 



[Schedule 3.19]

 
 


 


							
	
IXINITY

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
IXINITY
	
Registered
	
85/220,714
	
19-Jan-2011
	
4597459
	
02-Sep-2014

	
US
	
IXINITY (STYLIZED)
	
Registered
	
86/322,323
	
27-June-2014
	
4788624
	
11-Aug-2015

	
VN
	
IXINITY
	
Registered
	
4201205679
	
27-Mar-2012
	
205459
	
13-May-2013

	
ZA
	
IXINITY
	
Registered
	
201207095
	
19-Mar-2012
	
201207095
	
30-Sept-2013




 

 


							
	
IXPERIENCE

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
IXPERIENCE
	
Registered
	
86/322,313
	
27-June-2014
	
4923507
	
22-Mar-2016




 

 

 

 


							
	
VYDAPTIV

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
VYDAPTIV
	
Pending
	
86/972,975
	
21-April-2106
	
 
	
 




 

 

 

 


							
	
VYDAPTIV BIOTHERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date




 



[Schedule 3.19]

 
 


 


							
	
US
	
VYDAPTIV BIOTHERAPEUTICS
	
Under Opposition
	
86/972,988
	
12-April-2106
	
 
	
 




 

 


							
	
VYDAPTIV THERAPEUTICS

	
Country
	
Trademark Name
	
Status
	
Application No.
	
Filing Date
	
Registration No.
	
Registration Date

	
US
	
VYDAPTIV THERAPEUTICS
	
Under Opposition
	
86/972,981
	
12-April-2106
	
 
	
 




 

 

 

 

 

 


				
	
Trademark Clearinghouse Registrations (TMCH)

	
US
	
IXINITY Trademark Clearinghouse Registration
	
Active
	
00170514158981891415

	
US
	
ADAPTIR Trademark Clearinghouse

Registration
	
Active
	
00170513892841101389




 

 


	
 
	
C.
	
Registered Domain Names




 


					
	
Domain Desc
	
Domain Names
	
Registar Name
	
ExpirationDate
	
Domain Name registered by:

	
IXINITY
	
applygenerationixproject.com
	
Godaddy.com
	
11/11/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevo.biz
	
Godaddy.com
	
9/24/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevo.net
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics




 



[Schedule 3.19]

 
 


 


					
	
Domain Desc
	
Domain Names
	
Registar Name
	
ExpirationDate
	
Domain Name registered by:

	
Aptevo
	
aptevo.org
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotech.biz
	
Godaddy.com
	
12/22/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotech.com
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotech.net
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotech.org
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotechnology.biz
	
Godaddy.com
	
12/22/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotechnology.com
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotechnology.net
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevobiotechnology.org
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevobiotherapeutics.biz
	
Godaddy.com
	
12/22/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevobiotherapeutics.com
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevobiotherapeutics.net
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevobiotherapeutics.org
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevocommunitysupport.com
	
Godaddy.com
	
11/21/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevohemophilia.com
	
Godaddy.com
	
5/6/2018
	
Aptevo Therapeutics

	
IXINITY
	
aptevoinfo.com
	
Godaddy.com
	
9/27/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevoresearchanddevelopment.biz
	
Godaddy.com
	
12/22/2018
	
Aptevo Therapeutics




 



[Schedule 3.19]

 
 


 


					
	
Domain Desc
	
Domain Names
	
Registar Name
	
ExpirationDate
	
Domain Name registered by:

	
Aptevo
	
aptevoresearchanddevelopment.com
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevoresearchanddevelopment.net
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevoresearchanddevelopment.org
	
Godaddy.com
	
12/23/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevotherapeutics.biz
	
Godaddy.com
	
9/24/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevotherapeutics.com
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevotherapeutics.net
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevotherapeutics.org
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics

	
Aptevo
	
aptevotx.biz
	
Godaddy.com
	
3/1/2019
	
Aptevo Therapeutics

	
Aptevo
	
aptevotx.com
	
Godaddy.com
	
3/2/2019
	
Aptevo Therapeutics

	
Aptevo
	
aptevotx.mobi
	
Godaddy.com
	
3/2/2019
	
Aptevo Therapeutics

	
Aptevo
	
aptevotx.net
	
Godaddy.com
	
3/2/2019
	
Aptevo Therapeutics

	
Aptevo
	
aptevotx.org
	
Godaddy.com
	
3/2/2019
	
Aptevo Therapeutics

	
Aptevo
	
apvo.biz
	
Godaddy.com
	
3/10/2019
	
Aptevo Therapeutics

	
Aptevo
	
apvo.com
	
Godaddy.com
	
12/22/2018
	
Aptevo Therapeutics

	
Aptevo
	
apvo.info
	
Godaddy.com
	
3/11/2018
	
Aptevo Therapeutics

	
Aptevo
	
apvo.mobi
	
Godaddy.com
	
3/11/2018
	
Aptevo Therapeutics

	
Aptevo
	
apvo.org
	
Godaddy.com
	
3/11/2018
	
Aptevo Therapeutics




 



[Schedule 3.19]

 
 


 


					
	
Domain Desc
	
Domain Names
	
Registar Name
	
ExpirationDate
	
Domain Name registered by:

	
IXINITY
	
bmorescholarship.com
	
Godaddy.com
	
1/7/2019
	
Aptevo Therapeutics

	
IXINITY
	
defineyourexperience.com
	
Godaddy.com
	
1/5/2019
	
Aptevo Therapeutics

	
IXINITY
	
defineyourixperience.com
	
Godaddy.com
	
1/5/2019
	
Aptevo Therapeutics

	
IXINITY
	
emergenthemophilia.biz
	
Godaddy.com
	
1/3/2019
	
Aptevo Therapeutics

	
IXINITY
	
emergenthemophilia.com
	
Godaddy.com
	
1/4/2019
	
Aptevo Therapeutics

	
IXINITY
	
emergenthemophilia.net
	
Godaddy.com
	
1/4/2019
	
Aptevo Therapeutics

	
IXINITY
	
emergenthemophilia.org
	
Godaddy.com
	
1/4/2019
	
Aptevo Therapeutics

	
IXINITY
	
factoritforward.com
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics

	
IXINITY
	
factoritforwardfaces.com
	
Godaddy.com
	
9/13/2018
	
Aptevo Therapeutics

	
IXINITY
	
generationixproject.com
	
Godaddy.com
	
9/25/2018
	
Aptevo Therapeutics

	
IXINITY
	
hemophiliabcompany.com
	
Godaddy.com
	
10/24/2018
	
Aptevo Therapeutics

	
IXINITY
	
hemophiliabstories.com
	
Godaddy.com
	
10/22/2018
	
Aptevo Therapeutics

	
IXINITY
	
hemophiliastories.com
	
Godaddy.com
	
10/23/2018
	
Aptevo Therapeutics

	
IXINITY
	
hemophiliaterritorymanager.com
	
Godaddy.com
	
10/18/2018
	
Aptevo Therapeutics

	
IXINITY
	
ixinity.ca
	
Godaddy.com
	
4/10/2018
	
Aptevo Therapeutics

	
IXINITY
	
ixinity.co
	
Godaddy.com
	
6/5/2019
	
Aptevo Therapeutics

	
IXINITY
	
ixinity.com
	
Godaddy.com
	
1/12/2019
	
Aptevo Therapeutics




 



[Schedule 3.19]

 
 


 


					
	
Domain Desc
	
Domain Names
	
Registar Name
	
ExpirationDate
	
Domain Name registered by:

	
IXINITY
	
ixinity.info
	
Godaddy.com
	
1/12/2019
	
Aptevo Therapeutics




 

 


	
 
	
D.
	
Licenses




 

 


	
 
	
1.
	
License(s) pursuant to Non-Exclusive License Agreement, dated July 21, 2008, by between Trubion Pharmaceuticals and Hospital Clinic I Provincial de Barcelona
	
 




Is there a restriction on a right to grant a lien? NO Is there a restriction on a right to assign? NO

Is there a restriction on a right to sublicense? NO

 

 


	
 
	
2.
	
License(s) pursuant to Exclusive License Agreement, dated December 12, 2011, by and between University of Washington and Emergent Product Development Seattle LLC
	
 




Is there a restriction on a right to grant a lien? NO

Is there a restriction on a right to assign? NO, provided express written consent unless to Affiliate(s) Is there a restriction on a right to sublicense? YES, except to Affiliate(s) and Co-Development Partners

 


	
 
	
3.
	
License(s) pursuant to Commercial Platform License Agreement, dated January 8, 2016, by and between Open Monoclonal Technology, Inc. and Emergent Product Development Seattle, LLC
	
 




Is there a restriction on a right to grant a lien? NO Is there a restriction on a right to assign? NO

Is there a restriction on a right to sublicense? YES,” non-sublicenseable”

 

 


	
 
	
4.
	
License(s) pursuant to License Agreement, dated December 13, 2013, by and between Lonza Sales AG and Emergent Product Development Seattle, LLC
	
 




Is there a restriction on a right to grant a lien? NO

Is there a restriction on a right to assign? NO, provided prior written consent

 



[Schedule 3.19]

 
 


 

Is there a restriction on a right to sublicense? NO, provided written consent

 


	
 
	
5.
	
License(s) pursuant to Amended and Restated License Agreement, dated as of November 28, 2008, by and between Cangene Corporation (as successor-in-interest to Inspiration Biopharmaceuticals, Inc.) and The University of North Carolina at Chapel Hill, as amended on June 14, 2012
	
 




Is there a restriction on a right to grant a lien? NO

Is there a restriction on a right to assign? NO, provided written consent Is there a restriction on a right to sublicense? NO, provided notification

 


	
 
	
6.
	
License(s) pursuant to Life Technologies DG44 Commercial Production License Agreement, dated July 28, 2016, by and between Life Techonologies Corporation and Emergent BioSolutions Inc. (the “DG44 License Agreement”)
	
 




Is there a restriction on a right to grant a lien? NO

Is there a restriction on a right to assign? NO, provided prior written approval

Is there a restriction on a right to sublicense? YES, third party obtains a separate commercial license from LIFE

 


	
 
	
7.
	
License(s) pursuant to Research Evaluation Agreement, dated December 10, 2003, by and between Lonza Biologics PLC and Trubion Pharmaceuticals, Inc.
	
 




Is there a restriction on a right to grant a lien? NO

Is there a restriction on a right to assign? NO, provided prior written consent Is there a restriction on a right to sublicense? YES

 


	
 
	
8.
	
License(s) pursuant to Distributed Bio, dated March 14, 2016, by and between Distributed Bio Inc. and Emergent Product Development Seattle LLC.
	
 




 

Is there a restriction on a right to grant a lien? NO

Is there a restriction on a right to assign? NO, provided prior written consent Is there a restriction on a right to sublicense? NO

 



[Schedule 3.19]

 
 


Schedule 4.9 – Litigation, Governmental Proceedings and Other Notice Events

None.

 



[Schedule 4 .9]

 
 


Schedule 5.1 – Debt; Contingent Obligations

None.

 



[Schedule 5 .1]

 
 


Schedule 5.2 – Liens

None.

 



[Schedule 5.2]

 
 


Schedule 5.7 – Permitted Investments

None.

 



[Schedule 5.7]

 
 


Schedule 5.8 – Affiliate Transactions

None.

 



[Schedule 5.8]

 
 


Schedule 5.11 – Business Description

 

Aptevo Therapeutics Inc. (Aptevo, we, us, or the Company) is a biotechnology company focused on novel oncology (cancer) and hematology (blood disease) therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR (modular protein technology) platform. We currently have one revenue-generating product in the area of hematology, IXINITY, as well as various investigational stage product candidates in the area of immuno-oncology and autoimmune and inflammatory diseases.

 



[Schedule 5.11]

 
 


Schedule 5.14 – Deposit Accounts and Securities Accounts

 


					
	
Bank Name
	
Account Number
	
Account Type
	
Branch Address
	
NameofBorrower Holding Account

	
Wells Fargo
	
4106074107
	
Holding
	
999 3rd Ave Seattle, WA 98104
	
Aptevo Therapeutics Inc.

	
Wells Fargo
	
4106074115
	
Operating
	
999 3rd Ave Seattle, WA 98104
	
Aptevo Therapeutics Inc.

	
Wells Fargo
	
4419053285
	
Operating
	
999 3rd Ave Seattle, WA 98104
	
Aptevo Research and Development LLC

	
Wells Fargo
	
4419053277
	
Operating
	
999 3rd Ave Seattle, WA 98104
	
Aptevo BioTherapeutics LLC

	
Wells Fargo
	
4059551978
	
Corporate Card Collateral Account
	
999 3rd Ave Seattle, WA 98104
	
Aptevo Therapeutics Inc.

	
Wells Fargo
	
1BA97831
	
Money Market Investment Account
	
999 3rd Ave Seattle, WA 98104
	
Aptevo Therapeutics Inc.




 



[Schedule 5.14]

 
 


Schedule 6.2 – Minimum Net Commercial Product Revenue Schedule

 

 

 


		
	
Defined Period Ending
	
Minimum Net Commercial Product Revenue Amount

	
30-Sep-18
	
$16,300,000.00

	
31-Dec-18
	
$20,100,000.00

	
31-Mar-19
	
$21,700,000.00

	
30-Jun-19
	
$22,000,000.00

	
30-Sep-19
	
$23,500,000.00

	
31-Dec-19
	
$25,000,000.00

	
31-Mar-20
	
$29,900,000.00

	
30-Jun-20
	
$30,750,000.00

	
30-Sep-20
	
$31,500,000.00

	
31-Dec-20
	
$32,000,000.00

	
31-Mar-21
	
$32,500,000.00

	
30-Jun-21
	
$33,000,000.00

	
30-Sep-21
	
$33,500,000.00

	
31-Dec-21
	
$34,000,000.00

	
31-Mar-22
	
$34,500,000.00

	
30-Jun-22
	
$35,000,000.00

	
30-Sep-22
	
$35,500,000.00

	
31-Dec-22 and the last day of each calendar

quarter occurring thereafter
	
$36,000,000.00




 

 



Schedule 7.4 – Post Closing Requirements

 

 

Borrowers shall satisfy and complete each of the following obligations, or provide Agent each of the items listed below, as applicable, on or before the date indicated below:

 

 


	
 
	
1.
	
Borrowers shall, by August 17, 2018 (or such later date as Agent may agree in its sole discretion), ensure that each Deposit Account and Securities Account maintained by Borrowers (including, for the avoidance of doubt, Securities Account No. 1BA97831 at Wells Fargo but excluding Excluded Accounts) shall be subject to a Deposit Account Control Agreement or a Securities Account Control Agreement, as applicable, each of which shall be in form and substance reasonably satisfactory to Agent.
	
 




 

Borrower’s failure to complete any of the above obligations on or before the date indicated above (as such may be extended by Agent in its sole discretion), or Borrower’s failure to deliver any of the above listed items on or before the date indicated above (as such may be extended by Agent in its sole discretion), shall constitute an immediate Event of Default.

 

 



 

Schedule 8.2(a) – Licensing and Products Products:


		
	
Approved Products
	
Indication(s)

	
IXINITY [coagulation factor IX (recombinant)]
	
Control and prevention of bleeding episodes and for management of bleeding during operations in adults and children, 12 years of age and older, with hemophilia B




 

 


			
	
 
	
Investigational Stage Product Candidates

	
Product Candidates
	
Description

	
APVO414 (formerly MOR209/ES414)
	
a bispecific ADAPTIR candidate, currently in Phase 1 development, targeting prostate specific membrane antigen (PSMA), an enzyme that is expressed on the surface of prostate cancer cells, and, CD3, a  component of the T cell receptor complex expressed on all T cells. APVO414 redirects T cells to specifically kill PSMA expressing tumors and is being developed for metastatic castration-resistant prostate cancer, which is advanced prostate cancer that has spread to other organs and no longer responds to hormone blocking therapies.

	
otlertuzumab
	
a monospecific ADAPTIR candidate currently in Phase 2 clinical development for the treatment of peripheral T-cell lymphoma (PTCL). A previous Phase 2 clinical study evaluating otlertuzumab for the treatment of chronic lymphocytic leukemia (CLL) showed that otlertuzumab in combination with bendamustine, compared to bendamustine alone, demonstrated a significant increase in median progression free survival for the combination, from approximately 10 to 16 months.

	
APVO436
	
a bispecific ADAPTIR candidate targeting CD123, a cell surface receptor highly expressed on several hematological malignancies and CD3, a component of the T cell receptor. APVO436 engages T cells to initiate killing of tumor cells. Aptevo filed an IND in Q2 2018 and plans to begin clinical development of

APVO436 in Q4 2018.




 



[Schedule 8.2(a)]

 
 


 


		
	
 
	
 

	
APVO210
	
a bispecific ADAPTIR preclinical candidate with a novel mechanism of action based on targeted cytokine delivery. APVO210 is composed of a humanized anti-CD86 antibody fused with a modified form of IL-10 that specifically induces IL-10 signaling on antigen presenting cells, but not on lymphoid populations. APVO210 functions by suppressing immune responses and inducing certain tolerogenic responses and therefore may have potential benefit for the treatment of autoimmune and inflammatory diseases. Aptevo intends to file an IND for APVO210 in 2018.

	
ALG.APV-527
	
a bispecific antibody candidate, partnered with Alligator Bioscience, featuring a novel mechanism of action designed to simultaneously target 4-1BB (CD137) and 5T4, a tumor antigen widely overexpressed in a number of different types of cancer. 4-1BB, a costimulatory receptor on T cells, is known to enhance the immune response to cancer through activation of tumor-specific T cells and is believed to be a promising target for new immunotherapeutic approaches. ALG.APV-527 could potentially have utility in the treatment of a broad spectrum of cancers over-expressing the tumor antigen, including breast, cervical, non-small-cell- lung, prostate, renal, gastric, colorectal and bladder cancers.

	
 

ROR1 Bispecific
	
an immunotherapeutic protein targeting ROR1, a proof-of-concept bispecific candidate targeting ROR1, an antigen found on several solid tumors and hematologic, or blood-related malignancies. Initial preclinical data demonstrate redirected T cell killing of tumors expressing ROR1 in vitro and in vivo in animal models.

	
ADAPTIR Therapeutic Candidates
	
Other candidates that are focused on immuno-oncology and based on the ADAPTIR platform technology are in different stages of pre-clinical development




 

 

 

 

 

 

 

IXINITY

 



[Schedule 8.2(a)]

 
 




Country

Distributor

License Holder

Strength (IU)

Indication (currently proposed)

Licensure/ Filing Status (Approved, Launched, Withdrawn, In review, Not

submitted)

Original Licensure Approval Date

 

(yyyy-

mm-dd)

Licensure Renewal Period

 

(yrs)

Most Recent Renewal Date/ Withdrawl Date/ Exp Date

(yyyy-mm- dd)

Registration/ Licence #

Launch Date

 

(mm/yyyy)

U.S.

Aptevo

Aptevo

500 IU vial*

IXINITY is a coagulation factor IX (recombinant) indicated in adults and children ≥ 12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management. IXINITY is

not indicated for induction of immune tolerance in patients with hemophilia B.

Approved

 

N/A -

N/A -

NDC 70504-0270-1

3/27/2018

 

BioTherapeutics

BioTherapeutics

 

 

 

8/30/2016

Licensure

Licensure

 

 

 

LLC

LLC

 

 

 

(date of transfer

from

valid indefinitely

valid indefinitely

 

 

 

 

 

1000 IU

vial*

 

 

 

 

 

NDC 70504-0270-1

5/22/2017

 

 

 

 

 

 

Cangene)

 

 

 

 

 

 

 

1500 IU

 

 

 

 

 

NDC 70504-0270-1

5/16/2017

 

 

 

vial*

 

 

 

 

 

 

 

 

 

 

500 IU

 

 

 

 

 

NDC 70504-0282-5

3/26/2018

 

 

 

carton

 

 

 

 

 

 

 

 

 

 

1000 IU

 

 

 

 

 

NDC 70504-0283-5

5/22/2017

 

 

 

carton

 

 

 

 

 

 

 

 

 

 

1500 IU

 

 

 

 

 

NDC 70504-0284-

5/16/2017

 

 

 

carton

 

 

 

 

 

 

 

 

 

 

1000 IU -

 

 

 

 

 

NDC 70504-0285-6

N/A

 

 

 

x2 carton

 

 

 

 

 

 

 

 

 

 

1500 - x2

 

 

 

 

 

NDC 70504-0286-6

N/A

 

 

 

carton

 

 

 

 

 

 

 

 

 

 

5 mL

 

 

 

 

 

NDC 70504-0280-1

5/16/2017

 

 

 

Sterile, WFI

 

 

 

 

 

 

 

 

 

 

in a

 

 

 

 

 

 

 

 

 

 

prefilled 10

 

 

 

 

 

 

 

 

 

 

mL syringe

 

 

 

 

 

 

 

 

 

 

250 IU vial

 

 

 

 

NDC 70504-0275-1

N/A

 

 

 

2000 IU vial

 

 

 

 

NDC 70504-0276-1

N/A

 

 

 

3000 IU vial

 

 

 

 

NDC 70504-0277-1

N/A

 

 

 

250 IU

 

 

 

 

NDC 70504-0287-5

N/A

 

 

 

carton

 

 

 

 

 

 

 

 

 

2000 IU

 

 

 

 

NDC 70504-0288-5

N/A

 

 

 

carton

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
 



[Schedule 8.2(a)]

 
 


 

 

 

 

 



 

 

 

3000 IU

carton

 

 

 

 

NDC 70504-0289-5

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 
Only active strengths currently being manufactured

	
 
	
•
	







[Schedule 8.2(a)]

 
 


Schedule 8.2(b) – Exceptions to Healthcare Representations and Warranties

None.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Schedule 8.2(b)]

 

 



Schedule 9.1 – Collateral

 

The Collateral consists of all of Borrower’s assets (other than Excluded Property), including without limitation, all of Borrower’s right, title and interest in and to the following, whether now owned or hereafter created, acquired or arising:

 


	
 
	
(a)
	
all goods, Accounts (including health-care insurance receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, securities accounts, fixtures, letter of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located;
	
 




 


	
 
	
(b)
	
all of Borrowers’ books and records relating to any of the foregoing; and




 


	
 
	
(c)
	
any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.
	
 




 

Pursuant to the terms of a certain negative pledge arrangement with Agent and Lenders, Borrower has agreed not to encumber any of its Intellectual Property without Agent’s and Lenders’ prior written consent.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

iii

 

 



 

Schedule 9.2 – Location of Collateral

 


			
	
Borrower
	
Chief Executive Office
	
Location of Books/Records and/or Collateral

	
Aptevo Therapeutics Inc
	
2401 4th Ave, Suite 1050, Seattle,

WA 98121
	
2401 4th Ave, Suite 1050, Seattle,

WA 98121 (Leased)

	
Aptevo Research and Development LLC
	
2401 4th Ave, Suite 1050, Seattle,

WA 98121
	
2401 4th Ave, Suite 1050, Seattle,

WA 98121 (Leased)

	
Fretz Road, Souderton, PA 18964 (Third Party Location)

	
18 Reid Way, Melbourne Airport, Victoria 3045 (Third Party Location)

	
 
	
 
	
Catalent Pharma Solutions

 

10245 Hickman Mills Drive, Kansas City, MO 64137

	
 
	
 
	
BioReliance

14920 Broschart Road

Rockville, MD 20850

	
 
	
 
	
SciSafe

7 Corporate Drive, Suite 4 Cranbury, NJ

	
 
	
 
	
BioStorage

2910 Fortune Circle West, Suite E

Indianapolis, IN 46241




 



[Schedule 9.2]

 
 


 


			
	
 
	
 
	
Charles River

358 Technology Drive

Malvern, PA 17601

	
 
	
 
	
Eurofins

2425 New Holland Pike Lancaster, PA 17601

	
 
	
 
	
KBI Biopharma 1101 Hamlin Road

Durham, NC 27709

	
 
	
 
	
Fisher BioServices 14665 Rothgeb Drive

Rockville, MD 20850

	
 
	
 
	
Kryosphere

14001 Weeston Parkway,

Suite 106

Cary, NC 27513

	
Aptevo BioTherapeutics LLC
	
2401 4th Ave, Suite 1050, Seattle,

WA 98121
	
920 Cassatt RD Suite 100, Berwyn PA 19312 (Leased)

	
Camden Industrial Park Facility, 1111 S. Paca St., Baltimore, MD (Leased)

	
400 Professional Dr, Suite 400

Gaithersburg, MD 20879 (Third Party Location)

	
155 Innovation Dr. Winnipeg, MB, CA

R3T 5Y3 (Third Party Location)




 



[Schedule 9.2]

 
 


 


			
	
 
	
 
	
AGC Biologics (CMC ICOS Biologicals)

22021 20th Ave. SE

Bothell, WA 98021

	
 
	
 
	
Patheon

Italia S.p.A.2 Trav. S.X. Via Morolense, 5 03013 Ferentino

	
 
	
 
	
A+ Secure Packaging 339 Mason Road

La Vergne, TN 37086

	
 
	
 
	
Cardinal Health 105, Inc.

501 Mason Road, Suite 200 La Vergne, TN 37086




 



[Schedule 9.2]